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ABSTRACT
Background: Regular fish consumption is consistently associated with a range of
health benefits, particularly cardiovascular related. In excitable tissue such as skeletal
and cardiac muscle, fish or fish oil (FO) intake increases membrane phospholipid
concentration of long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA),
especially docosahexaenoic acid (DHA). Of physiological consequence, skeletal muscle
and cardiac function has been demonstrated to be modified, even during episodes of
hypoxia/ischaemia. There is evidence that shows variation in the patterns by which
DHA phospholipid incorporation occurs according to tissue type. However, little is
known about whether incorporation of DHA is associated with specific physiological
properties unique to the tissue. In addition, it is not known if physiological effects can
be attributed to the supplementation of FO doses achievable within a typical Westernstyle human diet (high SFA and n-6 PUFA). Some physiological effects have been
reported in skeletal muscle using human dietary achievable FO doses. The physiological
effects demonstrated within the myocardium and pacemaker regions of the heart are
postulated to underpin the cardiovascular health benefits of regular fish intake observed
at a population level. However, previous studies have relied upon FO doses well above
what could be achieved in the habitual human diet. This research therefore aimed,
firstly, to characterise patterns of phospholipid DHA incorporation throughout muscle
types with unique physiological properties, including ventricular myocardium,
following supplementation of FO doses achievable within a typical Western-style
human diet. Secondly, it aimed to relate ventricular myocardial phospholipid DHA
concentrations to cardiac physiology at rest; and during ischaemia and reperfusion; that
may explain the cardiovascular health benefits associated with regular fish consumption
in humans.
Methods: The research commenced with a study which evaluated the optimal
anaesthetic to use while characterising in vivo cardiac function in the rat using a Millar
conductance catheter. The remainder of studies investigated the effect of supplementing
FO to a control diet (10% fat wt/wt) devoid of LC n-3 PUFA and containing high
amounts of SFA (5%), MUFA (2.5%) and n-6 PUFA (2.5%), typical of a Western-style
diet in rats for 4 – 6 weeks. Dietary achievable FO doses (LowFO: 0.32% and ModFO:
1.25% wt/wt) were exchanged for MUFA in the control diet to ensure SFA and n-6
ix

PUFA content remained high. Following dietary supplementation, cardiac function was
assessed in vivo under pentobarbital anaesthetic (60mg/kg i.p), instrumented with lead-I
ECG and a 6mm miniaturised 2-French pressure-volume conductance catheter. The
heart rate, heart rate variability and ventricular haemodynamic function was evaluated:
under resting conditions; during prolonged regional ischaemia; and the post-ischaemic
recovery. Cardiac arrhythmias were evaluated from continuous ECG and aortic pressure
recordings during: 15 min regional ischaemia; and 15 min reperfusion. Regional
ischaemia was achieved by surgical occlusion of the left anterior descending coronary
artery with reperfusion induced by release of the occlusive snare. Tissue was collected
at completion of cardiac haemodynamic studies for morphological measurements and
the analysis of phospholipid fatty acid composition via gas chromatography.
Results: Relative fatty acid phospholipid concentrations of LC n-3 PUFA, particularly
DHA was higher in myocardial (Control: 5.0 ±0.2%; LowFO: 13.1 ±0.9%; ModFO:
18.3 ±0.4%, p <0.001) and skeletal muscles following supplementation with both doses
of FO. Across five different hind-limb muscles within the rat, selected for their unique
fibre type proportions, DHA preferentially incorporated in relation to the proportion of
fast oxidative glycolytic (FOG) fibre type (Control soleus DHA: 8.3 ±0.1%, proportion
of soleus FOG fibre type: 13%; Control gastrocnemius (red) DHA: 12.6 ±0.2%,
proportion of FOG fibre type: 62%; ρ = 0.94, r2 = 0.89). Phospholipid concentrations of
DHA were further increased with FO feeding in a dose-dependent manner across all
muscle types (ModFO soleus DHA: 18.9 ±0.7%; ModFO gastrocnemius (red) DHA:
23.0 ±0.5%). Supplementation of FO was associated with slower resting heart rate in a
dose-related manner (Control: 453 ±6, LowFO: 433 ±4, ModFO: 402 ±5 beats.min-1, p
<0.01) with no compromise to cardiac output and without change in time or frequency
domains of heart rate variability. During 15 min regional ischaemia, the ModFO dose
reduced the incidence and severity of arrhythmias, including reduced cases of fatal
ventricular fibrillation (Fatal VF: Control: 61%, LowFO: 40%, ModFO: 25%, p <0.05).
During 15 min reperfusion, the incidence and severity of arrhythmias was reduced by
both FO doses, with few statistical differences between FO doses. Prolonged ischaemiainduced reductions in rate pressure product (indirect index of myocardial oxygen
consumption) recovered faster in the ModFO group and post-ischaemic left ventricular
pressure-volume loop integrity (shifted downwards and right with reduced ejection
fraction in Control) was maintained in both FO groups (∆ in post-ischaemic ejection
x

fraction: Control: -18% LowFO: -11% ModFO: -10%, p <0.05). Ischaemic zone at risk
was not statistically different between groups, indicating an equivalent ischaemic insult.
Discussion and conclusions: This research establishes that supplementing FO doses
achievable within a typical Western-style human diet produces robust and preferential
fibre type dependent incorporation of DHA into excitable membranes of skeletal
muscles and the heart. Of physiological consequence, resting heart rate was slowed,
hearts remained in normal sinus rhythm for longer during an arrhythmogenic stimulus
and heart function was controlled during ischaemia to ensure maintenance of mean
arterial pressure. These effects occurred in the absence of any well-defined changes in
heart rate variability, indicative that the autonomic nervous system was not involved.
Rather, it appears that FO facilitates adaptations in the intrinsic control of the heart to
provide cardiac nutritional pre-conditioning, similar to ischaemic pre-conditioning and
exercise training. The physiological changes described in the heart were observed, for
the first time, after supplementing FO doses achievable within a typical Western-style
human diet (Human equivalence: LowFO ≈ EPA+DHA 570mg/d or ≈ 2 salmon [100g]
serve/week; ModFO ≈ EPA+DHA 2.3g/d or ≈ 6 capsules per/day). The LowFO dose
appears to be close to the threshold required for improving ischaemic heart function.
Whereas, during reperfusion both FO doses were almost equally effective, particularly
in relation to arrhythmia based outcomes, suggesting that the threshold for effectiveness
may be even lower. This research provides evidence to rationalise how increasing
dietary FO intake in a typical Western-style diet high in SFA and n-6 PUFA offers the
potential to slow resting heart rate, prevent sudden (arrhythmic) cardiac death and
attenuate the decline of post-ischaemic myocardial function leading to heart failure.
Consequently, increasing fish or FO intake in the Western diet offers a safe and
effective tactic for improving heart health and reducing the risk of cardiovascular
disease.
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CHAPTER 1

Introduction

1

1.1.1 Background

1.1 INTRODUCTION

According to the World Health Organisation approximately 38 million deaths
worldwide each year are caused by non-communicable or ‘chronic disease’ and this
number is disproportionately increased in populations with low to middle
socioeconomic status. Lifestyle factors such as dietary patterns have been identified to
place substantial influence on mortality and morbidity rates of chronic disease. Dietary
fish oil (FO) is a rich source of poly-unsaturated fatty acids (PUFA), in particular, it
contains high levels of long chain omega-3 PUFA (LC n-3 PUFA) which is a subclass
of PUFA, with the other being omega-6 (n-6 PUFA). Recently, blood levels of LC n-3
PUFA, specifically eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) have
been demonstrated to be in the very low or low range in populations investigated across
the globe (Stark et al., 2016). This is alarming given that decades of evidence from
numerous epidemiological, clinical, cohort, observational and animal studies
demonstrate dietary intake of fish or FO to be closely associated with a significant
number of health benefits and decreased risk of chronic disease.
Health benefits of FO include: improving brain development and functioning; mental
health outcomes; attenuating cognitive decline; and beneficial effects on metabolic
syndromes, dyslipidaemias and inflammatory problems (Gogus & Smith, 2010; Ruxton
et al., 2004; Sidhu, 2003). The most well known and researched effect, is the
association FO has with reduced cardiovascular disease morbidity and mortality
outcomes (Gogus & Smith, 2010; Yashodhara et al., 2009). However, limited
understanding of the underlying physiological mechanisms and FO doses required to
improve cardiovascular health is leading to confusing and mixed conclusions being
made about their benefits (Alexander et al., 2017; Nestel et al., 2015). The majority of
previous research has relied upon ex vivo animal models and unrealistic doses of FO,
which would not be achievable in the human diet to demonstrate physiological effects
(Matthan et al., 2005; McLennan, 2014). As such, this thesis aimed to characterise
cardiac function following supplementation of FO doses achievable in the typical
Western-style human diet whilst using a physiologically appropriate in vivo animal
model. This will help to establish the action by which increased fish or FO intake
benefits heart health in humans.
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1.1.2 What are fatty acids?
Dietary fats, along with carbohydrates and protein make up the three main
macronutrients of the mammalian diet. Most dietary fats are found in the form of
triglycerides which is a glycerol head group attached to three individual aliphatic fatty
acid chains. Other less common forms of dietary fat include phospholipids, phytosterols
and lipoproteins which are associated with cholesterol. Triglycerides are important
dietary sources of fuel for mammals because they yield substantial quantities of energy
(ATP) when they are metabolised into free fatty acids. Metabolism of triglycerides
occurs in the duodenum following the secretion of pancreatic lipases and bile which
hydrolyse the ester bond between the glycerol head group of the triglyceride and the
individual fatty acid chains. This process splits triglycerides into diglycerides,
monoglycerides and free fatty acids. They are subsequently mixed with fat soluble
contents of the diet such as vitamins, cholesterol and bile salts to form micelles.
Micelles are absorbed into enterocyte cells and their contents are resynthesized into
triglycerides before being repackaged with cholesterol and proteins to form lipoprotein
lipids. Lipoproteins are excreted into the lymphatic system and are then able to circulate
in the blood stream. Lipoprotein lipase enzymes located on endothelial surfaces of
capillaries throughout the body partially digest lipoproteins to release free fatty acids
and glycerol into the plasma (Kratky et al., 2005). Plasma free fatty acids can diffuse
rapidly across phospholipid bilayers, but there are a wide range of membrane associated
proteins which also act to facilitate the uptake of free fatty acids into the membrane, for
a detailed review see (Su & Abumrad, 2009). Free fatty acids are then incorporated into
the membrane phospholipid bilayer in variable proportions throughout different tissues
and play an important role in the functioning of cellular processes (Spector & Yorek,
1985).
Fatty acids are made up of a hydrocarbon chain with a hydrophobic methyl group at one
end and a hydrophilic carboxyl group at the other. Fatty acids chains contain different
numbers of carbon atoms and can therefore be categorised into short chain (< 6 carbon
atoms), medium chain (< 12 carbons atoms) and long chain (>18 carbon atoms).
Furthermore, each fatty acid can contain saturated or varied amounts of unsaturated
bonds, and each chain attached to the glycerol head group may be the same or different.
The degree of saturation refers to the bonding structure (i.e. whether each carbon is
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saturated with hydrogen bonds or one/more carbon atom is bonded to another carbon
via a double bond) of the carbon atoms found in the fatty acid aliphatic chain. There are
three major classes of fatty acids: saturated fatty acids (SFA) which contain no double
bond, monounsaturated fatty acids (MUFA) which contain one double bond and polyunsaturated fatty acids (PUFA) which contain more than one double bond (Figure 1.1).
The most common SFA found in the mammalian diet are Palmitic acid (16:0) and
Stearic acid (18:0) and are mainly derived from animal-based products including meat
and dairy. The typical Western-style diet contains high amounts of SFA (USDA, 2016).
The most relevant MUFA to the mammalian diet is Oleic acid (18:1n-9) which is also
found in animal fats but commonly sourced from plant-based foods such as processed
oils including olive, canola and sunola oil. There are several types of important PUFA
which will be discussed in the next section.
Several methods can be used for the nomenclature of fatty acid chains, most commonly
in nutritional literature, they are referred to using their trivial name e.g. Linoleic acid.
However, this method is often not concise enough to describe the chemical structure of
the fatty acid chain. Therefore ‘lipid number’ nomenclature which identifies the number
of carbon atoms and number/location of double bonds is also used. This method takes
the form of C:Dn-x, where C is the number of carbon atoms, D refers to the number of
double bonds and n-x gives information about the location of the first double bond. The
methyl end of the aliphatic chain is referred to as the ‘omega’ carbon which is
synonymous with ‘n’ and ‘ω’. Therefore n-x identifies precisely which carbon atom the
first double bond is found. For example, the omega-6 fatty acid Linoleic acid is named
18:2n-6, informing the reader that Linoleic acid is made up of eighteen individual
carbon atoms of which two have double bonds and the first double bond is found at the
sixth carbon from the omega end of the aliphatic chain (Figure 1.2). Throughout this
thesis, fatty acids will be referred to using their trivial name followed by the lipid
number description at the first instance and then abbreviated.
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Figure 1.1: Overview of fatty acid classification/nomenclature and biosynthesis of n-3 & n-6 PUFA
Example SFA (No double bonds), MUFA (1 double bond), n-6 PUFA (The first double bond appears at the 6th carbon atom from the omega carbon)
and n-3 PUFA (The first double bond occurs at the 3rd carbon atom away from the omega carbon) are shown.
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There are several important PUFA present in the mammalian diet which can be further
classified into n-6 or n-3 PUFA depending on the location of the first double bond from
the omega carbon (Figure 1.1). Mammals have the ability to produce a range of de novo
fatty acids from palmitic acid via elongation, desaturation and hydroxylation. However,
mammals lack the enzymes necessary to introduce double bonds beyond carbon 9,
meaning both n-6 and n-3 PUFA cannot be synthesised de novo. These fatty acids must
be obtained in the diet or formed from metabolism of other PUFA present in the diet.
PUFA that can only be obtained from the diet are referred to as ‘essential’ fatty acids.
The n-6 and n-3 biosynthetic pathways which are available in mammals predominantly
take place in the endoplasmic reticulum except for the final conversion which occurs in
the peroxisome (Figure 1.2). Linoleic acid (LA: 18:2n-6) is an essential n-6 PUFA in
the mammalian diet and acts as the precursor for n-6 PUFA de novo enzymatic
elongation and desaturation to form a range of longer chain n-6 fatty acids including
Arachidonic acid (AA: 20:4n-6), which is particularly important for platelet and
endothelial wall physiology.
The typical Western-style diet is rich in LA due to its presence in many common
cooking oils such as corn oil, sunflower oil, soybean oil and safflower oil. Short-chain
Alpha-linolenic acid (ALA: 18:3n-3) which is found in seeds and nuts such as
flaxseeds, soybeans and walnuts is an essential n-3 PUFA in the mammalian diet. 18C
ALA acts as a pre-cursor for n-3 PUFA de novo enzymatic synthesis of
eicosapentaenoic (EPA: 20:5n-3) acid and docosahexaenoic acid (DHA: 22:6n-3). For
this reason, it has been argued that EPA and DHA should not be considered essential
fatty acids (Sinclair et al., 2002). However, there is considerable debate regarding the
efficiency rate in the conversion of ALA to DHA in mammals, with studies showing
oral doses of ALA to produce blood levels of DHA ranging from non-detectable to
9.8% (Domenichiello et al., 2014; Gibson et al., 2013; Hussein et al., 2005; Metherel et
al., 2016). This is a result of delta (∆) six desaturase enzymes which are used in two
steps in the pathway for the conversion of ALA to EPA and DHA (Figure 1.2). Firstly,
ALA competes with the n-6 PUFA LA to produce EPA, secondly the EPA metabolite
docosapentaenoic acid (DPA: 22:5n-3), competes with both LA and ALA for the ∆ six
desaturase before the formation of DHA (Gibson et al., 2013; Leonard et al., 2004). A
recent systematic review suggested that increasing dietary intakes of ALA results in
6

some increased formation of EPA, but in the presence of high LA concentrations,
saturation of the ∆ six desaturase enzyme reduces the conversion of DPA to DHA
(Figure 1.2) (Wood et al., 2015). Further evidence for this suggestion is found in a
study that demonstrated synthesis rates of DHA to be higher when using precursors
beyond ALA (Metherel et al., 2018). Therefore, dietary intakes of foods high in preformed DHA & EPA, such as marine based foods, are essential to increase the
concentration of LC n-3 PUFA in the mammalian phospholipid membrane.

Figure 1.2: Overview of n-3 & n-6 PUFA biosynthesis in the mammalian body.
The pathway of enzymatic desaturation and elongation is shown for both n-3 & n-6
PUFA. Steps labelled with an * occur in the endoplasmic reticulum, the final step
labelled with # occurs in the peroxisome. It can be observed how increased dietary
intakes of ALA can saturate the ∆6 desaturase enzyme and reduce the conversion of
DPA – DHA. The figure was adapted from (Gibson et al., 2013).
Abbreviations: LA = Linoleic acid; ALA = Alpha-linolenic acid; AA = Arachidonic acid;
EPA = Eicosapentaenoic acid; DHA = Docosahexaenoic acid; DPA = Docosapentaenoic acid.
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1.1.3 Membrane phospholipid fatty acid incorporation
Phospholipids and cholesterol are the main components, which make up the membrane
lipid bilayer found in mammals. The phospholipid composition of the membrane lipid
bilayer, however, is not a static environment. Alterations of the fatty acid composition
of membrane phospholipids can occur through a range of factors including exercise
(Andersson et al., 2000; Andersson et al., 1998; Helge et al., 2001), oxidative stress
(Hulbert et al., 2007), ageing (Paradies et al., 1992) and pathological states
(Gudbjarnason, 1980). Perhaps of most importance to this thesis is the potent influence
that dietary interventions can exert on the membrane phospholipid composition
(Abeywardena et al., 2016; Charnock et al., 1986; Henry et al., 2015; Slee et al., 2010).
The proposed consequences of altering membrane phospholipid composition include
direct effects on: membrane fluidity and the environment surrounding membrane
receptors, proteins and channels; phospholipase release of fatty acids and indirect
effects of free fatty acids including: enzymatic and non-enzymatic eicosanoid
production; altered intracellular signalling processes; fatty acid oxidation and free
radical production and free radical induced upregulation of antioxidants (Mozaffarian &
Wu, 2011).
Tissue membrane phospholipid composition in the rat is made up predominantly of
Stearic acid (18:0), LA and AA, together these fatty acids represent approximately 45 –
60% of the relative phospholipid composition. The next greatest contributors are Oleic
acid (18:1n-9) which makes up approximately 10% and DHA which adds
approximately 10%; the remaining fatty acids contribute < 5%. The composition of
liver, cardiac, skeletal muscle and neural phospholipid has been demonstrated to
maintain relatively constant SFA and MUFA concentrations when changes to the diet
are made (Ayre & Hulbert, 1996a; Hulbert et al., 2005). However, when small changes
to n-3 and n-6 PUFA content are made in the diet, phospholipids are very responsive,
and the PUFA relative phospholipid composition can change dramatically (Hulbert et
al., 2005). Interestingly, AA is preferentially incorporated into phospholipids over EPA
when diets which are low in LC n-3 PUFA are supplied to rats (Slee et al., 2010). It is
thought this occurs as a result of any available EPA being metabolised to DHA to
maintain abundant phospholipid DHA concentrations (Tran et al., 2001). However,
when LC n-3 PUFA is made available in the diet via dietary FO, EPA and DHA are
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preferentially incorporated into phospholipids at the expense of n-6 PUFA such as AA
and LA (Owen et al., 2004; Slee et al., 2010). The level of incorporation of individual
fatty acids into phospholipids strongly reflects the type of fatty acids included in the diet
and varies in tissue with different functions including cardiac, kidney, liver, lungs,
plasma, neural, skeletal muscle and erythrocytes (Charnock et al., 1989; Spector &
Yorek, 1985).
1.1.4 The role of fish oil in excitable tissue
Excitable tissues are made up of cells which use the movement of ions between cellular
compartments and the extracellular environments to create a resting membrane potential
that is capable of depolarisation. In myocardial and skeletal muscle cells, depolarisation
culminates into a contraction via excitation-contraction coupling. Excitation-contraction
coupling is the process which allows an electrical stimulus to be converted into
mechanical energy at the actin and myosin filaments in skeletal and myocardial cells.
This process is dependent upon the movement of a range of ions between cellular
compartments. However, cellular membranes are impermeable to the movement of ions;
therefore this passage of ions relies upon a vast array of receptors, ligands, gates and
channels embedded within the membrane (Spector & Yorek, 1985). Interactions
between the hydrophilic fatty acid tails and membrane bound proteins, receptors and
channels are closely linked to cellular function (Stubbs & Smith, 1984). As such,
alterations in membrane phospholipid composition can lead to altered cellular
functioning.
The incorporation of DHA into skeletal and myocardial membrane phospholipids is an
important example of linking cellular function to membrane composition. It has been
well documented that excitable tissues including myocardial and skeletal muscle in
humans (Andersson et al., 2002; Harris et al., 2004; Innis, 2007) and animals (Ayre &
Hulbert, 1996a; McLennan & Abeywardena, 2005; Peoples & McLennan, 2010; Stark
et al., 2007b) exhibit similar phospholipid fatty acid composition, much higher in DHA
compared to tissues such as kidney, liver and plasma (Charnock et al., 1989; Nikolaidis
et al., 2006). Of particular interest to this thesis, it has now been established that very
small intakes of FO which are in the human dietary achievable range significantly
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influence phospholipid concentrations of LC n-3 PUFA, particularly DHA in excitable
membranes of the myocardium and skeletal muscles (Henry et al., 2015).
1.1.5 Skeletal muscle structure and function
Skeletal muscle can be classified into two overarching categories based on the
abundance of fibres making up the myofibril. The first class is known as slow-twitch
oxidative fibres otherwise referred to as Type I muscle fibres. The second are known as
fast twitch fibres. Fast twitch fibres can be further categorised to include two
subcategories: 1) fast oxidative glycolytic and 2) fast glycolytic fibres otherwise known
as Type IIa and Type IIb respectively. Type I, IIa & IIb categorisation of skeletal
muscles is based off contractile properties of the muscle, whereas oxidative or
glycolytic categorisation is based on enzymatic processes. Both methods aim to
describe the unique rate of contraction, metabolism and fatigue profiles displayed
between fibre types. For the simplicity of reading, discussion of muscle fibres will be
referred to using the slow oxidative (SO), fast glycolytic (FG) and fast oxidative
glycolytic (FOG) terminology throughout this thesis.
The specific muscle function characteristics observed throughout different muscle fibres
can be attributed to various isoforms of the myosin heavy chain (MHC) proteins located
in the thick filaments of the sarcomere (Wells et al., 1996). The MHC proteins found
within muscle fibres mediate metabolic and contractile responses of skeletal muscle
(Hashimoto et al., 2016). Skeletal muscles made up with predominately SO fibres are
characterised by a slow rate of contraction, primarily use oxidative metabolism and
display resistance to fatigue. Slow oxidative muscle fibres are primarily made up of
MHCslow isoform. This MHC isoform is associated with low basal rates of ATP
consumption and has a high ATP reserve capacity; this leads to the fatigue resistant
characteristics associated in muscles with high proportions of MHCslow isoform (Han et
al., 2001). In contrast, FG fibres are characterised by a fast rate of contraction, primarily
rely upon glycolytic metabolic pathways and display a rapid fatigue profile. Muscles
containing high proportions of FOG fibres display characteristics of both SO and FG
muscle fibres. For example, the FG and FOG have a high proportion of the MHC2
isoform (Sieck & Regnier, 2001). Muscles displaying a high proportion of the MHC2
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isoform rapidly fatigue because they rely upon high rates of ATP consumption and do
not have large ATP reserves (Han et al., 2001).
1.1.6 The influence of fish oil on skeletal muscle function
Human studies have demonstrated several unique physiological roles for FO which may
contribute to improved muscular performance (Mickleborough, 2013). These changes in
function include increased muscle blood flow (Walser et al., 2006), attenuated postexercise inflammation after eccentric exercise (Tartibian et al., 2011) and attenuated
loss of twitch potentiation following downhill running (Mickleborough et al., 2015).
Animal research investigating the health effects of adequate FO intake on skeletal
muscle function has produced contradicting results. It was suggested that both n-6
PUFA and n-3 PUFA are essential to maintaining muscle function in rats, as
deficiencies in either class of fatty acid were demonstrated to result in poor contractile
performance compared to rats receiving diets high in n-6 and n-3 PUFA (Ayre &
Hulbert, 1996b). Whereas, more recent studies have demonstrated that incorporation of
LC n-3 PUFA into skeletal muscle phospholipids contributes to improved fatigue
resistance (Henry et al., 2015; Peoples & McLennan, 2010, 2014) and enhanced oxygen
efficiency (Peoples & McLennan, 2010).
Perhaps most important to this research is evidence which demonstrates dietary
achievable FO doses to maintain skeletal muscle contractile performance during
normoxic conditions (Henry et al., 2015). Diving mammals such as the seal are required
to maintain contractile function during periods of hypoxia when they dive for >12
minutes. It has now been demonstrated that the seal concentrates large amounts of DHA
in swimming skeletal muscle phospholipids and it has been hypothesised that this helps
conserve oxygen (Trumble & Kanatous, 2012). Additionally, it has been demonstrated
that therapeutic doses of FO in the auto-perfused in vivo rat hind-limb delays hypoxic
skeletal muscle fatigue, suggesting a physiological role of DHA in skeletal muscle
during low-oxygen stress (Peoples & McLennan, 2017). The outcomes of both animal
and human studies combined suggest DHA play an important role in skeletal muscle
function and health. However, the recent identification of a specific physiological role
of DHA in skeletal muscle function, particularly during hypoxia/ischaemia has never
been investigated using human nutritionally relevant FO doses in the rat heart.
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1.1.7 Myocardial membrane structure and function
Striated myocardium is an involuntary excitable tissue that is found in the walls of the
heart. Myocardial cells (myocytes) form a thick muscular layer between the epicardium
and endocardium of the heart and coordinate contractions to ensure blood is
rhythmically pumped away from the heart into the circulation. Like skeletal muscle,
calcium ions (Ca2+) are the principal intracellular signalling ions which play critical
roles in both the action potential and contractile phase of the myocyte through
excitation-contraction coupling. The handling, storage and re-uptake of Ca2+ in the
myocardium are tightly regulated throughout the entire cardiac cycle and has been
described in depth elsewhere (Berridge, 2006; Bers, 2008; Fearnley et al., 2011).
Ventricular myocytes contain a slightly different MHC isoform to what is observed for
skeletal muscle. Ventricular myocytes predominately contain the MHCβ isoform, which
is associated with low basal rates of ATP consumption and high ATP reserves (Sieck &
Regnier, 2001). Interestingly, MHCβ isoform found in myocytes is somewhat similar to
the the MHCslow isoform found predominantly in SO skeletal muscle fibres. This
similarity may be reflective of both types of muscle requiring a fatigue resistant
physiological role. Both SO skeletal and cardiac muscles are required to sustain
repeated contractile force production and relaxation over prolonged periods of time.
Given that SO skeletal muscle and cardiac muscle share a somewhat similar MHC
isoform and fatigue resistant profile, it is likely that the fatty acid incorporation patterns
between the two types of muscle are also similar.
1.1.8 The influence of fish oil on the cardiovascular system
Dietary fish intake has been consistently associated with a cardio-protective effect in
decades of human epidemiological and observational studies (Bang & Dyerberg, 1972;
Burr et al., 1989; Hirai et al., 1980; Kagawa et al., 1982; Kromhout et al., 1985).
Initially, research suggested that reduced CVD outcomes associated with FO intake was
attributable to an anti-atherogenic and anti-thrombotic mechanism (Fischer & Weber,
1984; Siess et al., 1980). More recently, research has identified other vascular effects
including favourable changes to blood pressure and endothelial functioning, all of
which likely contribute to the cardiovascular protective effect observed (Adkins &
Kelley, 2010; De Caterina et al., 2006; Robinson & Stone, 2006). However, the
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majority of experiments which have demonstrated anti-atherogenic, anti-hypertensive,
anti-thrombotic actions from FO have relied on very high doses to produce a typically
modest effect, and this effect is usually only demonstrable in previously diseased
populations (Geleijnse et al., 2002; Sekikawa et al., 2008). Despite the focus of initial
research on vascular related outcomes, there is now growing evidence which
demonstrates that regular fish consumption has a direct cardio-protective effect on the
myocardium rather than vascular outcomes (Flock et al., 2013; McLennan, 2014). It is
hypothesised that the direct cardio-protective action of FO upon the myocardium is
closely linked to the incorporation of LC n-3 PUFA into myocardial membrane
phospholipids (Abeywardena et al., 2016; McLennan, 2014). The effects of FO
supplementation attributable to the heart directly include modification of heart rate
(Dallongeville et al., 2003; Geelen et al., 2005; Grimsgaard et al., 1998; Mozaffarian. et
al., 2005), heart rate variability (Christensen et al., 2001; Xin et al., 2013) and improved
cardiac contractile function in healthy (McLennan et al., 1992a) and ischaemic hearts
(Pepe & McLennan, 2002). However, the most extensively studied and important effect
of FO is its anti-arrhythmic action (Matthan et al., 2005; McLennan, 2014).
The current thesis builds on several decades of original animal research that points to
the essential role that DHA, derived from FO, plays in optimal heart function in both
health and disease (Abdukeyum et al., 2008; Abeywardena et al., 2016; Charnock et al.,
1992; Hartog et al., 1987; McLennan, 2014; McLennan & Abeywardena, 2005;
McLennan et al., 1992a; McLennan et al., 2007; Peoples et al., 2008; Pepe &
McLennan, 1996, 2002). Such studies have investigated the physiological effects of LC
n-3 PUFA on cardiac function in animals using doses of FO ranging from 1.25% to
12% wt/wt. Despite the consistent demonstration of FO providing a cardio-protective
action in epidemiological and animal studies, there is still debate as to the potential
cardiovascular health benefits of FO in humans. This is because of the consistent mixed
conclusions published regarding FO by large-scale random control trials (RCT) using
supplements in order to replicate dietary fish intake and the meta-analyses of these trials
(Alexander et al., 2017; Bosch et al., 2012; Galan et al., 2010; Kromhout et al., 2010;
O’Keefe et al., 2017; Rauch et al., 2010; Roncaglioni et al., 2013; Svensson et al.,
2006; Tavazzi et al., 2008; Valagussa et al., 1999; Yokoyama et al., 2007). An example
of this can be found in the recently released Heart Foundation of Australia updated
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recommendations on clinical evidence for LC n-3 PUFA in the prevention and
treatment of cardiovascular disease. The review concludes that while there are clear
benefits of eating fish, there is no support from RCT or their meta-analyses to
recommend the use of refined FO supplements (Nestel et al., 2015). Given that the
observational and animal evidence remains consistent, yet there are regularly
differences reported between RCT, perhaps the design and interpretation of RCT
outcomes requires a better understanding of the doses of FO required and the underlying
physiological mechanisms of action of FO. The challenge in explaining physiologically
plausible mechanisms of action of FO requires animal and cellular work to be
completed.
1.1.9 Linking animal fish oil studies to human health
Historically, animal work has relied upon high doses of FO which would not be easily
achieved in the human diet. Consequently, the relevance of findings from such studies
are ambiguous when extrapolated to human health. However, diets supplemented with
1.25% wt/wt FO consistently exhibit the same or very similar physiological effects as
diets supplemented 12%. For example, the anti-arrhythmic, heart rate slowing and
enhanced oxygen efficiency actions attributable to FO have been demonstrated at doses
of 1.25, 3, 6 and 12% FO (Abeywardena et al., 2016; McLennan, 1993; McLennan et
al., 1992a; McLennan et al., 1992b; Pepe & McLennan, 2002; Pepe & McLennan,
2007). Despite this observation, no studies to date have characterised the effect of FO
on cardiac function using dietary achievable equivalent doses. Currently, 250mg/day
EPA+DHA has been identified in epidemiology and randomized trials for
cardiovascular protection (Kris-Etherton et al., 2009; Mozaffarian et al., 2005a) and
500mg/day of EPA+DHA is recommended for cardiovascular health in males
(Colquhoun et al., 2008). Furthermore, it has been demonstrated that dietary intakes of
FO ranging from as low as 180mg/day up to 1g/day in men and women are associated
with reduced risk of primary cardiac arrest and sudden cardiac death, (Patterson et al.,
2015; Siscovick et al., 1995). Therefore, the minimum dose of FO this series of projects
will supplement animals will be equivalent to ∼570mg/day EPA+DHA in humans
(Chapter 2). In addition, to ensure the doses of FO are nutritionally relevant to human
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health, they will be supplemented to a background diet high in SFA and high in n-6
PUFA, typical of the current Western-style dietary fat proportions (USDA, 2016).
Characterising the effectiveness of FO in the heart also requires the most
physiologically stable experimental model. The importance of using a physiologically
stable model is highlighted in skeletal muscle studies investigating muscle function. It
has been demonstrated that the auto-perfused in vivo hind-limb model provides
improved oxygen delivery, long term viability, physiologically relevant blood flow and
vascular tone when compared to in situ hind-limb perfusion methods (Peoples et al.,
2013). This explains the different outcomes observed in original animal investigations
of skeletal muscle metabolism using an in situ rat hind-limb model (Ayre & Hulbert,
1996b) compared to research using the auto-perfused in vivo hind-limb model (Henry et
al., 2015; Peoples & McLennan, 2010, 2014, 2017). Both skeletal (Bonen et al., 1994)
and cardiac (Kuzmiak-Glancy et al., 2015) muscle performance are intimately linked to
blood flow and oxygen delivery. This makes the choice of experimental model critical
when trying to evaluate physiologically relevant muscle function. In fact, recently it has
been suggested that FO does not enhance myocardial efficiency (Goo et al., 2014), yet
the experiment was conducted using perfusate in an in situ model. There is extensive
evidence demonstrating the importance of whole blood perfusion when using this type
of model (Pepe & McLennan, 1993; Topping & Trimble, 1985). In effect, the
physiologically relevant aspect of oxygen conductance is altered and renders the heart to
conditions never experienced in vivo when perfusate is used ex vivo instead of whole
blood. Although ex vivo studies using perfusate have provided many insights, a whole
blood perfusion method offers specific advantages for the physiological questions
relating to FO and cardio-protection being explored in this thesis. As such, this research
will use a physiologically stable in vivo model of cardiac function to assess the effects
of FO on healthy and ischaemic cardiac function. Not only does an in vivo model
optimise oxygen diffusion and conductance to the heart but it also gives a more accurate
representation of normal physiological function because metabolic waste clearance,
vascular responses, humoral changes and neural inputs to the heart are maintained.
Cardiovascular disease persists as a principal contributing factor to worldwide mortality
rates and the impact of cardiovascular disease is expected to increase substantially as
the proportion of the aged population increases (Heidenreich et al., 2011). Despite vast
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improvements in the treatment and prevention of cardiovascular disease over recent
decades, it has been demonstrated that traditional risk factors are evolving and there are
increasing cases of cardiovascular disease in the absence of Standard Modifiable
cardiovascular Risk Factors ‘SMuRFs’ (Vernon et al., 2017). Therefore, elucidating the
physiological actions of FO doses achievable within a typical Western-style human diet
containing high amounts of SFA and n-6 PUFA, whilst using a physiological relevant in
vivo model, is important for informing further human research. A better understanding
of the benefits fish or FO intake provides the heart will contribute to informed
preventative approaches targeting cardiovascular disease in the 21st century.
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AIMS AND HYPOTHESES

This thesis took a translational approach, using human research to inform in vivo animal
studies, which in turn aims to inform further human research. The overarching aim
relevant to all studies completed was to characterise cardiac function following
supplementation of human dietary achievable FO doses, within a nutritionally relevant
Western-style diet (high SFA and n-6 PUFA) and a physiologically appropriate in vivo
animal model.

More specifically, this thesis aimed to determine the effects of suppleming dietary
acheivable FO doses on:
Aim 1: (Chapter 2)
incorporation patterns of LC n-3 PUFA throughout excitable tissue with unique
physiological roles from within the same animal.
Aim 2: (Chapter 4)
resting cardiac function, including heart rate, heart rate variability and
haemodynamic performance of the heart.
Aim 3: (Chapter 5)
arrhythmia generation during ischaemia and reperfusion injury.
Aim 4: (Chapter 6)
cardiac haemodynamic function during ischaemia and in the proceeding postischaemic recovery.
Hypotheses directly related to each of these aims are given in the corresponding
chapters.
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CHAPTER 2

Membrane fatty acid incorporation,
tissue mass and body weight following
supplementation of human dietary
achievable fish oil doses
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2.1 INTRODUCTION

Investigations of FO supplementation in animals have historically used high intake
ranges to achieve membrane phospholipid incorporation and elucidate physiological
mechanisms of action of LC n-3 PUFA (Charnock et al., 1989; Charnock et al., 1986;
Matthan et al., 2005; McLennan, 2014; McLennan et al., 1992a; Slee et al., 2010).
However, phospholipid incorporation does not need the high intakes previously
supposed. It has now been demonstrated that myocardial and skeletal muscle
composition is particularly sensitive to DHA incorporation and changes occur in the rat,
when using low doses of DHA-rich FO (Henry et al., 2015; McLennan et al., 2007; Slee
et al., 2010).
2.1.1 Skeletal muscle phospholipid fatty acid composition
Comparative physiology studies have demonstrated that incorporation of PUFA into
skeletal muscle phospholipids across mammals is closely linked to the contractile
characteristics of the muscle. For example, phospholipids from the rapidly contracting
skeletal muscle in the European brown hare which can reach peak running velocities of
80kmh-1 have been reported to contain a very high concentration of PUFA (Valencak et
al., 2003). Furthermore, n-6 PUFA has been demonstrated to be associated with
increased maximum running speed in a range of land based mammals (Ruf et al., 2006)
and in salmon (McKenzie et al., 1998). Likewise, pectoral muscles in the hummingbird
or shaker muscles in the rattlesnake which both have very high contractile frequencies
have been shown to incorporate DHA preferentially compared to slow frequency
contracting leg and ventral muscles within each animal respectively (Infante et al.,
2001). Interestingly, despite having similar contractile profiles, the pectoral muscle of
the hummingbird contained almost two-fold more DHA than the shaker muscle of the
rattle snake. The authors attributed this difference to double packing of mitochondrial
inner phospholipids (where the oxidative phosphorylation machinery is located) in the
hummingbird pectoral muscles to optimise the rapid and sustained contraction (Infante
et al., 2001).
It has also been hypothesised that enhanced muscle performance associated with
increased PUFA content is due to changes in the membrane fluidity and permeability
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(Daveloose et al., 1993; Stillwell & Wassall, 2003). However, the aforementioned
studies are linked by the type of skeletal muscle fibre required to achieve these types of
contraction. Muscle comprised of predominately FG and FOG fibres are characterised
by a powerful and fast rate of contraction. To produce powerful and rapid contractions
an extensive network of sarcoplasmic reticulum (SR) is needed for the distribution and
reuptake of Ca2+ by the SR Ca2+-ATPase (SERCA) (Berchtold et al., 2000). Therefore,
preferential DHA incorporation into muscles with greater SERCA content suggests that
the role of PUFA in skeletal muscle is not only related to increased membrane fluidity
and improved oxidative phosphorylation, but also intimately linked to Ca2+ handling.
Exercise training also exerts an influence on membrane phospholipid fatty acid profiles
observed in skeletal muscle. Human studies have demonstrated that low-intensity
exercise increases oleic acid concentrations and reduces the concentration of total n-6
PUFA, particularly AA in skeletal muscle membrane phospholipids (Andersson et al.,
1998). Similarly, oleic acid and DHA have been demonstrated to increase in the
phospholipids of knee extensor muscles (Helge et al., 2001) and the vastus lateralis
muscle following endurance training in healthy males when compared to untrained
males consuming the same diet (Andersson et al., 2000). Therefore, it appears as though
intrinsic contractile properties of the muscle combined with exercise training could
partly explain the differences observed in relative phospholipid composition between
muscle fibre types.
Importantly for this thesis, manipulation of dietary fatty acid profiles strongly
influences skeletal muscle phospholipid fatty acid composition. Altering the diet has
been demonstrated to produce rapid changes in fatty acid phospholipid profiles of
skeletal and cardiac muscle in animals (Ayre & Hulbert, 1996a; Pan & Storlien, 1993)
and in humans (Andersson et al., 2002; McGlory et al., 2014). In fact, it has been
demonstrated that altering the diet produces a much stronger effect on the fatty acid
profile of skeletal muscle then exercise training does in the rat (Turner et al., 2004).
Furthermore, there is evidence to show that when FO is supplemented to the diet of rats,
LC n-3 PUFA, in particular, DHA is preferentially incorporated into cardiac and
skeletal muscle phospholipids (Henry et al., 2015; Peoples & McLennan, 2014; Stark et
al., 2007b). Preferential incorporation of DHA into skeletal muscle phospholipids is
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observed regardless of whether more EPA or DHA is present in the original oil
preparation supplied (Ayre & Hulbert, 1996a).
2.1.2 Myocardial phospholipid fatty acid composition
Myocardial membrane phospholipid LC n-3 PUFA concentrations reflect the type of
fatty acids supplied in the diet in a similar manner to what is observed in skeletal
muscles. Increased incorporation of LC n-3 PUFA into myocardial phospholipids
occurs at the cost of reduced total n-6 PUFA as also observed in skeletal muscle
(Charnock et al., 1986; Metcalf et al., 2007; Slee et al., 2010). It has also been
demonstrated that myocardial phospholipids preferentially accumulate DHA, well
above circulating fatty acid levels (Christensen & Høy, 1992; Owen et al., 2004; Slee et
al., 2010), regardless of whether a DHA (Slee et al., 2010) or EPA (Pepe & McLennan,
1996) predominant oil is used in the diet, similar to skeletal muscle. Dose-response
investigations have shown a linear relationship between FO supplementation and LC n3 PUFA phospholipid concentrations in myocardial cells (Matthan et al., 2005; Owen et
al., 2004). However, these findings have been reconsidered after Slee, E.L. et al., 2010
demonstrated dosages above 1.25% wt/wt lay in the asymptotic range of a hyperbolic
curve when doses below 1.25% are considered, particularly for DHA (Figure 2.1). This
study also demonstrated that the lowest concentration of FO in the rat to alter
phospholipid incorporation is 0.16%, and the authors predicted that the threshold for
DHA incorporation is even lower at 0.0027%. This observation, together with the
demonstration that similar cardiac physiological effects occur when using doses of
1.25% or 12%, suggests that doses above 1.25% are beyond a critical saturation point to
produce phospholipid and physiological changes. Time-course investigation of fatty
acid incorporation demonstrates that DHA is rapidly up-taken by the myocardium
before reaching a plateau point, whereas EPA increases linearly (Owen et al., 2004).
However, the optimal supplementation time for dietary achievable doses to achieve
maximal myocardial phospholipid DHA incorporation in the rat is four weeks (Slee et
al., 2010).
Throughout this thesis, ‘low doses' of FO will be referred to as ‘dietary achievable FO
doses’. This terminology will be used because ‘low intake’ is commonly used to
describe the problem (deficiencies of LC n-3 PUFA intake (de Goede et al., 2010)),
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whereas ‘low doses’ describes the treatment (supplementing FO using doses lower than
previous studies (Owen et al., 2004)). Human ‘dietary achievable’ equivalent doses of
FO in the rat, range from 0.16 – 1.25% wt/wt with 0.16% representing an easily
achievable dose from direct fish consumption (≈1 salmon [100g] serve/week) and
1.25% representing a dose achieved via capsule supplements (≈6 capsules per/day)
(Slee et al., 2010). Doses higher than 1.25% and below 3% (≈15 capsules per/day)
would not be easily achievable in the human diet except with concentrated products;
they will be referred to as ‘therapeutic’. Doses above 3% will be referred to as ‘supratherapeutical’ because they would be hard to achieve in the human diet even with
concentrated capsule supplements, making findings from previous studies using such
high doses inappropriate to extrapolate to human health (Table 2.1).
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Figure 2.1: Dose relationships of dietary fish oil feeding & rat myocardial DHA & EPA
incorporation. Colours bands represent doses described in Table 2.1. Figure adapted
from Slee, E.L et al., 2010.

Table 2.1: Equivalence of rat fish oil doses to the human diet.
Rat Diet
Human*
Human†
Fish oil %
EPA+DHA
Serve (100g)
weight diet
per/day (g)
salmon/week
5
9.1
33
1.25
2.3
8
0.31
0.57
2

Human‡
Fish Oil
capsule/day
28
6.8
1.7

*Based on human energy intake of 8700 kJ per day, †Based on salmon n-3 content of
1.9g/100g, ‡Based on typical FO capsule content of 330mg EPA+DHA. (Slee et al.,
2010)
Fill represents historically common doses which will be referred to as supratherapeutical in this thesis.
Fill represents the ModFO dose of this study which would require ≈6 FO capsules
per/day in humans.
Fill represents LowFO dose of this study which would require ≈2 salmon [100g]
serve/week in humans.
Abbreviations: DHA = Docosahexaenoic acid; EPA = Eicosapentaenoic acid.
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2.1.3 The effect of fish oil on excitable membrane composition
Skeletal muscle membrane phospholipids incorporate DHA in a very similar fashion to
myocardial phospholipids with dietary intervention. However, very few studies have
investigated the specific incorporation patterns of DHA throughout skeletal muscle fibre
types, and the conclusions have been mixed. Originally, studies demonstrated that DHA
concentrations are highest in SO muscles such as the soleus (Blackard et al., 1997;
Kriketos et al., 1995), but more recently it has been demonstrated that DHA levels are
higher in mixed FOG and FG fibres of the gastrocnemius (Henry et al., 2015). To the
knowledge of the author, no studies to date have investigated the specific phospholipid
incorporation patterns of DHA throughout an entire array of skeletal muscle fibre types
within the one animal. Therefore, systematic investigations to be completed in this
thesis, within the rat, will allow observations to be made for the first time. Phospholipid
DHA incorporation patterns will be determined, with knowledge of the type of muscle
fibre predominantly making up each individual skeletal muscle. Using the rat hind-limb
is the ideal model to investigate a cross section of muscles due to the well-known and
consistent fibre type composition profile available (Armstrong & Phelps, 1984).
Additionally, the use of the rat allows for sampling of heart and skeletal muscle tissue
from within the same animal. Most importantly, the use of an animal model allows for
precision dosing of LC n-3 PUFA and removes the influence of exercise training which
is difficult to control in human trials, allowing definitive separation of dietary groups
and confident conclusions to be made as a direct result of altering the diet only.
Furthermore, all animals in the dietary investigations of this thesis will be fed a Control
diet which contains 5% SFA, 2.5% SSO and the remaining 2.5% will be OO which will
be exchanged for FO to provide a LowFO (0.31%) and ModFO (1.25%) diet. This
replicates a typical Western style diet more closely with a high SFA and high ratio of n6 to n-3 PUFA content (USDA, 2016) than previous low dose studies (Henry et al.,
2015; Slee et al., 2010). Therefore, the primary objective of the this study was to
characterise the influence of providing human dietary achievable FO doses, for four
weeks, on phospholipid DHA incorporation across a range of skeletal muscles and
myocardium within the rat.
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2.1.4 The effect of fish oil on skeletal muscle mass
Incorporation of LC n-3 PUFA into skeletal muscle phospholipids is associated with
anti-catabolic and/or anabolic properties leading to maintenance of and increased lean
muscle mass. Skeletal muscle hypertrophy occurs when the ratio of muscle protein
synthesis exceeds that of muscle protein breakdown (Phillips et al., 1997).
Supplementing therapeutic doses of FO has been demonstrated to improve muscle
protein synthesis rates independent of training in elderly, middle-aged and young
individuals (Smith et al., 2011; Smith et al., 2015). Muscle protein synthesis rates in
mammals are closely linked to the rapamycin complex and key regulatory kinases,
including mTOR, p70S6K1 and focal adhesion kinase (Dickinson et al., 2011).
Supplementation of FO in humans has been demonstrated to increase phosphorylation
of mTOR and p70S6K1 (Smith et al., 2011), increase the total protein content of focal
adhesion kinase (McGlory et al., 2014) and altered mitochondrial function along with
extracellular matrix organisation (Yoshino et al., 2016). Animal studies have
demonstrated that supra-therapeutical doses of FO stimulates endogenous glucose
production and increases phosphorylation of anabolic signaling kinases in ageing rats
(Kamolrat et al., 2013), enhances insulin-sensitive protein metabolism in steers
(Gingras et al., 2007), reduce myosin heavy chain loss during hindlimb immobilisation
in the rat (You et al., 2010) and enhance gene expression of growth regulatory factors
involved in myogenesis (Castillero et al., 2009). Given the evidence, it is likely that LC
n-3 PUFA is acting through a combination of the mechanisms discussed to increase
muscle protein synthesis rates resulting in increased skeletal muscle mass. As such, the
second objective of this study was to determine the influence of human dietary
achievable FO doses on skeletal muscle mass.
2.1.5 The effect of fish oil on body weight
In contrast to the lean tissue anabolic effects of LC n-3 PUFA discussed, it has also
been suggested that increasing FO intakes may help reduce body weight in humans via
an anti-obesity effect (Buckley & Howe, 2009, 2010; Couet et al., 1997; Kabir et al.,
2007). The changes in body weight observed with FO supplementation in humans have
been attributed to changes in fat oxidation pathways, gene expression, altered energy
expenditure (Baillie et al., 1999; Couet et al., 1997), suppression of appetite
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(Thorsdottir et al., 2007) and reduced fat deposition (Baillie et al., 1999). Animal
studies have provided some evidence to support this by demontrating that FO
supplementation can attenuate body fat gain in obesogenic dietary models (Belzung et
al., 1993), particularly visceral fat accumulation (Ruzickova et al., 2004) and reduce
body weight in mice which were obese before supplementation began (Huang et al.,
2004). However, the animal research that supports effects in obesity to date has used FO
doses which are extremely high even in reference to supra-therapeutical doses (5 to 60%
wt/wt, equivalent in man to FO: 28g/d and more) and could not be achieved in the
human diet. Therefore, the third objective of this study was to determine the influence
of human dietary achievable FO doses, provided in the presence of a typical Westernstyle background diet, on body weight in rats.
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2.2 AIMS AND HYPOTHESES

The primary aim of this study was to establish fatty acid composition of a range of
skeletal muscles and myocardial phospholipids in the rat following supplementation of
FO doses achievable within a typical Western-style human diet. The secondary aim was
to describe the effect of FO on skeletal muscle mass and identify any changes to whole
body weight.
Specifically, these experiments had the following aims and hypotheses:
Aim 1: Determine the influence of supplementing human dietary achievable FO doses
to a typical Western-style diet on phospholipid DHA concentrations in excitable tissues
including cardiac and skeletal muscle from within the same animal.
Hypothesis 1: Myocardial and skeletal muscle phospholipids will
incorporate DHA at the expense of total n-6 PUFA concentrations, in
particular AA.
Hypothesis 2: Incorporation of DHA into skeletal muscle phospholipids will
be muscle fibre type specific.

Aim 2: Quantify if the supplementation of human dietary achievable FO doses to a
typical Western-style diet high in SFA and n-6 PUFA influences muscle mass.
Hypothesis 3: Incorporation of LC n-3 PUFA into skeletal muscle
phospholipids will result in increased muscle mass.

Aim 3: Describe the influence of supplementing human dietary achievable FO doses to
a typical Western style diet high in SFA and n-6 PUFA on body weight.
Hypothesis 4: The addition of human dietary achievable FO doses to a
typical Western-style diet will attenuate weight gain.
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2.3 METHODS

2.3.1 Animals & ethical considerations

A primary cohort (cohort 1) of twenty three (23) male rats (Sprague Dawley) was used
for the general methods of this thesis (Chapter 3) and a second cohort (cohort 2) of sixty
two (62) male rats (Sprague Dawley) were used for the investigations of the effects of
LC n-3 PUFA on biochemical and physiological outcomes (Chapters 2, 4, 5 & 7). All
animals were obtained from the Animal Resource Centre (Perth, Western Australia) and
housed at the University of Wollongong’s animal housing facility. All experiments
contained within this thesis were approved by the University of Wollongong animal
ethics committee and were conducted according to the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes (NHMRC, 2004).
2.3.2 Standardisation
The animals were housed with a 12-hour light-dark cycle, and the temperature
maintained between 20°C-22°C. Animals were able to access food and water ad libitum
prior to the feeding protocol beginning. All animals were weighed upon arrival at the
animal housing facility and before any experiments taking place.
2.3.3 Diet composition
Animals were randomly assigned to one of three isoenergetic prefabricated diets after
consuming regular lab chow for a minimum of one week. The pre-fabricated diets have
been previously developed for use in similar feeding studies (Slee et al., 2010). All diets
contained 10% fat, 50% carbohydrate and 20% protein by weight plus minerals and
vitamins based on the American Institute of Nutrition AIN-93M diet (Reeves, 1997),
differing only in the fatty acid composition making up the total fat. All components
used in the diets were carefully weighed and combined in the laboratory by the primary
investigator and then frozen at -20ºC to ensure quality control. A small amount of food
dye was added to the mixture to allow identification of the different dietary groups. The
diets contained a balanced mix of macro and micro nutrients consisting of (as a
percentage of dry weight) 56.5% corn-starch, 10% sucrose. 9% casein, 5% fibre, 10%
oil, 1% vitamin mix and 3.5% mineral mix (Table 2.2). Four sources of fats and oils
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were used to make up the total 10% of fat in the diet. All diets contained 5.5% beef
tallow, 2.5% n-6 PUFA rich sunflower seed oil and the remaining 2.5% was made up of
olive oil. This specific mix of oils was used to replicate the high amounts of SFA and n6 PUFA found in a typical western diet (Simopoulos, 2008; USDA, 2016). Extra light
olive oil was used as the refining process to produce extra light olive oil removes the
majority of the antioxidant polyphenols commonly present in less refined oils. FO
(0.31% - LowFO, 1.25% - ModFO) was substituted for olive oil using DHA-rich tuna
FO (Nu-Mega Ingredients Pty Ltd, Australia) to create experimental groups. The DHArich tuna FO provided LC n-3 PUFA concentrations of 26% DHA and 7% EPA, with
the remaining major fatty acids being made up of 20% 16:0 Palmitic acid and 15% 18:1
Oleic acid (Table 2.3). The experimental doses of FO used in this thesis were selected
as they were calculated to be equivalent to doses that are achievable in the human diet
and they have previously been demonstrated to increase incorporation of LC n-3 PUFA
into myocardial and skeletal muscle phospholipids (Henry et al., 2015; Slee et al.,
2010). Conversion of doses from rat to human equivalent is completed based on an
average human energy intake of 8700kJ per/day, average salmon n-3 PUFA content of
1.9g/100g and the typical capsule content of 330mg EPA+DHA (Slee et al., 2010). The
equivalent rat energy intake is approximately 325kJ/day, based on a 300g rat eating
approximately 20g/day prefabricated food.
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Table 2.2: Nutrient composition of rat diets.
Ingredient

Amount

Source

Cornstarch
Sucrose
Casein
Fibre
Vitamin
Mineral
Oil*
Gelatine
Total
Water

565g
100g
90g
50g
10g
35g
100g
50g
1000g
400mL

Frutex (Aus)
Commercially available
Rogers & Company (Aus)
MP BioMedicals (Aus)
MP BioMedicals (Aus)
MP BioMedicals (Aus)
Variable sources
Commercially available

*Oil composition was different in each diet, see Table 2.3.
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Table 2.3: Proportion of oils and fatty acids of all three diets.
Control

LowFO

ModFO

Beef Tallow

5.5%

5.5%

5.5%

Sunflower Oil

2.5%

2.5%

2.5%

Olive Oil

2.0%

1.69%

0.75%

0%

0.31%

1.25%

14:0
16:0
18:0
18:1n-9
18:2n-6 (LA)
18:3n-3 (ALA)
20:4n-6 (AA)
20:5n-3 (EPA)
22:5n-3 (DPA)
22:6n-3 (DHA)

2.04
17.21
12.07
41
19.29
0.55
0.02
0
0
0

2.13
17.51
12.14
39.12
19.07
0.55
0.08
0.22
0.03
0.89

2.41
18.40
12.37
33.45
18.43
0.56
0.24
0.87
0.14
3.61

Σ SFA
Σ MUFA
Σ PUFA
Σ n-6 PUFA
Σ n-3 PUFA
Σ EPA + DHA
n-6:n-3

32.22
43.73
19.9
19.35
0.55
0
35.35

32.73
42.06
20.89
19.19
1.69
1.11
11.32

34.28
37.01
23.87
18.7
5.17
4.48
3.62

Fat Source (% of diet)

DHA-rich Tuna FO
Fatty Acid Profile (% fat in diet)

Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 18:0 = stearic acid; 18:1n-9 = oleic
acid; 18:2n-6 = linoleic acid (LA); 18:3n-3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic
acid (AA); 20:5n-3 = eicosapentaenoic acid (EPA); 22:5n-3 = docosapentaenoic acid (DPA);
22:6n-3 = docosahexaenoic acid (DHA); SFA = saturated fatty acid; MUFA =
monounsaturated fatty acid; PUFA = polyunsaturated fatty acid.
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2.3.4 Dietary feeding protocol
Animals were randomly placed on the pre-fabricated diet between 8-10 weeks of age
and allowed ad libitum access to the diet and water for a minimum of four (4) weeks
and a maximum of six (6) weeks. Animals and their food were checked every two days
to ensure the diet was being consumed and there were no signs of animal distress. All
animals were weighed before beginning the diet and then weighed once again before
experimental procedures.
2.3.4a Body weight and food intake measurements
A subgroup (N=32) of animals were investigated throughout the feeding protocol to
determine if there were any differences in feeding patterns or weight gain with the
different oils. Food intake was measured twice weekly to the nearest gram and then
normalised to grams consumed/100 g body weight/day. Body weight change was
measured weekly to the nearest gram, and tissue was collected at the end of the feeding
protocol. A correction factor was calculated for the daily evaporation of water weight in
the different diets while stored in the same environmental conditions as the animals to
make an accurate measurement of the amount of food consumed by the animals.
2.3.5 Tissue collection
Note: The methods and results for tissue collection and biochemical analyses are
reported in this chapter. However, the animals used for tissue collection were
anaesthetised and physiological protocols (Chapter 4, 5 and 7) were undertaken
beforehand. Upon completion of the protocols animals were euthanased via rapidly
removing the heart from the animal and exsanguination and tissue collection began.
2.3.5a Cardiac tissue collection
The major vessels were cut from the heart, and the heart was submerged into an ice cold
perfusate to arrest beating. Excised hearts were then flushed with an ice cold 0.9% NaCl
solution to remove any remaining blood. The great vessels were then dissected off the
heart, and the heart was weighed to obtain a heart mass. The atria were dissected off to
obtain a ventricle mass, and the right ventricle was dissected off to obtain a left ventricle
mass. The left ventricle was then sliced in 2mm diameter pieces and immediately frozen
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in liquid nitrogen, then stored at -80oC until fatty acid or tissue morphological and
biochemical analyses.
2.3.5b Skeletal muscle tissue collection
Following exsanguination and removal of the heart, muscles were dissected from the
left lower limb. An incision was made from the ileum toward the foot, and the skin was
removed via blunt force. A selection of muscles from the upper thigh and lower limb
were then carefully dissected. Physical force was used to separate larger muscle groups
into red, white and red/white sections (Armstrong & Phelps, 1984). Surgical scissors
and curved forceps were used to separate the fascia between smaller muscle groups
being dissected; scissors were used to remove any remaining connective tissue/tendon.
Following muscle dissection, the tibia was removed via cutting the ligaments at the
knee and ankle using a scalpel and then measured to the nearest millimetre.
2.3.5c Skeletal muscle mass measurement
Following dissection, a pre-defined selection of muscles representing a cross section of
SO, FG and FOG fibre types from the left thigh and lower limb were weighed to the
nearest milligram. The muscles of the upper limb included the: quadricep(red),
quadricep(white), quadricep(mixed), pectineus and adductor longus. Muscles from the lower
limb included the: soleus, gastrocnemius(red), gastrocnemius(white), gastrocnemius(mixed)
plantaris, extensor digitorum longus (EDL) (Table 2.4).

Muscles which were

predominantly made up of SO fibres included: soleus and Adductor longus. Muscles
which were predominantly made up of FG fibres included: quadricep(white),
gastrocnemius(white), EDL and pectineus. Muscles which were predominantly made up of
FOG fibres included: quadricep(red), gastrocnemius(red) and plantaris (Armstrong &
Phelps, 1984). Following measurements, each muscle was immediately frozen in liquid
nitrogen using liquid nitrogen cooled tongs. Muscles were then stored at -80oC until
fatty acid or tissue morphology analysis.
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Table 2.4: Known fibre-type composition of the selected rat hind-limb muscles
used to analyse LC n-3 PUFA phospholipid concentrations.
Skeletal muscle
Upper-limb
quadricep(red)
quadricep(white)
pectineus
adductor longus
Lower-limb
soleus
gastrocnemius(red)
gastrocnemius(white)
plantaris
extensor digitorum
longus (EDL)

Mass (g)

Fibre type (% population)
FOG
FG
SO

0.75 ± 0.02
0.78 ± 0.06
0.28 ± 0.01
0.10 ± 0.01

53 ± 9
25 ± 6
35 ± 4
18 ± 4

40 ± 8
74 ± 6
55 ± 4
1±1

7±1
1±1
10 ± 2
81 ± 4

0.19 ± 0.02
0.15 ± 0.03
0.13 ± 0.01
0.45 ± 0.03

13 ± 4
62 ± 3
16 ± 3
50 3

0
8±4
84 ± 3
41 ± 3

87 ± 4
30 ± 2
0
9±1

0.23 ± 0.08

42 ± 7

56 ± 8

2±1

Typical muscle mass and fibre type population (%) according to FOG, FG & SO
classifications of the rat hind-limb skeletal muscles measured in this study. Ordered by
muscle mass (heaviest to lightest). Table adapted from Armstrong et al. 1984.
Abbreviations: FOG = fast oxidative glycolytic; FG = fast glycolytic; SO = slow oxidative.

34

2.3.6 Membrane phospholipid fatty acid analysis
The fatty acid composition of heart and skeletal muscle tissue collected at the end of
experimental procedures was analysed using gas chromatography to determine
phospholipid LC n-3 PUFA incorporation of DHA and EPA. The following outlines in
detail the acidified total lipid extraction (Folch et al., 1957), solid phase separation into
phospholipid fractions (Kim & Salem, 1990) and transesterification (Lepage & Roy,
1986) techniques used in this study. All solvents used throughout the process contained
0.01% butylated hydroxytoluene as an antioxidant.
2.3.6a Total lipid extraction
Heart and skeletal muscle tissue samples were thawed on ice before preparation
occurred. Tissues were cut into sample sizes of 100-150mg and washed with a
phosphate buffered saline solution to remove any external contaminants (blood etc.) and
placed into labelled 2mL Eppendorf tubes. An equal volume of stainless steel beads to
tissue mass were then added to the tube along with 1mL of chloroform: methanol (2:1).
The tubes were capped and then placed in a cardiac tissue homogenization blender
(Bullet Blender®, Next Advance Inc, New York, USA) and homogenised following the
manufacturer's instruction’s for 4 minutes at speed 8. The homogenates were then
transferred to labelled Pyrex PTFE screw cap tubes and another 2mL of chloroform:
methanol was used to wash out Eppendorf tubes. The samples were then rotated for 3-4
hours at 4ºC to separate lipid from protein. Following rotation, 2mL of 1M H2SO4 was
added to the tubes, and they were vortexed for 10seconds before being centrifuged at
1000rom (210 x g) and 4ºC for 10min (Hettich Zentrifugen Rotina 46 R). The top (acid)
layer was removed to a waste beaker, and a Pasteur pipette was used to go through the
middle protein plug and transfer the bottom solvent layer into new tubes. A further 2mL
of 1M H2SO4 was added, and the procedures described above were repeated. The
bottom layer was then again collected, and a small amount of sodium hydrosulphite was
added, and the tube was shaken to remove any remaining aqueous phase. The solution
was then filtered through a Pasteur pipette with a small amount of silane treated glass
wool pushed down into the stem of the pipette and stored at -20ºC overnight.
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2.3.6b Phospholipid separation
The samples were dried down under nitrogen while sitting in a heating block set at
37ºC. The phospholipid filters (Sep-Pak Silica Classic Filters, Waters Corporation,
NSW, AUS) were numbered and placed into holding racks with 10mL glass syringes
inserted into the filters as the reservoir for solvents. The filters were washed with 5mL
hexane before running the samples through the filter. Once samples were dry, 5mL of
hexane was added to bind the lipids in the tube and given a vortex (10sec) before being
passed through the filters. A further 3mL hexane was used to wash out test tubes, and
this was run through the filter also. Triglycerides were then eluted with 3 x 5mL ethyl
acetate and discarded. Phospholipids were eluted with 3 x 5mL methanol.
2.3.6c Transesterification
Extracted phospholipids were dried under nitrogen in a heating block and then
redissolved in 2mL methanol: toluene (4:1 v/v). A Gilson positive displacement pipette
was used to add 200µL of the volatile acetyl chloride to the culture tubes very slowly
while vortexing to methylate the samples. Teflon tape was then wrapped clockwise
around the thread of the tubes, and they were capped tightly. The tubes were placed into
a heating block which had been pre-heated to 100ºC for sixty minutes. This enhances
the methylation process of the fatty acids. Following methylation, the tubes were
transferred to a metal rack sitting in icy water and allowed to cool for ten minutes. Very
slowly, 5mL of a 6% solution of potassium carbonate (K2CO3) was added to neutralise
the volatile acetyl chloride. The tubes were transferred to a pre-cooled centrifuge (4ºC)
and spun at 3000rpm (1895 x g) for ten minutes resulting in an upper toluene phase of
fatty acid methyl esters. This upper toluene phase was carefully drawn off and
transferred into labelled gas chromatography vials.
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2.3.6d Analysis using gas chromatography
Samples were analysed using a Shimadzu GC-17A gas chromatograph with flame
ionisation detection. The gas chromatograph used a 30m x 0.25mm internal diameter
capillary column under the following conditions:

Running Conditions:

Injector Temperature: 260 °C
Detector Temperature: 260°C
Carrier Gas: Ultra-high purity hydrogen
Column Flow: 1.54ml/min

Temperature Program:
Initial: 185 °C
Ramp: 5°C / minute for 15 minutes
Maintain: 260 °C for 5 minutes
Total Run time: 20 minutes

Individual fatty acid peaks on the chromatograph were identified by comparison to
authentic fatty acid methyl ester standards (F.A.M.E MIX C4-C24, Sigma-Aldrich,
Castle Hill, Aus). Peak quantitation was calculated by area for corrected normalisation.
The relative proportions of EPA+DHA and other fatty acids in the tissue samples were
divided by the total area of fatty acids to give the relative amount of each fatty acid (%
total fatty acids).
2.3.7 Chemicals
All chemical used in this study were sourced from Sigma-Aldrich (Castle Hill, Aus).
Solvents used in this study including chloroform, hexane, methanol, ethyl acetate and
toluene were analytical grade. Butylated hydroxyl toluene was made up to 0.01% w/v in
saline and added to all solvents as an antioxidant. Sulphuric acid H2SO4 was purchased
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in concentrate and diluted to make a stock 1M solution. Sodium hydrosulphite and
Potassium carbonate (K2CO3) were purchased as powders and stored according to
manufacturer’s instructions before use. Fatty acid standards (F.A.M.E MIX C4-C24,
Sigma-Aldrich, Castle Hill, Aus) were purchased neat and were stored at -20ºC until
use; they were then dissolved in toluene for analysis.
2.3.8 Statistics
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise
stated. The effects of diet treatment on experimental outcomes were tested via ANOVA.
Individual group means were compared using Bonferroni’s post-hoc analysis. All
statistical analyses were performed in a blinded manner and completed using SPSS 21
for Windows (SPSS Inc, Chicago, IL, USA). Alpha was set at p <0.05.
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2.4 RESULTS

Fatty acids are reported as relative percent composition of phospholipid membranes;
minor fatty acids were analysed but omitted from the reported results. Fatty acid
analysis was started from Stearic acid (16:0) in cardiac phospholipids and Myristic acid
(14:0) in skeletal muscle phospholipids and continued until docosahexaenoic acid
(DHA - 22:6n-3).
2.4.1 The effect of fish oil supplementation on cardiac phospholipid fatty acids
Total LC n-3 PUFA content was significantly higher in the LowFO and ModFO group
compared to the Control group. Elevated LC n-3 PUFA concentrations were
predominantly associated with a significantly greater DHA incorporation in both FO
supplemented groups. The composition of DHA in myocardial phospholipids was
5.02% in the Control group, 13.10% in the LowFO group and 18.35% in the ModFO
group (Table 2.5). EPA was not detected in the Control group but was present in both
FO groups (LowFO: 0.11%, ModFO: 0.39%) in very small amounts. Elevated LC n-3
PUFA concentrations were associated with lower total n-6 PUFA content. More
specifically, the LowFO and ModFO groups displayed significantly less AA and LA in
their phospholipid composition compared to the Control group (Table 2.5). As a result
of these differences the n-6:n-3 ratio for both the FO supplemented groups was lower
than the Control group. Additionally, Oleic acid (18:1n-9) and total MUFA was
significantly lower in the ModFO group compared to both the Control and LowFO
group.
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Table 2.5: The effect of fish oil on phospholipid fatty acid composition in the
left ventricle.
Control

LowFO

ModFO

18:3n-3 (ALA)
20:4n-6 (AA)

12.0 (±0.5)
0.79 (±0.1)
22.2 (±0.7)
9.3 (±0.5)
3.4 (±0.1)
26.1 (±1.4)
0.39 (±0.02)
19.7 (±0.6)

13.1 (±0.4)
0.79 (±0.1)
21.4 (±0.3)
8.5 (±0.3)
3.3 (±0.2)
20.8 (±0.6)*
0.43 (±0.01)
16.7 (±0.4)*

13.1 (±0.3)
0.55 (±0.06)*†
23.0 (±0.5)
6.0 (±0.3)*
3.2 (±0.1)
18.5 (±0.6)*
0.39 (±0.02)
14.2 (±0.7)*†

20:5n-3 (EPA)

ND

0.11 (±0.01)

0.39 (±0.02)†

< 0.001

22:5n-3 (DPA)

0.98 (±0.08)

1.3 (±0.1)*

1.3 (±0.02)*

0.002

22:6n-3 (DHA)

5.0 (±0.2)

13.1 (±0.9)*

18.3 (±0.4)*†

< 0.001

Σ SFA
Σ MUFA
Σ PUFA
Σ n-6 PUFA

34.2 (±0.4)
13.5 (±0.7)
52.2 (±0.9)
45.7 (±1.0)

34.5 (±0.3)
12.7 (±0.5)
52.7 (±0.3)
37.7 (±0.7)*

36.1 (±0.8)
9.8 (±0.3)*
53.9 (±0.8)
33.3 (±1.1)*†

< 0.001

Σ n-3 PUFA

6.4 (±0.3)

14.9 (±0.8)*

20.5 (±0.4)*†

< 0.001

Σ EPA + DHA

5.0 (±0.2)

13.1 (±0.9)*

18.7 (±0.4)*†

< 0.001

n-6:n-3

7.1 (±0.4)

2.5 (±0.2)*

1.6 (±0.07) *

< 0.001

16:0
16:1
18:0
18:1n-9
18:1n-7
18:2n-6 (LA)

Trend p

0.031
0.002
< 0.001
< 0.001

0.007

Values are mean ± SEM (n = 4 – 5 per group). ND = Not Detected. *p <0.05 vs Control
diet. †p <0.05 vs LowFO diet (One-way ANOVA with Bonferroni post-hoc test).
Abbreviations: 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 = stearic acid; 18:1n-9 =
oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n-3 = α-linolenic acid
(ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid (EPA); 22:5n-3 =
docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA = saturated fatty
acid; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid.
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2.4.2 The effect of fish oil supplementation on skeletal muscle phospholipid fatty
acids
soleus phospholipid DHA composition was significantly greater in the LowFO
(13.79%) and ModFO (18.98%) groups compared to the Control (8.35%) group (Table
2.6). EPA was not detected in the soleus of the Control or LowFO group but was
present in the ModFO group in a very small amount. The Control group displayed the
highest AA phospholipid concentration (16.61%) and reduced in a dose-dependent
manner in the LowFO (13.46%) and ModFO (10.89%) groups. Other differences unique
to the soleus which occurred in the phospholipid composition included a significantly
lower concentration of LA and Stearic acid in the ModFO group compared to the
Control group (Table 2.6).
quadriceps(red) phospholipid DHA composition was significantly greater in the LowFO
(15.94%) and ModFO (21.72%) groups compared to the Control (11.24%) group
(Table 2.7). EPA was not detected in the quadriceps(red) of the Control but was present
in the LowFO and ModFO groups. The Control group displayed the highest AA
phospholipid concentration (16.19%) and reduced in a dose-dependent manner in the
LowFO (12.23%) and ModFO (9.37%) groups. Other differences unique to the
quadriceps(red) which occurred in the phospholipid composition included a significantly
lower concentration of Vaccenic acid (18:1n-7), LA and ALA in the ModFO group
compared to the Control group (Table 2.7).
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Table 2.6: The effect of fish oil on phospholipid fatty acid composition of the
soleus.
Control

LowFO

ModFO

Trend p

18:1n-9
18:1n-7
18:2n-6 (LA)

4.3 (±0.3)
12.9 (±0.2)
0.94 (±0.1)
19.9 (±0.1)
9.7 (±0.2)
2.7 (±0.1)
21.7 (±0.5)

5.6 (±0.3)
13.6 (±0.6)
0.90 (±0.1)
18.9 (±0.3)
9.9 (±0.9)
2.2 (±0.07)
18.9 (±0.3)

0.03
0.07

18:3n-3 (ALA)

0.70 (±0.02)

0.61 (±0.01)*

5.9 (±0.4)
13.9 (±0.5)
0.7 (±0.1)
18.4 (±0.2)*
7.9 (0.2)
2.3 (±0.0)
17.8 (±0.7)*
0.64 (±0.02)

20:4n-6 (AA)

16.6 (±0.2)

10.8 (±0.6)*†

< 0.001

20:5n-3 (EPA)

0.55 (±0.09)*†
1.7 (±0.1)
18.9 (±0.7)*†

< 0.001

22:5n-3 (DPA)
22:6n-3 (DHA)

ND
1.7 (±0.1)
8.3 (±0.1)

13.4 (±0.4)*
ND
1.6 (±0.1)
13.7 (±0.2)*

Σ SFA
Σ MUFA
Σ PUFA
Σ n-6 PUFA

37.3 (±0.2)
13.4 (±0.3)
49.1 (±0.4)
38.3 (±0.4)

38.3 (±0.4)
13.1 (±1.2)
48.5 (±1.4)
32.4 (±1.3)*

38.2 (±0.3)
11.0 (±0.3)
50.7 (±0.6)
28.7 (±1.1)*

< 0.05

Σ n-3 PUFA

10.7 (±0.1)

16.1 (±0.4)*

21.9 (±0.7)*†

< 0.001

Σ EPA + DHA

8.3 (±0.1)

13.7 (±0.2)*

19.5 (±0.7)*†

< 0.001

n-6:n-3

3.5 (±0.07)

2.0 (±0.07)*

1.3 (±0.09)*†

< 0.001

14:0
16:0
16:1
18:0

0.014
0.013

< 0.001

Values are mean ± SEM (n = 5 per group). ND = Not Detected. *p <0.05 vs Control
diet, †p <0.05 vs LowFO diet (One-way ANOVA with Bonferroni post-hoc test).
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 =
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA
= saturated fatty acid; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty
acid.
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Table 2.7: The effect of fish oil on phospholipid fatty acid composition in the
quadriceps (red).
Control

LowFO

ModFO

Trend p

14:0
16:0
16:1
18:0
18:1n-9
18:1n-7

4.6 (±0.8)
15.5 (±0.3)
0.82 (±0.09)
18.1 (±0.4)
7.4 (±0.2)
3.0 (±0.1)

4.9 (±0.3)
16.8 (±0.5)
1.0 (±0.2)
17.6 (±0.9)
8.0 (±0.2)
2.7 (±0.08)

5.3 (±0.4)
15.8 (±0.5)
0.79 (±0.05)
16.9 (±0.2)
7.1 (0.3)
2.4 (±0.09)*

0.008

18:2n-6 (LA)

20.5 (±0.7)

17.9 (±0.1)

17.8 (±0.8)*

0.029

18:3n-3 (ALA)

0.62 (±0.04)

0.68 (±0.03)

0.5 (±0.02)*

0.022

20:4n-6 (AA)

16.1 (±0.2)

12.2 (±0.3)*

9.3 (±0.5)*†

< 0.001

20:5n-3 (EPA)

a

0.31 (±0.02)
1.7 (±0.1)
15.9 (±0.2)*

0.5 (±0.06)*
1.4 (±0.1)
21.7 (±0.6)*†

< 0.05

22:5n-3 (DPA)
22:6n-3 (DHA)

ND
1.7 (±0.1)
11.2 (±0.3)

< 0.001

Σ SFA
Σ MUFA
Σ PUFA
Σ n-6 PUFA

38.3 (±0.3)
11.3 (±0.1)
50.3 (±0.2)
36.7 (±0.5)

39.4 (±0.6)
11.8 (±0.4)
48.6 (±0.5)
30.1 (±0.3)*

38.1 (±0.5)
10.4 (±0.4)
51.4 (±0.8)†
27.2 (±0.8)*†

0.021
< 0.001

Σ n-3 PUFA

13.6 (±0.4)

18.4 (±0.3)*

24.2 (±0.5)*†

< 0.001

Σ EPA + DHA

11.2 (±0.3)

16.0 (±0.3)*

22.2 (±0.6)*†

< 0.001

n-6:n-3

2.6 (±0.1)

1.6 (±0.03)*

1.1 (±0.05)*†

< 0.001

Values are mean ± SEM (n = 4 – 5 per group). ND = Not Detected. a Only detected in 3
samples. *p <0.05 vs Control diet, †p <0.05 vs LowFO diet (One-way ANOVA with
Bonferroni post-hoc test).
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 =
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA
= saturated fatty acid; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty
acid.
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quadriceps(white) phospholipid DHA composition was significantly greater in the LowFO
(14.05%) and ModFO (20.50%) groups compared to the Control (8.56%) group (Table
2.8). EPA was not detected in the quadriceps(white) of the Control group but was present
in the LowFO and ModFO groups. The Control group displayed the highest AA
phospholipid concentration (17.45%) and reduced in a dose-dependent manner in the
LowFO (15.29%) and ModFO (12.83%) groups. Other differences unique to the
quadriceps(white) included a significantly lower concentration of Oleic acid (18:1n-9) in
the LowFO and ModFO group compared to the Control group and a significantly lower
concentration of LA and Palmitoleic acid in the LowFO group compared to the Control
group (Table 2.8).
extensor digitorum longus (EDL) phospholipid DHA composition was significantly
greater in the LowFO (15.82%) and ModFO (20.71%) groups compared to the Control
(10.82%) group (Table 2.9). EPA was detected in small amounts in the EDL of all
groups; however it was significantly greater in both FO supplemented groups. The
Control group displayed the highest AA phospholipid concentration (15.85%) and
reduced in a dose-dependent manner in the LowFO (13.49%) and ModFO (9.96%)
groups. Other differences unique to the EDL included a significantly higher total PUFA
concentration in the ModFO group compared to the Control group (Table 2.9).
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Table 2.8: The effect of fish oil on phospholipid fatty acid composition in the
quadriceps (white).
Control

LowFO

ModFO

Trend p

6.3 (±0.1)
22.3 (±0.2)
0.82 (±0.03)
14.2 (±0.5)
7.1 (±0.09)*
2.7 (±0.1)
12.7 (±0.6)*
0.8 (±0.03)
15.2 (±0.1)*

5.1 (±0.1)†
21.9 (±0.1)
0.93 (±0.01)
13.7 (±0.1)
7.6 (±0.1)*
2.5 (±0.1)
11.6 (±0.07)*
0.79 (±0.03)
12.8 (±0.3)*†

<0.01

18:3n-3 (ALA)
20:4n-6 (AA)

5.9 (±0.3)
21.7 (±0.4)
0.92 (±0.1)
14.5 (±0.3)
8.7 (±0.1)
2.9 (±0.1)
15.3 (±0.3)
0.96 (±0.05)
17.4 (±0.6)

< 0.001

20:5n-3 (EPA)

ND

0.07 (±0.01)*

0.37 (±0.09)*†

< 0.001

22:5n-3 (DPA)

2.5 (±0.3)

2.3 (±0.1)

1.7 (±0.3)*

0.045

22:6n-3 (DHA)

8.5 (±0.2)

14.0 (±0.4)*

20.5 (±0.3)*†

< 0.001

Σ SFA
Σ MUFA

42.5 (±0.9)
12.6 (±0.2)

40.9 (±0.1)
11.1 (±0.09)*

0.021

Σ PUFA

44.8 (±0.9)

43.8 (±0.6)
10.7 (±0.2)*
45.4 (±0.7)

47.9 (±0.2)*

0.035

Σ n-6 PUFA

32.7 (±0.6)

28.0 (±0.5)*

24.4 (±0.2)*†

< 0.001

Σ n-3 PUFA

12.0 (±0.4)

17.3 (±0.4)*

23.4 (±0.2)*†

< 0.001

Σ EPA + DHA

8.5 (±0.2)

14.1 (±0.4)*

20.8 (±0.2)*†

< 0.001

n-6:n-3

2.7 (±0.06)

1.6 (±0.04)*

1.0 (±0.02)*†

< 0.001

14:0
16:0
16:1
18:0
18:1n-9
18:1n-7
18:2n-6 (LA)

< 0.01

Values are mean ± SEM (n = 5 per group). ND = Not Detected. *p <0.05 vs Control
diet, †p <0.05 vs LowFO diet (One-way ANOVA with Bonferroni post-hoc test).
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 =
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA
= saturated fatty acid; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty
acid.
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Table 2.9: The effect of fish oil on phospholipid fatty acid composition in the
extensor digitorum longus (EDL).
Control

LowFO

ModFO

Trend p

3.2 (±0.1)
19.8 (±0.3)
0.85 (±0.09)
18.1 (±0.5)
8.2 (±0.2)
2.8 (±0.1)
17.7 (±0.5)
0.73 (±0.05)
15.8 (±0.2)

2.8 (±0.2)
20.7 (±0.5)
0.77 (±0.07)
17.2 (±0.2)
7.0 (±0.08)
2.5 (±0.1)
16.7 (±0.7)
0.74 (±0.04)
13.4 (±0.4)*

2.8 (±0.1)
20.2 (±0.1)
0.82 (±0.06)
16.7 (±0.2)
7.9 (±0.2)
2.4 (±0.05)
15.4 (±0.3)
0.71 (±0.02)
9.9 (±0.2)*†

< 0.001

22:5n-3 (DPA)
22:6n-3 (DHA)

0.03 (±0.02)
1.6 (±0.09)
10.8 (±0.2)

0.15 (±0.04)*
1.7 (±0.05)
15.8 (±1.1)*

0.48 (±0.04)*†
1.6 (±0.04)
20.7 (±0.4)*†

Σ SFA
Σ MUFA
Σ PUFA

41.2 (±0.3)
11.9 (±0.2)
46.7 (±0.5)

40.8 (±0.4)
10.3 (±0.2)
48.7 (±0.5)

39.8 (±0.2)
11.2 (±0.2)
48.9 (±0.4)*

0.047

Σ n-6 PUFA

33.5 (±0.3)

30.2 (±0.8)*

25.3 (±0.2)*†

< 0.001

Σ n-3 PUFA

13.2 (±0.1)

18.4 (±1.0)*

23.5 (±0.5)*†

< 0.001

Σ EPA + DHA

10.8 (±0.2)

15.9 (±1.1)*

21.1 (±0.4)*†

< 0.001

n-6:n-3

2.5 (±0.02)

1.6 (±0.1)*

1.1 (±0.03)*†

< 0.001

14:0
16:0
16:1
18:0
18:1n-9
18:1n-7
18:2n-6 (LA)
18:3n-3 (ALA)
20:4n-6 (AA)
20:5n-3 (EPA)

a

< 0.001
< 0.001

Values are mean ± SEM (n = 4 – 5 per group). a Only detected in 2 samples. *p <0.05 vs
Control diet, †p <0.05 vs LowFO diet (One-way ANOVA with Bonferroni post-hoc
test).
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 =
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA
= saturated fatty acid; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty
acid.
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gastrocnemius(red) phospholipid DHA composition was significantly greater in the
LowFO (19.32%) and ModFO (23.07%) groups compared to the Control (12.61%)
group (Table 2.10). EPA was detected in small amounts in the gastrocnemius(red) of all
groups; however it was significantly greater in both FO supplemented groups. The
Control group displayed the highest AA phospholipid concentration (15.83%) and
reduced in a dose-dependent manner in the LowFO (12.29%) and ModFO (9.44%)
groups. Other differences unique to the gastrocnemius(red) included a significantly lower
concentration of Vaccenic acid, ALA and total MUFA in the LowFO and ModFO
groups compared to the Control group. The ModFO group also showed a significantly
lower amount of ALA compared to the LowFO group (Table 2.10).
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Table 2.10: The effect of fish oil on phospholipid fatty acid composition in the
gastrocnemius (red).
Control

LowFO

ModFO

Trend p

14:0
16:0
16:1
18:0
18:1n-9
18:1n-7

3.9 (±0.1)
16.5 (±0.4)
0.23 (±0.08)
17.0 (±0.4)
8.3 (±0.2)
2.8 (±0.1)

4.9 (±0.4)
16.0 (±0.2)
0.20 (±0.01)
16.4 (±0.3)
7.6 (±0.04)
2.3 (±0.08)*

4.1 (±0.2)
17.3 (±0.5)
0.23 (±0.07)
17.4 (±0.2)
7.6 (±0.2)
2.2 (±0.06)*

< 0.01

18:2n-6 (LA)

19.7 (±0.8)

18.1 (±0.7)

16.0 (±0.4) *

0.01

18:3n-3 (ALA)

0.70 (±0.03)

0.59 (±0.07)*

0.49 (±0.07)*†

< 0.001

20:4n-6 (AA)

15.8 (±0.4)

12.2 (±0.1)*

9.4 (±0.3)*†

< 0.001

20:5n-3 (EPA)

0.11 (±0.01)

0.28 (±0.01)*

0.54 (±0.06)*†

< 0.001

22:5n-3 (DPA)

1.9 (±0.1)

1.6 (±0.1)

1.3 (±0.1) *

0.021

22:6n-3 (DHA)

12.6 (±0.2)

19.3 (±0.2)*

23.0 (±0.5)*†

< 0.001

Σ SFA
Σ MUFA
Σ PUFA
Σ n-6 PUFA

37.6 (±0.2)
11.4 (±0.2)
50.9 (±0.3)
35.6 (±0.5)

37.4 (±0.3)
10.2 (±0.1)*
52.3 (±0.4)
30.4 (±0.6)*

38.9 (±0.7)
10.1 (±0.3) *
50.9 (±0.7)
25.5 (±0.7)*†

< 0.001

Σ n-3 PUFA

15.3 (±0.2)

21.8 (±0.1)*

25.4 (±0.5)*†

< 0.001

Σ EPA + DHA

12.7 (±0.2)

19.6 (±0.2)*

23.6 (±0.5)*†

< 0.001

n-6:n-3

2.3 (±0.06)

1.3 (±0.04)*

1.0 (±0.04)*†

< 0.001

< 0.01

Values are mean ± SEM (n = 5 per group). *p <0.05 vs Control diet, †p <0.05 vs
LowFO diet (One-way ANOVA with Bonferroni post-hoc test).
Abbreviations: 14:0 = myristic acid; 16:0 = palmitic acid; 16:1 = palmitoleic acid; 18:0 =
stearic acid; 18:1n-9 = oleic acid; 18:1n-7 = vaccenic acid; 18:2n-6 = linoleic acid (LA); 18:3n3 = α-linolenic acid (ALA); 20:4n-6 = arachidonic acid (AA); 20:5n-3 = eicosapentaenoic acid
(EPA); 22:5n-3 = docosapentaenoic acid (DPA); 22:6n-3 = docosahexaenoic acid (DHA). SFA
= saturated fatty acid; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty
acid.
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2.4.2a Differences in phospholipid composition between muscles following fish
oil supplementation
Total phospholipid LC n-3 PUFA, particularly DHA following dietary FO
supplementation was significantly greater in cardiac muscle and across all skeletal
muscles sampled in the hind-limb for the LowFO and ModFO groups compared to the
Control group. The lowest concentration of phospholipid DHA were observed in the
Control group left ventricle (5.02%) phospholipids and the greatest DHA concentrations
were observed in the gastrocnemius(red) (23.07%) skeletal muscle phospholipids of the
ModFO group (Figure 2.2). When DHA was plotted against the percentage of muscle
fibre type typical for each muscle there was a strong association between % fast
oxidative glycolytic and % phospholipid DHA (Spearman correlation ρ = 0.91, r2 =
0.87). However, no relationship was apparent between % fast glycolytic or % slow
oxidative fibres (Figure 2.3). The association was even stronger when the left ventricle
(not containing FOG) was included in the analysis (ρ = 0.94, r2 = 0.89). Interestingly,
different muscle’s with unique fibre type profiles such as the Control gastrocnemius(red)
(%FOG: 62) and LowFO soleus (%FOG: 13) showed ‘overlap’ of DHA concentrations
(Control gastrocnemius DHA: 12.61%, LowFO soleus DHA: 13.79%) when comparing
between dietary treatments.
Total phospholipid n-6 PUFA following dietary supplementation was significantly
lower in cardiac muscle and across all skeletal muscles sampled in the hind-limb for the
LowFO and ModFO groups compared to the Control group. The lowest concentration
of phospholipid AA were observed in the ModFO gastrocnemius(red) (9.44%) skeletal
muscle phospholipids and the greatest phospholipid AA concentrations were observed
in the left ventricle (19.74%) phospholipids of the Control group. Additionally, LA was
significantly lower in all muscles of the ModFO group except the EDL when compared
to the Control group. These changes in muscle phospholipid composition were reflected
by a significantly lower n6:n3 ratio across all muscle in the LowFO and ModFO groups
following supplementation compared to the Control group.
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Figure 2.2: The effect of supplementing dietary achievable fish oil doses on
phospholipid concentrations of DHA and AA across different muscles.
Values are mean ± SEM (n = 4 – 5 per group). *p <0.05 vs Control diet, †p <0.05 vs
LowFO diet (One-way ANOVA with Bonferroni post-hoc test).
Abbreviations: EDL = extensor digitorum longus; DHA = docosahexaenoic acid; AA =
arachidonic acid.
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Figure 2.3: Spearman correlations of DHA incorporation across cardiac and skeletal muscles with different proportions of muscle fibre
types.
Overlap Zone: A potential area where similar metabolic properties may be displayed in muscles with different fibre type composition but similar
DHA concentration following supplementation. For example, the LowFO muscle with 0% FOG fibres shares similar DHA levels to the Control muscle
with over 60% FOG fibres.
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2.4.3 The effect of fish oil supplementation on tissue mass
The mass of the muscles collected in this study was comparable to previously published
data in the rat (Armstrong & Phelps, 1984). Total heart mass and tibia length were in
the healthy range (Yin et al., 1982). Total heart mass was not significantly different
between groups and this did not change when normalised to tibia length (Table 2.11).
Individual hind-limb skeletal muscles were anatomically referenced to the upper hindlimb or lower hind-limb to calculate a total mass. There were no significant differences
demonstrated between any of the groups for total upper hind-limb or lower hind-limb
muscle mass. Comparison of individual muscle mass was also completed. There were
no significant differences between dietary groups for the mass of any of the individual
muscles measured (Table 2.11). Muscles were categorised into fibre type groups (SO,
FG, FOG) based on the proportion of muscle fibres present within the muscle
(Armstrong & Phelps, 1984). When analysing muscles categorised as SO, FG or FOG
the gastrocnemius(mixed) and quadriceps(mixed) were not included as it is unclear what the
fibre type proportions would have been in these muscles. There were no significant
differences between any of the groups when muscle were analysed in this way (Table
2.11).
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Table 2.11: The effect of fish oil on tissue mass in the rat.
Control

Tibial length (cm)

LowFO

ModFO

4.6 (±0.04)

4.68 (±0.09)

4.63 (±0.04)

1.51 (±0.05)
1.27 (±0.03)
0.98 (±0.02)

1.55 (±0.05)
1.28 (±0.03)
0.99 (±0.03)

1.62 (±0.04)
1.32 (±0.03)
1.04 (±0.03)

0.32 (±0.01)

0.34 (±0.01)

0.35 (±0.01)

0.19 (±0.03)
0.23 (±0.03)
0.22 (± 0.02)
2.03 (±0.09)
0.49 (±0.02)
0.19 (±0.01)
3.39 (±0.12)

0.18 (±0.02)
0.24 (±0.01)
0.20 (±0.01)
2.02 (±0.06)
0.52 (±0.04)
0.17 (±0.02)
3.31 (±0.07)

0.24 (±0.03)
0.29 (±0.04)
0.17 (±0.02)
1.77 (±0.07)
0.47 (±0.03)
0.20 (±0.01)
3.33 (±0.27)

0.26 (±0.02)
0.30 (±0.02)
2.23 (±0.11)
0.14 (±0.03)
0.14 (±0.04)
2.97 (±0.15)

0.25 (±0.01)
0.29 (±0.01)
2.28 (±0.20)
0.11 (±0.01)
0.12 (±0.02)
3.08 (±0.19)

0.31 (±0.03)
0.29 (±0.03)
2.38 (±0.14)
0.10 (±0.02)
0.13 (±0.02)
3.20 (±0.17)

0.34 (±0.03)
0.88 (±0.06)
1.03 (±0.05)

0.29 (±0.02)
0.80 (±0.03)
0.99 (±0.05)

0.42 (±0.27)
0.81 (±0.04)
1.07 (±0.08)

Cardiac muscle mass (g)
^

Total heart
Ventricular
Left ventricle
Total heart/Tibial length
(g/cm)
#

Skeletal muscle mass (g)
Lower hind-limb
soleus
gastrocnemius(red)
gastrocnemius(white)
gastrocnemius(mixed)
plantaris
extensor digitorum longus
Total – Lower hind-limb
Upper hind-limb
quadriceps(red)
quadriceps(white)
quadriceps(mixed)
adductor longus
pectineus
Total – Upper hind-limb
Fibre type
Slow oxidative
Fast glycolytic
Fast oxidative glycolytic

Values are mean ± SEM (n = 12 – 16 per group). ^ Total heart mass included the atria
but not the great vessels. # Ventricular mass included the left and right ventricle. No
statistical significant differences were present between dietary groups.
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2.4.4 The effect of fish oil supplementation on body weight and food consumption
Body weight and food consumption were monitored in a subgroup from the Control,
LowFO and ModFO diets throughout the feeding protocol. There were no significant
differences between the baseline body weights of all groups prior to dietary
supplementation (Table 2.12). Body weight significantly increased at each week of
measurement for all groups (Figure 2.4A). However, there were no significant
differences between any of the groups for total weight gain. The ModFO group
displayed a significantly greater weight gain to week three and four compared to the
Control group (Figure 2.4B). At week four the LowFO group had significantly greater
weight gain compared to the Control group. At the end of the feeding protocol, there
were no significant differences between the groups in post supplementation body weight
or body weight normalised to tibia length (Table 2.10).

Table 2.12: The effect of fish oil on body weight measurements.
Control

LowFO

ModFO

Body weight (pre) (g)

426 (±9)

434 (±11)

425 (±9)

Body weight (post) (g)

512 (±16)

540 (±18)

542 (±14)

Body weight (post)/Tibial length

109 (±3.5)

116 (±4.2)

116 (±2.9)

Key: Pre = Prior to fatty acid supplementation, Post = Following 4 weeks of dietary
fatty acid supplementation.
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Figure 2.4: The effect of fish oil on A: Change in body weight from baseline B:
Body weight at weekly intervals.
Values are mean ± SEM (n = 20 – 22 per group). *p <0.05 vs Control diet, †p <0.05 vs
LowFO diet (One-way ANOVA with Bonferroni post-hoc test).
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Food intake is represented as grams consumed/100grams body weight/day. Food intake
was reduced at each week of the feeding period by all groups (Figure 2.5). There was
no statistically significant interaction found between dietary treatment and food intake

Food intake (g/100g/day)

over the four-week feeding period (p =0.220).

10
8
6
4
2
0

1
Control

2

3
Week

LowFO

4
ModFO

Figure 2.5: The effect of fish oil on food intake at weekly intervals.
Values are mean ± SEM (n = 20 – 22 per group). All values are in grams / 100grams
body weight / day.
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2.5 DISCUSSION

Excitable tissues incorporated LC n-3 PUFA, particularly DHA following
supplementation of FO doses achievable within a typical Western-style human diet
(high SFA and n-6 PUFA). Compared to the Control group, concentrations of DHA in
myocardial phospholipids were more than twice as high in the LowFO diet and
approximately three-fold higher in the ModFO group; some skeletal muscle
phospholipids displayed even greater changes. Higher phospholipid concentration of
DHA predominantly occurred at the expense of n-6 PUFA, particularly AA, although it
was not in direct exchange for only one type of fatty acid or even for n-6 PUFA
entirely. For the first time, this study demonstrated that DHA is incorporated
preferentially into predominantly fast oxidative glycolytic (FOG) fibre type skeletal
muscle membranes compared to slow oxidative (SO) and fast glycolytic (FG) fibre type
membranes. Nonetheless, FO supplementation did not influence individual skeletal
muscle mass or total hind-limb skeletal muscle mass. However, and in contrast to the
fourth hypothesis, relative change of body weight at the completion of supplementation
was greater in the FO diets. The robust and preferential incorporation of DHA into
excitable membrane phospholipids when made available via the diet emphasises the
important role it plays in the healthy physiological functioning of excitable tissue.
2.5.1 Excitable tissue phospholipid LC n-3 PUFA concentrations
Following supplementation of dietary achievable FO doses to animals, substantial
changes were observed in the membrane phospholipid fatty acid composition of all
excitable tissues measured. The current study is the first to report changes in cardiac and
skeletal muscles encompassing a full range of contractile properties. The doses used in
this study were chosen as they are equivalent to what can be achieved in the human diet
either by fish consumption or via supplementation (Table 2.1). A 100g serve of salmon
has been demonstrated to contain 2000mg of LC n-3 PUFA, in the form of EPA
≈550mg and DHA ≈1450mg (USDA, 2009). Considering an average salmon portion is
≈250g, this would require only a single salmon meal per week to achieve equivalent
levels of incorporation as the LowFO dose. The ModFO dose would represent
approximately 7-8 fish meals per week which would be towards the upper boundary of
human dietary achievable doses but is also achievable by taking six FO capsules per day
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(Slee et al., 2010). Therefore, the doses used in this study indicate that a modest
increase in fish intake in humans would alter phospholipid DHA incorporation and
could contribute to some of the physiological benefits displayed in populations with
high habitual intakes of fish.
Higher total phospholipid LC n-3 PUFA concentrations were driven via DHA that
appeared to be preferentially incorporated into excitable phospholipids rather than EPA.
Incorporation of DHA into excitable membrane phospholipids was largely due to the
DHA-rich tuna oil used in the FO diets which contains 30% DHA and only 7% EPA.
Interestingly, myocardial phospholipid DHA composition has been demonstrated to
increase (15.4 > 27.2, ↑ 11.8%) more than phospholipid EPA (0.3 > 3.1, ↑ 2.8%)
composition even when a high EPA oil is used (Pepe & McLennan, 1996).
Notwithstanding, DHA-rich tuna oil was specifically used to better replicate the oils
available in typical oily table fish. Table fish such as tuna, salmon, sardine, mackerel
and anchovy contain naturally higher concentrations of DHA than EPA (Strobel et al.,
2012). Whereas, the supplements used in the majority of RCT predominantly have
much higher doses of EPA than DHA (Bays, 2006). Therefore, the use of DHA-rich
tuna oil in future RCT would allow stronger conclusions to be drawn between the
outcomes described and directly relating them to an increase in fish intake in the human
diet.
The current study demonstrated that when n-6 PUFA and SFA were held constant, inline with levels consumed in the typical Western diet, the supplementation of dietary
achievable FO doses resulted in higher phospholipid DHA concentrations in excitable
tissues of the animals. It has been well established that incorporation of fatty acids into
excitable membrane phospholipids of the rat are reflective of the fatty acids being
supplied in the diet, particularly at therapeutic and supra-therapeutical doses, not easily
achievable in the human diet (Charnock et al., 1986; Peoples & McLennan, 2010; Pepe
& McLennan, 2002). However, in recent centuries the typical n-6 to n-3 ratio in humans
has increased to ≈10:1 from an estimated 1:1 prior to the agricultural revolution
(DeFilippis & Sperling, 2006). It has been suggested that it is essential to reduce the n6:n-3 ratio, by altering intakes of both n-3 and n-6 PUFA, to reduce competition for
phospholipid space and enable phospholipid incorporation of LC n-3 PUFA (Hulbert et
al., 2005; Simopoulos, 2008). However, the recommendation to balance the n-6:n-3
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ratio is based on trials which have altered the amount of LC n-3 PUFA supplied while
maintaining n-6 PUFA levels (Ayre & Hulbert, 1996a; Hulbert et al., 2005). Studies
which have altered both sub-classes of PUFA, demonstrate that incorporation of DHA
into myocardial phospholipids occurs relative to the absolute LC n-3 PUFA supplied in
the diet, regardless of background concentrations of n-6 PUFA (Slee et al., 2010; Stark
et al., 2007a; Stark et al., 2007b). Comparison of myocardial phospholipid
incorporation patterns between studies using dietary achievable FO doses demonstrates
that DHA is preferentially incorporated into myocardial phospholipids, regardless of the
background fat profile (Table 2.13). Results from this study support the latter
observations and extend them to demonstrate that high concentrations of SFA together
with high concentrations n-6 PUFA does not prevent the incorporation of DHA into
excitable phospholipids of the rat. In fact, the incorporation of DHA into myocardial
and skeletal phospholipids resulted in a concomitant reduction of AA in all tissues
measured, with some equal and smaller decreases in LA in some tissues, causing a
reduction in total n-6 PUFA content. These changes resulted in a reduction of the n3:n6
ratio of the phospholipid without changing the total n-6 PUFA being supplied in the
diet.
Table 2.13: Comparison of myocardial phospholipid DHA concentrations from
studies using diets with different background oil blends.
Membrane phospholipid DHA composition
Background oil
Study
blend
Control 0.31%FO
∆
1.25%FO
∆
Henry et al.
(2015)
Slee et al.
(2010)
Slee et al.
(2010)
Current study

OO

6.2

16.8

+10.6

20.4

+14.2

OO

7.7

14.9

+7.2

19.3

+11.6

OO/SSO (High n6 PUFA)
SFA/SSO (High
SFA & n-6
PUFA)

6.7

14.3

+7.6

19.4

+12.7

5.0

13.1

+8.1

18.4

+13.4

Abbreviations: SFA = saturated fatty acid; OO = olive oil; SSO = sunflower seed oil; ∆:=
change from control.

Interestingly, phospholipid DHA composition was not absent in Control animals despite
LC n-3 PUFA being removed from the diet. Animals in the Control diet likely obtained
their phospholipid DHA from several sources. Long chain essential fatty acids,
59

particularly DHA and AA are crucial in the healthy development of the foetus neural
and vascular systems (Crawford, 1993; Crawford et al., 1997). Because of this, these
fatty acids are incorporated very efficiently from maternal into foetal phospholipids via
the placenta throughout the third trimester of pregnancy in a process known as
biomagnification (Ruyle et al., 1990). Additionally, it is well established that the
newborn continues to receive DHA and AA postnatally through maternal breast milk
(Makrides et al., 1996). This means the newborn tissue is supplied with abundant DHA
and is one of the reasons why deficiency studies need to use two generations of animals
to produce a truly DHA-deficient model (Moriguchi et al., 2001).
Another possible source of DHA in the Control animals is via conversion from ALA
that was present in small amounts from OO using ∆ six desaturase enzymes (Gibson et
al., 2013). The conversion of EPA to DHA using this pathway also explains why EPA
was either not detected or only detected in very small amounts, yet DHA was present in
Control animal phospholipids. Incorporation of DHA may have also occurred during the
lab chow feeding before the beginning of the animals being placed on the experimental
diets. Lab chow contains a mixture of protein sources, one of which is fishmeal
containing LC n-3 PUFA (Pepe & McLennan, 1996). Trace amounts of ALA and LC n3 PUFA may also have been present in the Control diet due to their presence in the
casein and starch being used in the diet mixture and contamination of equipment used to
mix the different diets (Greiner et al., 2003). Importantly, this demonstrates the strong
response of excitable tissue including cardiac and skeletal muscle to preferentially
incorporate and maintain even very small amounts of DHA made available.
2.5.2 Excitable tissue membrane phospholipid fatty acid differences
Very few studies have investigated the specific incorporation patterns of DHA
throughout muscle fibre types, and the conclusions have been mixed. Some studies have
demonstrated that DHA levels are highest in SO muscles such as the soleus (Blackard et
al., 1997; Kriketos et al., 1995) but more recently it has been demonstrated that DHA
levels are higher in mixed FOG and FG fibres of the gastrocnemius (Henry et al., 2015).
In this study, muscles with an abundance of SO fibres such as the soleus and
quadriceps(white) had the lowest concentration of DHA, whereas muscles with high
proportions of FOG fibres such as the gastrocnemius(red) and quadriceps(red) had the
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highest DHA concentrations. Therefore, this study supports the findings demonstrated
by Henry et al. 2015, and extends them to demonstrate that DHA incorporation into
skeletal muscles is strongly correlated with the population of FOG muscle fibres in the
rat hind-limb. The contrasting findings demonstrated by Kriketos et al. 1995 and
Blackard et al. 1997 can be accounted for by differences in dietary feeding protocols.
The current study used a diet which contained 10% fat wt/wt, whereas the diet used by
Kriketos et al. 1995 contained 59% fat wt/wt, which does not represent a diet relevant to
human nutrition and likely influenced muscle phospholipid fatty acid incorporation
patterns. Animals in the study conducted by Blackard et al. 1997 were fed lab chow ad
libitum before measurements were made. Lab chow contains a mixture of protein
sources, one of which is fishmeal containing DHA (Pepe & McLennan, 1996).
Incorporation of DHA may have occurred as a result of lab chow feeding artificially
increasing phospholipid DHA concentrations of the soleus. Importantly, Control
animals in this study were fed a pre-fabricated diet which did not contain any DHA and
all muscles compared were sampled from within the same animal, allowing a precise
representation of incorporation patterns. Therefore, this study investigated tissue DHA
incorporation in a systematic way, confirming differences and establishing a pattern
associated with muscle fibre type. For the first time, muscle fibre type dependent
incorporation of DHA was demonstrated in the rat, with FOG muscles able to
preferentially incorporate DHA and maintain it in the phospholipid at higher
concentrations than FG and SO muscles, even in the absence of FO supplementation.
Previous research has demonstrated that incorporation of DHA into skeletal muscle
membrane phospholipids results in improved fatigue resistance (Peoples & McLennan,
2010), maintained force development over a range of contraction patterns (Henry et al.,
2015) and enhanced oxygen efficiency (Peoples & McLennan, 2010). Human studies
have also demonstrated several unique physiological roles for FO during exercise which
may contribute to improved muscular performance (Mickleborough, 2013) and
improved whole body oxygen efficiency (Peoples et al., 2008). Therefore, although not
investigated directly in this study, the correlation between greater DHA concentrations
and high proportions of FOG muscle fibres is likely linked to the physiological
properties of the muscle.
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Muscle fibres of the quadriceps(red) and gastrocnemius(red) are predominantly used for
powerful and rapid contractions such as jumping and sprinting. This type of contraction
is suited to FOG muscle fibres as it requires a high turnover of rapidly produced ATP
via non-oxidative pathways. These types of muscles display a high proportion of the
MHC2 isoform that rapidly fatigues due to high rates of ATP consumption and small
ATP reserves (Han et al., 2001). Comparative physiology studies have demonstrated
that mammals which rely upon FOG muscle fibres for increased running speeds are
closely associated with high concentrations of PUFA in skeletal muscle membrane
phospholipids irrespective of the animals diet (Ruf et al., 2006; Valencak et al., 2003).
Whereas, cardiac and soleus membranes which, respectively, display high amounts of
the MHCβ and MHCslow isoform, had the least amount of DHA. These MHC isoforms
are associated with low basal rates of ATP consumption and high ATP reserve capacity
to serve their similar physiological function of slow and regular contractions without
fatigue (Han et al., 2001). Therefore, differences in ATP turnover and storage displayed
within these isoforms of MHC may be one reason for the associated differences in DHA
incorporation displayed between FOG and SO muscles in this study.
It is well-established that mitochondrial membrane phospholipids are intricately
involved in the electron transfer and oxidative phosphorylation pathways of ATP
production (Fleischer et al., 1962). Due to the reliance upon ATP, the ventricle and
soleus contain very high concentrations of mitochondria relative to FOG muscles fibres
of the quadriceps(red) and gastrocnemius(red), which predominantly use non-oxidative
metabolism to generate ATP. Mitochondrial phospholipids naturally contain less PUFA
than the whole tissue; this difference in phospholipid composition is proposed to be a
result of selective pressure towards oxidative damage resistant membranes to counteract
the increased concentrations of reactive oxygen species in the vicinity (Tsalouhidou et
al., 2006). Membrane fractions were not separated in this study when measuring fatty
acid composition. This is important because the mitochondrial membrane would contain
lower relative concentrations of PUFA, which would contribute to reduced whole tissue
phospholipid LC n-3 PUFA. Therefore, the lower phospholipid DHA concentrations
measured in ventricular and soleus tissue could also be associated with the overall high
proportion of mitochondrial membranes making up the whole tissue measurement.
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Cardiac and skeletal muscles are intimately reliant upon the efficient movement and
handling of Ca2+ in the sarcoplasmic reticulum (SR). In particular FOG muscle fibres
have been demonstrated to have extensive networks of SR (Welch & Altshuler, 2009),
and these muscles were associated with much higher levels of DHA. Phospholipids in
the rabbit (Gould et al., 1987) and trout SR have been demonstrated to incorporate
DHA at high levels, even when the diet is deficient of PUFA (Ushio et al., 1997).
Higher phospholipid DHA concentrations in SR phospholipids helps explain why SRrich predominantly FOG muscle fibres of the quadriceps(red) and gastrocnemius(red) were
observed to have the highest phospholipid concentrations of DHA in this study. The SR
is responsible for excitation-contraction coupling in both cardiac and skeletal muscle.
This is an energy dependent pathway which relies on the sarcoplasmic reticulum Ca2+
ATPase (SERCA) active pump.
It is well established that membrane protein interactions and function can be affected by
changing the phospholipid fatty acid composition (Bretscher, 1973). The role of
SERCA in the membrane is to transfer Ca2+ from the cytosol to the lumen of the SR via
active ATP hydrolysis during muscle relaxation (Endo, 1977). Therefore, muscles made
up of majority FOG fibres which produce rapid and powerful contractions such as the
quadriceps(red), and gastrocnemius(red) rely upon SERCA to cycle Ca2+ efficiently to
allow repeated contractions. Comparative biology studies have shown that pectoral
muscles in the hummingbird or shaker muscles in the rattlesnake which both contract
very rapidly and require efficient SERCA activity incorporate LC n-3 PUFA,
particularly DHA preferentially into the SR compared to other muscles within the
animal (Infante et al., 2001). Additionally, skeletal muscle in rat’s supplemented FO has
been demonstrated to be more resistant to fatigue and able to maintain contractile force
production (Henry et al., 2015; Peoples & McLennan, 2010, 2014). Therefore, it
appears likely that when made available in the diet, DHA is preferentially incorporated
into FOG membranes because of the high proportion of SR membrane, leading to
improved SERCA activity.
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2.5.3 Skeletal muscle mass
There was no evidence of catabolic or anabolic properties associated with FO
supplementation from the skeletal muscle mass measured in healthy animals from this
study. This finding contrasts the demonstration of FO producing anabolic effects in
healthy elderly subjects with (Da Boit et al., 2016) or without resistance training (Smith
et al., 2015). However, the Control group in the study conducted by Smith et al. 2015,
on average had a reduction of 1% thigh muscle volume, and the FO group showed an
increase of 2%. The catabolic changes observed in the Control groups muscle volume
were much greater (∼1% over six months) than what normally occurs with ageing
(∼0.5%-1%/y) (Goodpaster et al., 2006). This made the overall muscle volume change
effect between groups larger than if FO had only been compared to the group’s relative
baseline levels.
The evidence provided of an anabolic effect of FO supplementation in these studies is
when the skeletal muscles are in a state of decay e.g., sarcopenia associated with ageing
rather than a healthy state which is likely why they contrast to the current findings of
this study. In fact, eight weeks of FO supplementation in healthy, resistance-trained
males has been shown to have no effect on muscle protein synthesis (McGlory et al.,
2016). Several recent reviews have also come to similar conclusions that FO
supplementation results in an anti-catabolic rather than an anabolic effect in skeletal
muscle (Jeromson et al., 2015), particularly in older individuals (Molfino et al., 2014).
A large-scale three-year cross-sectional study of elderly patients supplemented FO
demonstrated protection against physical performance decline (Abbatecola et al., 2009).
The maintenance of physical performance was likely due to attenuation of muscle mass
loss rather than increased muscle protein synthesis. Animal studies have demonstrated
that muscle mass loss is attenuated in the tibialis anterior during a cachetic cancer model
(van Norren et al., 2009) and also in a burn injury model using the guinea pig
(Alexander et al., 1986). Similarly, soleus muscle atrophy measured via muscle mass
and myosin heavy chain levels was alleviated in an immobilisation protocol of rats fed a
diet rich in FO (You et al., 2010). Lean body mass is also preserved in patients
following oesophageal cancer surgery when EPA enriched enteral nutrition is used
following the surgery (Ryan et al., 2009). When these findings are combined with
results observed in this study, it does not seem likely that dietary achievable FO doses
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induce an anabolic or catabolic effect in skeletal muscle. Dietary achievable FO doses
may play a role in attenuating muscle loss in diseased conditions or conditions of
muscle decline such as sarcopenia associated with ageing. However, further research is
needed to understand whether it has a role in promoting anabolic actions in healthy
skeletal muscle.
2.5.4 Body weight management
Both FO groups had gained significantly more weight than the Control group by week
four of the feeding protocol, despite no increases in skeletal muscle mass and no
changes observed in food intake. This indicates that FO did not restrict body weight
gain in healthy lean animals following four weeks of supplementation with dietary
achievable doses. This finding aligns with non-obesogenic aninmal studies which
consistently demonstrate that there is no significant effect of FO on weight management
when using dietary achievable, therapeutic and supra-therapeutical doses of FO, and
feeding durations ranging from four weeks to thirty months (Table 2.14). However,
these findings along with the findings from the current study are in contrast to some
studies in rodents that have demonstrated an attenuation of body fat accumulation in
growing (Baillie et al., 1999; Hainault et al., 1993) and adult (Belzung et al., 1993;
Huang et al., 2004; Ruzickova et al., 2004) animals exposed to obesogenic high-fat
diets incorporating supra-therapeutic doses of LC n-3 PUFA. The conflicting
conclusions between studies investigating a weight management effect of FO can be
explained by the trial design and dietary supplementation methods used.
The anti-obesity effect is consistently attributed to reductions in visceral adipose tissue
deposition (Baillie et al., 1999; Hainault et al., 1993; Huang et al., 2004; Ruzickova et
al., 2004). Diets high in SFA promote fat deposition to visceral adipose tissue (Rosqvist
et al., 2014). The diets used in this study contained 10% background fat made up by 5%
animal fat (high in SFA), 2.5% SSO (high in n-6 PUFA) and 2.5% OO (high in MUFA,
which was substituted to make FO diets) to replicate a typical Western-style dietary fat
distribution. Importantly, the diets in this study did not exchange SFA out of the diet for
increased amounts of FO as is commonly performed in obesogenic models (Baillie et
al., 1999; Hainault et al., 1993; Huang et al., 2004; Ruzickova et al., 2004). It has also
been hypothesized that appetite suppression may be a mechanism by which FO can lead
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to weight reduction (Thorsdottir et al., 2007). However, there were no significant
differences in food intake levels in FO supplemented animals in this study, in line with
several other animal studies (Kamolrat et al., 2013; Peoples & McLennan, 2014).
Interestingly, some human studies have also suggested that supplementing LC n-3
PUFA to the diet has a weight loss effect (Couet et al., 1997; Kabir et al., 2007),
particularly when supplementation occurs in combination with exercise training
(Buckley & Howe, 2009, 2010). The results from the current study showing greater
weight gain, aligns with evidence of increased oxygen efficiency following FO
supplementation in animals (Pepe & McLennan, 2002; Pepe & McLennan, 2007) and
humans (Hingley et al., 2017; Peoples et al., 2008). This suggests that there is no
potential for FO alone to produce a weight reduction effect and perhaps its efficacy in
conjunction with exercise is due in part to the ability of FO to increase exercise capacity
through improved fatigue-resistance (Henry et al., 2015; Hingley et al., 2017; Peoples
& McLennan, 2010). Therefore, it appears that in the presence of unchanged SFA
intakes, dietary achievable and therapeutic FO doses alone do not produce a weight loss
effect but may provide fatigue-resistance to enhance the weight loss effects attributable
to exercise.
2.5.5 Conclusions
It is now well established that obesity may lead to the development of hypertension,
type II diabetes and atherosclerosis which are all high-risk factors for cardiovascular
disease (Yusuf et al., 2001). Collectively, previous epidemiology, intervention trials and
animal research has demonstrated a cardio-protective effect of fish consumption (Burr
et al., 1989; McLennan, 2014; Mozaffarian & Wu, 2011). It is well established that
obesity is associated with CVD outcomes, as such it has been hypothesised that the
ability of FO to aid weight loss in obesity may reduce the risk of obesity driven CVD
outcomes (Buckley & Howe, 2010). However, this study showed results that FO doses
achievable within a typical Western-style human diet did not have a weight reduction
action. This suggests that FO at these doses has questionable relevance to weight gain
management and is likely acting via another mechanism (anti-arrhythmic, heart rate
lowering, improving heart rate variability) to provide protection from cardiovascular
disease, which will be explored further in the proceeding chapters. Confirmation of
66

DHA phospholipid incorporation allows any altered cardiovascular function
demonstrated in the proceeding chapters to be confidently related directly to higher
myocardial phospholipid DHA concentrations.
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Table 2.14: Comparison of the effect of fish oil on body weight in animals from different studies.
Duration of
FO Dose
Animal
Outcome
feeding
< 1.25%

Author

Human dietary achievable (∼2 serves salmon/wk – 6 capsules/day)
Rat (Sprague
Dawley)
Rat (Sprague
Dawley)

15 weeks

↔ Body weight, muscle mass or muscle mass:tibia length

(Henry et al., 2015)

12 weeks

↔ Energy intake, body weight or body weight gain

(Slee et al., 2010)

1.25 – 6%

Human therapeutic range (∼6 capsules/day – 28 capsules/day)
Rat (Rowett)
Rat (Sprague
Dawley)
Rat (Sprague
Dawley)

8 weeks

↔ Food intake, body weight or body composition

(Kamolrat et al., 2013)

12 weeks

↔ Tibia length, body weight, body size or heart mass

(McLennan et al., 2012)

12 weeks

↔ Energy intake, body weight or body weight gain

(Slee et al., 2010)

> 6%

Human supra-therapeutical range ( > 28 capsules/day)
Rat (Wistar)
Rat (Wistar)
Rat (Wistar)
Rat (Wistar)
Marmoset Monkey
Rat (Wistar)
Rat (Wistar)

8 weeks
6 weeks
16 weeks
4 weeks
30 months
10 months
8 months

↔ Food intake, body weight or muscle mass.
↔ Body weight, body size as indicated by tibia length or heart mass
↔ Body weight
↔ Final body weight and body weight gain.
↔ Body weight or heart mass
↔ Body weight
↔ Weight gain or food intakes

(Peoples & McLennan, 2014)
(Abdukeyum et al., 2008)
(Pepe & McLennan, 1996)
(Belzung et al., 1993)
(Abeywardena et al. 1991)
(Charnock et al., 1992)
(McIntosh et al., 1985)

↔ = No significant difference between FO and Control group.
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CHAPTER 3

General Methods
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3.1 INTRODUCTION

Cardiac function has been demonstrated to be positively influenced by FO
supplementation in healthy populations (Macartney et al., 2014; Peoples et al., 2008)
and is consistently associated with reduced CVD rates in epidemiological and cohort
studies (Burr et al., 1989; Kagawa et al., 1982; Kromhout et al., 1985). Several metaanalyses have provided evidence to support these observations (Mozaffarian et al.,
2008; Mozaffarian. et al., 2005; Xin et al., 2013), however some RCT (Galan et al.,
2010; Roncaglioni et al., 2013; Svensson et al., 2006) and meta-analyses (Alexander et
al., 2017; Nestel et al., 2015) of studies using supplements have produced mixed results
which do not support the notion that FO is acting in a cardio-protective manner. The
discrepant findings produced in large scale clinical trials can be explained by poor
design because of i) misunderstandings of the underlying mechanisms and/or ii)
misunderstanding the doses of FO required to modify cardiac function and dysfunction
and/or iii) failure to account for significant pre-existing DHA incorporation in control
groups (Ip et al., 2017; McLennan & Pepe, 2015).
Chapter two of this thesis demonstrated that supplementing dietary achievable FO doses
to a typical Western-style diet in the rat caused robust and preferential incorporation of
DHA into phospholipids of excitable tissue, most notably skeletal muscle
phospholipids. It is well-established that incorporation of DHA into skeletal muscle
phospholipids improves fatigue resistance during both normoxic (Henry et al., 2015;
Peoples & McLennan, 2010, 2014) and hypoxic contractions (Peoples & McLennan,
2017), even while using dietary achievable FO doses. However, there are no studies
which have investigated the effects of myocardial phospholipid DHA incorporation
attributable to dietary achievable FO doses on healthy and ischaemic cardiac
physiological function. As such, the remaining studies in this thesis aim to characterise
whether dietary achievable FO doses alter rested healthy cardiac function and confer
protection to cardiac function during and directly following ischaemia and reperfusion
injury of the heart. Such experiments will help establish the physiological relevance of
any health benefits associated with supplementing dietary achievable FO doses to a
typical Western-style human diet high in SFA and n-6 PUFA.
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Prior research has established the importance of physiological conditions, principally
oxygenation and temperature (Henry et al., 2015; Peoples et al., 2013; Pepe &
McLennan, 1993), in establishing real effects of altered cardiac and skeletal muscle
phospholipid composition. Functional evaluation of the rat heart in vivo meets that
requirement and is coupled with scaled down clinically relevant techniques to describe
cardiac function in clinical terms and thereby optimise interpretation and translation of
the findings into practice. Therefore, the primary objective of this study was to
investigate the use of left ventricular pressure volume loops (PV-loops) for the
assessment of cardiac performance and the optimisation of surgical protocols used to
measure in vivo PV-loops in the rat heart.
3.1.1 Left ventricular pressure volume loops
To date, multiple techniques have been used to assess left ventricular cardiac
haemodynamic performance such as ultrasonography, flow probes, micromanometers,
magnetic resonance imaging (MRI), and more recently miniaturised conductance
catheters (Burkhoff et al., 2005). The use of conductance catheters allows for the
generation of instantaneous pressure and volume measurements (Figure 3.1 &Figure
3.2). Plotting instantaneous pressure against volume creates a two-dimensional
representation of the cardiac cycle and generates a PV-loop. The PV-loop has long been
recognised as an indicator of the work done by a system (the heart in this case) and the
efficiency at which it completes this work. Although instantaneous pressure and volume
measurements alone can provide valuable insights into the performance of the left
ventricle, PV-loops provide a more powerful tool to assess left ventricular function. For
these reasons, PV-loops provide a unique framework to assess a range of physiological
relevant haemodynamic parameters and describe left ventricular performance of the
heart.
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Figure 3.1: Presentation of the Millar 6mm micromanometer conductance
catheter along a longitudinal section of the left ventricle.
Figure 3.1 notes: The catheter is placed along the longitudinal axis of a sliced rat left ventricle.
The tip of the catheter sits at the apex of the ventricle and the proximal part runs through the
aortic valve. Two conductance (volume) electrodes can be observed at the top (E1 & E2) and
bottom (E3 & E4) of the catheter and the pressure transducer is found in between them.

Figure 3.2: Representative instantaneous pressure and volume traces coupled
with ECG.
Figure 3.2 notes: This recording is an un-calibrated pressure and volume trace which was
recorded in the left ventricle of a rat heart using the Millar 6mm micromanometer conductance
catheter. Red trace = Pressure (mmHg), Blue trace = Volume (mL) & Pink trace = ECG (mV).

72

The conductance catheter can be used to assess both in vivo and ex vivo cardiac function
from large and small animals. The use of conductance catheters in animal models
permits detailed characterisation of a range of invasive parameters which are not easily
measured in human subjects for research purposes (Pacher et al., 2008). Using an
animal model gives the researcher the ability to have precise nutritional control of the
diet, ease of handling and housing, and control over a range of stimuli during
experimentation which can influence cardiac function including temperature,
anaesthesia and blood oxygenation concentrations (Pacher et al., 2008). As such, the rat
in vivo and ex vivo heart model are commonly used in research laboratories, both of
which offering their own set of advantages and disadvantages (Milani-Nejad & Janssen,
2014). The ex vivo model allows direct conclusions to be made in regard to the heart
itself as measurements are collected in the absence of confounding homeostatic
feedback responses. The ex vivo model is preferred in some research settings
investigating the effects of FO because it provides a highly reproducible preparation
which allows easy access for measurement of oxygen consumption, cardiac workload
and other coronary biochemistry (McLennan et al., 2012; Pepe & McLennan, 2002).
However, Pepe & McLennan have suggested that using whole-blood perfusate to ensure
adequate oxygenation is critical when using this model to draw accurate observations,
particularly when considering mechanisms related directly to oxygen efficiency (Pepe &
McLennan, 2002). Advances in technology such as the micro-conductance pressurevolume catheters allow the in vivo heart model to provide a relatively easier and
inexpensive method to measure clinically relevant indices of cardiac function. However,
measurements can be confounded by factors such as preload, afterload and heart rate.
The retention of autonomic control, neurohormonal influences on the heart and most
importantly beat-to-beat whole blood perfusion of the heart via the coronary arteries,
makes the measurements collected in vivo more physiologically relevant to this thesis.
Therefore, using the conductance catheter in the rat in vivo heart was chosen to
investigate the hypotheses in this thesis regarding identification of any cardiac
physiological changes attributable to LC n-3 PUFA. This approach permits more
confident extrapolation of observations made in the studies to human heart health.
Consequently, the first focus of this study was to successfully reproduce relevant
cardiac measurements from the rat in vivo heart to evaluate cardiac performance.
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A PV-loop from a single cardiac cycle is illustrated in Figure 3.3, labelled according to
key phases and events (Each point is labelled A-D). The following discussion will start
from the bottom right corner of the loop (A) with the heart filled and about to contract.
Point A of the loop represents completion of the diastolic filling phase. Closure of the
mitral valve occurs as the left ventricle begins to contract and build pressure at this
point but there is no movement of blood from the ventricle as the aortic valve is also
closed at this point, this is known as the isovolumic contractile phase (A to B). Point B
indicates the opening of the aortic valve, this occurs when the pressure in the left
ventricle becomes higher than the pressure in the aorta. Increased left ventricular
pressure forces the aortic valve open, allowing blood to travel down its pressure
gradient from the left ventricle into the aorta; this is known as the ejection phase (B to
C). Point C illustrates when ventricular pressure falls below aortic pressure as
myocardial relaxation begins, causing aortic valve closure as blood begins to flow in a
retrograde direction towards the left ventricle. Myocardial relaxation occurs before and
following the closure of the aortic valve. Once both the mitral and aortic valves are
closed, the isovolumetric relaxation phase occurs (C to D). At this point, no blood enters
the ventricle and the ventricle relaxes causing a substantial decrease in pressure with no
change in volume. Point D signifies completion of relaxation and the mitral valve opens
again. When the mitral valve opens the left ventricle begins the next diastolic filling
phase (D to A) which occurs passively as blood flows down its pressure gradient from
the left atrium into the left ventricle.
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Figure 3.3: Illustration of key phases and events in the left ventricle cardiac
cycle as observed through a PV-loop.
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Commonly reported indices of cardiac physiological function are illustrated on a P-V
loop in Figure 3.4. Point 1 represents end-diastolic volume and end-diastolic pressure;
this shows the volume of blood which has filled the left ventricle during the diastolic
filling phase and the resultant ventricular pressure. Physiologically, this point is
synonymous with what is known as the ‘preload’ of the heart. Preload represents the
extent to which myocardial sarcomeres are stretched at the time contraction commences.
Thus, a greater end-diastolic volume produces increased distention of the ventricle,
resulting in increased preload of myocardial sarcomeres, the opposite occurs with a
reduced end-diastolic volume. In a healthy beating heart this is usually the lowest
pressure reported between heart beats. The pressure at point 2 represents what is known
as the ‘afterload’ of the heart. Afterload is an indirect representation of the tension that
the left ventricular sarcomeres need to generate to overcome the resistance provided by
aortic blood pressure. Changes in afterload are closely linked to the force-velocity
relationship for cardiac myocytes. For example if afterload increases the velocity of
myocyte shortening decreases, reducing the rate of volume ejection during the ejection
phase, leaving more blood in the ventricle at the end of systole, the opposite occurs for
decreases in afterload. The pressure measured at point 3 represents end-systolic pressure
and the volume at point 3 represents end-systolic volume; this shows the volume of
blood remaining in the ventricle after the ejection phase. The difference between endsystolic pressure and end-diastolic volume is known as stroke volume. With analogy to
a piston pump, this is the amount of blood pumped out of the ventricle in one heartbeat
(Dashed line in Figure 3.4).
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Figure 3.4: Illustration of common physiological indices measured in the left
ventricular cardiac cycle as observed through a PV-loop.
Abbreviations:
SV = stroke volume; SW = stroke work; ESV = end-systolic volume; EDV = end-diastolic
volume; ESP = end-systolic pressure; EDP = end-diastolic pressure.
‘Preload’ = The extent to which myocardial sarcomeres are stretched at the time contraction
commences.
‘Afterload’ = An indirect representation of the tension that the left ventricle sarcomeres need to
generate to overcome the resistance provided by aortic blood pressure.
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In addition to the physiological indices that can be measured directly from the PV-loop,
there are a range of measurements which can be calculated from the PV-loop. Cardiac
output can be calculated by multiplying the stroke volume with heart rate. Ejection
fraction can be calculated using stroke volume as a proportion of end-diastolic volume
(stroke volume/end-diastolic volume*100), this is an important measure for tracking
pumping function of the left ventricle and in a healthy heart ejection fraction is usually
fifty five percent or higher. The area within the loop can be calculated (shaded blue in
Figure 3.4) and represents the stroke work completed by the left ventricle to eject
blood into the aorta each cardiac cycle. The maximal rate of pressure rise (dP/dtmax) and
maximum rate of relaxation (dP/dtmin) can also be calculated from the ventricular
pressure measurements. The dP/dtmax calculated represents the maximal rate at which
the heart generates pressure during the isovolumic contraction phase of each beat and is
a good indicator of systolic function. The dP/dtmin calculated represents the maximal rate
at which the heart relaxes during the isovolumic relaxation phase and is a good indicator
of diastolic function. It can be appreciated that all aspects of the cardiac cycle can be
intimately characterised through direct and calculated measurements made from the PVloop. Therefore, the PV-loop provides a unique framework to assess physiological
relevant cardiac haemodynamic parameters and describe left ventricular performance.
For these reasons, PV-loops are regarded as the gold standard for assessment of in vivo
cardiac haemodynamic function in animals (Calligaris et al., 2013; Clark & Marber,
2013; Pacher et al., 2008).
3.1.2 The effect of anaesthetic on cardiac performance
The use of anaesthetic for surgical protocols in animals is essential when investigating
invasive measurements. However, anaesthetics can significantly alter baseline inotropic
and chronotropic function of the cardiovascular system (Stein et al., 2007). As such,
careful consideration of the anaesthetic used is needed when planning a study such as
this, which aimed to measure cardiovascular performance. Sodium pentobarbital
(pentobarbital) or a ketamine + xylazine mixture are amongst the most common
anaesthetic agents used when measuring cardiovascular function in rats (Hanusch et al.,
2007).
Pentobarbital is an oxybarbiturate that has been used for veterinary anaesthesia since the
1930s. Evidence suggests that pentobarbital provides anaesthesia via acting as an
78

agonist at the GABAA receptor which is the principle inhibitory neurotransmitter in the
central nervous system in mammals (Krasowski & Harrison, 1999). When given at
higher doses in the anaesthetic relevant range, pentobarbital also acts to block excitatory
glutamate receptors in the central nervous system and neuronal nAChR channels
(Krasowski & Harrison, 1999). These mechanisms of action result in pentobarbital
having a slightly depressive chronotropic and inotropic effect on the cardiovascular
system (Saha et al., 2007), and it has been demonstrated that when used for prolonged
periods of anaesthesia (+3hrs), cardiac output can be significantly reduced (Nash et al.,
1956).
The pharmacology of ketamine is quite complex as it is known to interact with Nmethyl-D-aspartate (NMDA) receptors directly, opioid receptors, monoaminergic
receptors, muscarinic receptors and voltage sensitive Ca2+ channels (Bergman, 1999).
However, the main action of ketamine is through its non-competitive binding of NMDA
receptors resulting in antagonism of the central nervous system. There is also some
evidence that ketamine binds to α & β adrenergic receptors (Bevan et al., 1997). This
results in ketamine having a sympathomimetic action on the cardiovascular system. As
such, induction of anaesthesia with ketamine leads to increases in heart rate and
increased systemic and vascular blood pressure. To diminish the effects of ketamine on
the cardiovascular system, the concomitant administration of xylazine is commonly
used. Xylazine is a α2-receptor agonist from the non-opioid group that blocks the release
of catecholamine’s by sympathetic nerves, thereby reducing the sympathomimetic effect
of ketamine alone (Sumitra et al., 2004).
Both pentobarbital and ketamine offer a surgical grade of anaesthesia suitable for
invasive measurements without pain to the animal. However, as just described, they are
different classes of anaesthetic and act via different mechanisms of action to achieve
this. Therefore, the secondary objective of this study is to compare these two anaesthetic
agents for the purpose of reliably quantifying in vivo cardiac haemodynamic function in
the rat.
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3.2 AIMS AND HYPOTHESES

This study aimed to optimise the reliability and reproducibility of the in vivo animal
surgical model used to measure cardiac function and identify the most appropriate
anaesthetic for cardiac measurements.
Specifically, this experiment had the following aims:
Aim 1: Optimise the surgical techniques and protocols required to measure cardiac
haemodynamics with a conductance catheter in a physiologically stable in vivo model
relevant to normal bodily cardiovascular function.
Aim 2: Directly compare the effect of pentobarbital and ketamine + xylazine on
cardiovascular haemodynamic function to determine which anaesthetic produces the
most reliable and reproducible measurements of cardiac function.
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3.3 METHODS

3.3.1 Animals, ethical considerations & standardisation
A primary cohort (cohort 1) of male rats (Sprague Dawley) were used in this study and
ethical approval was completed (Section 2.3.1). Animals were housed and weighed
according to procedures outlined in Section 2.3.2. Animals for this study were supplied
lab chow and water ad libitum, but were not provided with dietary supplementation of
FO.
3.3.2 Groups
Twenty-three (N=23) animals were randomly assigned to receive i.p injection of either
pentobarbital (Hospira, Lyppards, SA, Aus) (n=11) or a mixture of ketamine + xylazine
(Ceva brand Ketamine & Ilium brand Xylazine, Lyppards, SA, Aus) (n=12).
Intraperitoneal injections of pentobarbital or ketamine + xylazine were chosen because
of their ease of use when compared to gaseous anaesthetics which require specialised
ventilation and gas extraction equipment.
3.3.3 Experimental preparation
Haemodynamic variables were obtained using a Millar pressure-volume single segment
foundation system for animals connected to PowerLab 8/35 software (ADInstruments,
Bella Vista, NSW, Aus) following established methods from previous studies (Abraham
& Mao, 2015; Pacher et al., 2008). A 6mm miniaturised 2-French (2F) pressure-volume
conductance catheter (SPR-638 Millar Instruments, Houston, USA) was used to assess
in vivo left ventricular function in the animals. The sampling rate of the conductance
catheter was set at 1kHz in PowerLab. The conductance catheter has four electrodes
(E1, E2, E3 and E4) with a spacing of 6mm between electrode E2 and E3 which
contained a 2F pressure transducer (Figure 3.1). To measure volume, the catheter emits
a constant current to the blood inside the left ventricle from the two most outer
electrodes (E1 & E4) and the voltage changes in the electrical field are then detected by
the inner two electrodes (E2 & E3). Therefore, by Ohm’s law, the conductance of the
blood surrounding the catheter in the left ventricle is inversely proportional to the
measured electrical potential. A constant sinusoidal alternating current (0.02 mA root
means square at 20kHz) is applied to drive the conductance. The catheter was placed in
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saline heated to 37°C for 30 minutes prior to experimentation to replicate the biological
working environment and electronically calibrated before being used in the procedures.
The catheter was connected to the Millar pressure volume suite (MPVS) ultra-control
interface and the pressure and volume signals were electronically calibrated following
the manufacturer’s instructions. This consisted of a two point electronic pressure
calibration. The software output a pressure trace which was recorded at 0mmHg
followed by 100mmHg and then the corresponding voltages were assigned to the trace.
The electronic pressure calibration was confirmed using a manual mercury column
sphygmomanometer calibration. The sphygmomanometer cuff port was fit with a 3-way
stopcock. The transducer was carefully placed into a fluid filled (0.9% NaCl solution)
haemostasis valve and gently secured. The haemostasis valve was then connected to the
sphygmomanometer via the stopcock, and the sphygmomanometer was then inflated to
100mmHg. The pressure measured via the MVPS software was then checked to
determine if it matched the pressure in the inflated sphygmomanometer. Volume was
calibrated using the relative volume unit (RVU) method which converts conductance to
RVU (Pacher et al., 2008). A volume tracing was output from the software and recorded
at 119 RVU and 289 RVU and voltages were assigned to the corresponding volume
traces. Volume measurements were then recorded throughout the experimental
procedures as raw RVU (conductance). Further calibration was completed at the end of
procedures to convert conductance into true volumes (mL).
3.3.4 Surgical procedures
3.3.4a Animal anaesthesia
Animals were anaesthetised throughout all procedures to ensure physiological stability.
Animals were weighed and then given an i.p injection of anaesthetic using a 1mL BD
micro-fine insulin needle. Anaesthetic was dosed according to body weight
(pentobarbital: 60mg/kg or ketamine 100mg/kg + xylazine 10mg/kg) using the
formulary provided by the British small animal veterinary association (BSAVA) manual
of practical animal care for small animal anaesthesia and analgesia. The depth of
anaesthesia was confirmed prior to beginning procedures via monitoring of the foot
withdrawal reflex to toe pinch and corneal reflex to touch (on average this was <15min).
The depth of anaesthesia was continuously monitored throughout protocols via toe
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pinch reflexes for signs of inadequate anaesthesia. Additional doses (ketamine 25mg/kg,
pentobarbital 20mg/kg) of anaesthetic were provided according to the standard practices
on checking the animal’s reflex reaction responses (Hanusch et al., 2007).
3.3.4b Temperature control
Once anaesthetised, all surgical procedures and experimental protocols were performed
with the animals placed on a heating mat (T-CAT 2 temperature controller, Braintree
Scientific, MA, USA) which maintained animal core body temperature at 37oC as
measured via a rectal probe (T-CAT 2 rectal probe, Braintree Scientific, MA, USA)
throughout the procedures. Because of the automated nature of the heating mat with
instantaneous feedback which ensured body temperature fluctuated from 37 oC only
minimally at any time point, body core temperature was not recorded and is not reported
in any of the studies conducted in this thesis.
3.3.4c Electrocardiogram
Electrical activity within the heart was monitored throughout surgical procedures and
experimental protocols using the single lead surface electrocardiogram (ECG – lead I)
method. This involved the placement of a positive electrode on the left fore-limb, a
negative electrode on the right fore-limb and an earth electrode on the left hind-limb
of the animal shortly after the animal was placed on the heating mat. Butterfly clip
electrodes were attached to needles (27gx1/2, Terumo, Elkton, MD, USA) which were
then placed through the superficial skin of the animals at each site. The surface ECG
recorded at a frequency of 1000Hz to a computer with PowerLab software
(ADInstruments Dual Bioamp, Bella Vista, NSW, Aus) and then saved for offline
analysis. The ECG measurements record electrical activity of the heart, thus, tracing
ventricular depolarisation periods. The ventricular depolarisation of the heart
generates the R wave found in the QRS phase of the ECG recording of the cardiac
cycle. Each QRS phase represents a new heart beat therefore the time between
consecutive R waves was used to calculate instantaneous heart rate.
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3.3.4d Tracheal, venous and arterial cannulation
Following placement of electrodes and collection of baseline resting ECG
measurements, a 3-4cm superior-inferior incision was made in the midline anterior
neck of the animal and the trachea was bluntly dissected from the surrounding tissue.
A small anterior incision was made between the c-shaped cartilage rings of the trachea
to allow the placement of a 40mm polyethylene tube (Microtube Extrusions, North
Rocks, NSW, Aus) into the trachea. Using blunt scissors and micro-curved forceps,
the left internal jugular vein was then bluntly dissected away from the surrounding
connective tissue just distal to where it merges with the left subclavian vein to form
the left brachiocephalic vein. Two sterile siliconized (Dysilk, Dynek Pty Ltd,
Australia) 6/0 silk sutures were loosely tied around the proximal and distal ends of the
vein. The suture which was most distal (away from the chest) was then tightened and
tied to stop blood flow returning from the head. A small transverse incision was then
made in the vein using microsurgical scissors and a length of 0.96 x 0.58mm PE
tubing was placed through the incision into the left internal jugular vein. The
remaining suture at the proximal end (closer to the chest) was then pulled tight to
secure the vein to the tubing. The distal suture was then also re-tied to the tubing to
ensure it did not come loose during the procedures. The tubing was connected to a
three-way valve to allow for the administration of physiological (0.9%) and
hypertonic (30%) saline during experimental protocols.
Following jugular vein cannulation, using blunt scissors and micro-curved forceps, the
right common carotid artery was bluntly dissected away from the vagus nerve and
surrounding connective tissue. Three sterile siliconized (Dysilk, Dynek Pty Ltd,
Australia) 6/0 silk sutures were loosely tied around the artery, one in the proximal
location and two distally. One of the distal sutures was then tightened and secured to
occlude blood flow from the head. The proximal suture was held in a pair of hemostat
scissors and then gently pulled and secured by clamping to the skin to occlude blood
flow from the aorta. A small transverse incision was then made in the right common
carotid artery using microsurgical scissors just in front of the distal suture. The precalibrated miniaturised 2F pressure-volume conductance catheter was then advanced
into the artery via the incision. The third suture was then secured to the catheter using a
single loop knot and the proximal suture was released from the hemostat which
removed the occlusion in the artery ahead of the catheter. The catheter was then able to
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be advanced through the right common carotid artery and into the aortic arch retrograde
towards the heart. At this point the rodent ventilator system was turned on and artificial
ventilation began.
3.3.4e Artificial ventilation
The tube placed into the trachea was attached to a rodent ventilator (Rodent Ventilator,
Basile 7025, Italy) for the animal’s breathing to be maintained by machine (artificial
ventilation); the rate and volume for ventilations were calculated using the following
formula: Tidal Volume (Vt, ml) = 6.2M1.01 (M = animal mass, kg); Respiration Rate
(RR, min-1) = 53.5 x M-0.26 (Pacher et al., 2008). For example, a rat weighing 400g
would have a Vt = 2.4mL and an RR = 68. This ensured that the concentration of
oxygen in the arterial blood remained high and constant, independently of the animal’s
natural breathing cycle and depth throughout the experimental protocol. Additionally,
controlling the respiratory rate maintains an adequate acid base balance during the
experimental period. Changes in acid base balance can have a strong influence on the
oxyhaemoglobin curve and unloading of oxygen (Stickland et al., 2011). Therefore, the
primary role of the artificial ventilation was to deliver a standardised high level of
arterial oxygen to all animals, and the secondary role was to maintain an adequate acid
base balance which did not influence unloading of oxygen at the tissue.
3.3.5 Experimental protocol and measurements
Prior to surgery occurring heart rate was calculated from the ECG recording, using one
(1) minute R-R interval averages. Following surgical procedures, the conductance
catheter was placed in the aortic arch for baseline measurement of arterial pressures and
heart rate was calculated from the ECG recording. Placement of the catheter in the
aortic arch was confirmed in real time via the presence of the dicrotic notch in the
pressure wave channel on PowerLab software (Figure 3.5). The catheter was then
advanced across the aortic semilunar valve into the left ventricle of the heart via probing
the valve with small to-and-fro movements of the catheter against the valve while
rotating it, so the catheter tip moved across different parts of the valve. Once the
catheter advanced past the aortic valve and entered the ventricle the pressure wave
would drop from aortic pressure ranges (120mmHg – 80mmHg) to ventricular pressure
ranges (120mmHg – 5-10mmHg). Thus, real-time placement of the catheter within the
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left ventricle was confirmed via the pressure output channel in the Powerlab software
(Figure 3.6).

Figure 3.5: Experimental pressure tracing showing the dicrotic notch which
confirmed placement of the transducer in the aorta.

Figure 3.6: Experimental pressure tracing showing pressure drop as catheter
moved from the aorta into the left ventricle.
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Once catheter placement was confirmed in the left ventricle, animals were given fifteen
minutes rest to allow stabilisation of left ventricular function, heart rate was calculated
from the ECG at this stage. Resting cardiac haemodynamic function was then recorded
for twenty minutes via the conductance catheter, the final five minutes of the recorded
data was used for analysis of baseline resting cardiac haemodynamic function and PVloops, and heart rate was calculated from the ECG recording at this time point. The
catheter was then withdrawn from the left ventricle into the aortic arch to measure aortic
blood pressure. The catheter was then returned to the ventricle for saline calibration
procedures.
3.3.5a Saline calibration of the conductance catheter
The current applied to the excitation electrodes on the catheter is conducted through the
blood in the left ventricle, but also it flows through the surrounding ventricular tissue. If
the conductance of the surrounding tissue is not accounted for, it can lead to an
overestimation of the blood volume within the left ventricle . This is known as the
parallel conductance of the ventricle (Gp). Therefore, a value for (Gp) was obtained by
providing a bolus dose of hypertonic saline (30% NaCl) to the left ventricle via the right
internal jugular vein at the end of experimental measurements. The saline was injected
into the right internal jugular vein (Section 3.3.4d). The respirator was turned off for
five seconds, and then 20-40mL of a 30% NaCl solution was injected into the right
internal jugular vein until the PV loop visibly shifted to the right without a significant
decrease in the pressure signal. This was conducted three times in each animal with 35min rest periods between to allow the volume signal to recover between injections.
Following completion of saline calibration procedures the conductance catheter was
withdrawn into the aorta and remained there while the animals were euthanised via
exsanguination and rapid removal of the heart. An overview of the experimental
protocol and measures used can be seen in Figure 3.7.
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Figure 3.7: Overview of the surgical preparation and experimental protocol.
1.
2.
3.
4.

Rodent ventilator
Cannulation of left internal jugular vein for administration of saline
Cannulation of right common carotid artery for entry of the conductance catheter
Rectal temperature probe with automatic feedback loop to heat pad set at 37oC

Abbreviations: HR = heart rate; BP = blood pressure; Xyl = xylazine.
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3.3.6 Euthanasia & tissue collection
All animals were euthanised without recovery from the anaesthetic using methods that
were approved by the University of Wollongong’s animal ethics committee. Euthanasia
was completed via removing the artificial ventilator and then rapid exsanguination and
removal of the heart.
3.3.6a Blood collection
Exsanguination was completed using a 21-gauge needle (Terumo Europe, Leuven,
Belgium) inserted into the bifurcation of the aorta at the common iliac artery. The blood
was collected into a 5mL syringe containing 0.2mL of a 5,000 U/mL Heparin Sodium
solution (Hospira, Lyypards, SA, AUS). The blood was then separated into 1mL
EDTA-treated tubes. One tube of blood was used to complete cuvette calibration in
order to calculate blood viscosity. The blood sample was immediately placed into a rat
insulator-type calibration cuvette with known well diameters provided by the
manufacturer (SPR-638 Millar Instruments, Houston, USA). The first five wells were
filled with blood and the cuvette was placed on a heating pad at 37°C to keep the blood
at biological temperature. The catheter was then placed into each of the five wells and
held in the centre of each well while submerging all four electrodes by blood for 1015secs. The conductance changes were recorded in the volume channel in RVU via the
PowerLab software (LabChart 8, PV Loop module, ADInstruments, Bella Vista, NSW,
Aus). The remaining blood tubes were frozen at -80oC for further analysis.
3.3.6b Cardiac tissue collection
The heart was rapidly removed from the animal following exsanguination through a
thoracic incision of the sternum. The major vessels were cut from the heart, and the
heart was submerged into an ice cold perfusate to arrest beating. Excised hearts were
then flushed with an ice cold 0.9% NaCl solution to remove any remaining blood. The
great vessels were then dissected off the heart, and the heart was weighed. The atria
were dissected off to obtain a ventricle weight, and the right ventricle was dissected off
to obtain a left ventricle weight. The left ventricle was then sliced in 2mm diameter
pieces and immediately frozen in liquid nitrogen, then stored at -80oC until fatty acid or
tissue morphological and biochemical analyses.
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3.3.7 Post-experimental conductance catheter calibration
The recorded raw conductance data was converted to true volumes (mL) to allow for a
more physiologically relevant assessment of ventricular work. Previously established
cuvette and saline calibration calculations were completed using LabChart 8 PV loop
software (Pacher et al., 2008). The conductance output collected in RVU during cuvette
calibration was correlated with known volumes to develop a calibration curve that
converted all recorded data from RVU into units of estimated volume (mL). However,
these estimated volume recordings are still larger than expected due to the parallel
conductance of the tissue surrounding the left ventricular blood volume. Therefore,
parallel conductance was calculated using a series of linear equations. The LabChart 8
PV-loop software calculated both of the linear equations; the first plotted the saline
calibration data as the end-diastolic volume vs end-systolic volume. The second plotted
end-diastolic volume = end-systolic volume, which represented the equivalent of a heart
chamber devoid of blood. The value at the intersection between the two plotted lines
was then used as a value to represent the parallel conductance of the left ventricular
tissue. This value was then automatically subtracted from the estimated volumes
calculated via the cuvette calibration curve. Following the cuvette and saline calibration
calculations the recordings were in units of true volume (mL). This allowed for accurate
and detailed assessment of the ventricular haemodynamics measured with the catheter
in animals.
3.3.8 Post-experimental data analysis
3.3.8a Heart rate
Offline analysis of the saved ECG recordings was completed using LabChart 8
software. Files were visually inspected and filtered for the presence of ectopic beats,
unusual electrical activity or interference. The ventricular depolarisation of the heart
generates the R wave found in the QRS complex of the ECG recording of each cardiac
cycle. Each QRS complex represents a new ventricular depolarisation therefore the time
between consecutive R waves can be used to calculate instantaneous heart rate.
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3.3.8b Left ventricular cardiac haemodynamics
Resting cardiac haemodynamic function was analysed from the final five minutes of the
recorded data collected. A smoothing filter (Triangular Barlett, window with 25 points)
was applied to the volume channel due to regular noise which was distorting the
channel and most likely due to the electrical network that the system was plugged into,
the pressure signal was never filtered in order to maintain integrity of maximal and
minimal rate of pressure development measurements (Pacher et al., 2008). Systolic and
diastolic function was assessed via investigation of volume and pressure related indices
measured and collated directly by the PowerLab software analysis tools. Analysis of
pressure and volume indices was conducted on a minimum of thirty (30) consecutive
cardiac cycles to create an average value for each animal.
3.3.8c Statistics
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise
stated. The effects of anaesthetic treatment on experimental outcomes were tested via
ANOVA. Individual group means were compared using Bonferroni’s post-hoc analysis.
All statistical analyses were performed in a blinded manner and completed using SPSS
21 for Windows (SPSS Inc, Chicago, IL, USA). Alpha was set at p <0.05.
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3.4.1 Anthropometrics

3.4 RESULTS

Anthropometric measures were collected on all animals. There were no statistically
significant differences between the groups for age, body weight, respiratory rate and
respiratory volume (Table 3.1). The pentobarbital group displayed a slightly larger
total heart weight than the ketamine + xylazine group which approached significance (p
=0.06). However, once heart weight was normalised to body weight, there was no
statistical significant difference between the groups (p =0.17).

Table 3.1: Anthropometric measurements between anaesthetic groups.
Ketamine +
xylazine

Pentobarbital

Trend p

Animals (N)
Age (weeks)
Body Weight (g)

11
13.8 (±0.2)
505 (±8)

12
14.1 (±0.3)
517 (±10)

NS
NS

Ventilation
Respiratory Rate (b/min)
Respiratory Volume (mL)

63 (±2)
3.1 (±0.1)

64 (±2)
3.2 (±0.2)

NS
NS

1400 (±22)
2.78 (±0.04)

1484 (±36)
2.86 (±0.03)

0.06
0.17

Tissue
Heart Weight (mg)
Heart/Body weight Ratio (mg/g)

Values are mean ± SEM (n = 11 – 12 per group). NS = Not significant.

92

3.4.2 The effect of anaesthetic on in vivo cardiovascular function
The heart rate of animals anaesthetised with ketamine + xylazine was significantly
lower at all time points measured from the induction of anaesthesia until the end of the
protocol when compared to animals anaesthetised with pentobarbital (Figure 3.8).
Baseline resting heart rate was significantly lower in the ketamine + xylazine group
compared to the pentobarbital group. Following surgery, heart rate of the ketamine +
xylazine group (240 ±7 beats.min-1) had dropped further, whereas heart rate in the
pentobarbital group remained stable (424 ±11 beats.min-1). At the beginning and end of

Heart rate (beats.min-1)

cardiac function measurements heart rate remained stable in both groups.

500

*

*

*

*
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Time (mins)
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400
300
200
0

10 40

Ketamine + xylazine

90

Pentobarbital

Figure 3.8: Heart rate (beats.min -1 ) calculations during different time points of
the experimental protocol.
Values are mean ± SEM (n = 11 – 12 per group). *p <0.05 vs Ketamine + xylazine
(One-way ANOVA with Bonferroni post-hoc test).
Figure 3.8 notes: Time 0 = Anaesthetic injection, Time 5 = Pre-surgery, Time 45 = Postsurgery. Time 60 = Start of baseline measures following rest period, Time 80 = End of baseline
measures. Error bars are omitted when smaller than the symbol.

93

The ketamine + xylazine group displayed a significantly lower systolic blood pressure,
diastolic blood pressure and mean arterial pressure compared to the pentobarbital group
at both measurement points (Table 3.2). Measurement of left ventricular function
demonstrated cardiac output and heart rate to be significantly lower in the ketamine +
xylazine group compared to the pentobarbital group. However, the stroke volume of the
ketamine + xylazine group was significantly greater than the pentobarbital group. There
were no significant differences between groups in any of the other haemodynamic
measurements recorded including end-systolic volume, end-diastolic volume, endsystolic pressure and end-diastolic pressure. Ejection fraction was significantly lower in
the pentobarbital group compared to the ketamine + xylazine group, however there were
no differences in any of the other systolic contractile indices measured including stroke
work and dP/dtmax (Table 3.2). There was no difference in dP/dtmin between groups but
the isovolumic relaxation constant Tau was significantly higher in the ketamine +
xylazine group compared to the pentobarbital group.
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Table 3.2: Haemodynamic parameters measured by conductance catheter in
rats while anaesthetised with Pentobarbital or Ketamine + xylazine and
expected normal range.
Ketamine +
xylazine

Pentobarbital

Systolic (Pre)

111(±2)

122(±3)*

Systolic (Post)

115(±3)

127(±2)*

Diastolic (Pre)

78(±3)

95(±3)*

Diastolic (Post)

79(±2)

95(±3)*

MAP (Pre)

92(±2)

93 - 120

MAP (Post)

94(±2)

107(±3)*
108(±2)*

Heart rate (beats.min-1)

285 (±25)

457 (±8)*

300 – 450

SV (μL)

105 (±3)

95 (±4)*

101 – 154

26 (±3)

37 (±2)*

42 – 62

3.62 (±0.4)

2.92 (±0.3)*

29 (±5)
117 (±10)
108 (±13)
13 (±1)

44 (±7)
139 (±11)
132 (±9)
14 (±2)

36 – 160
170 – 266
113 – 142
1–7

8286 (±612)

8990 (±321)

12,800 – 21,000

89 (±3)

42 – 87
7,600 – 11,500

Normal rangea

Blood Pressure (mmHg)

Ventricular function

-1

CO (mL.min )
Estimated TPR
(mmHg.min.ml-1)
ESV (μL)
EDV (μL)
ESP (mmHg)
EDP (mmHg)
b

Systolic indices
Stroke work (mmHg*μL)
Ejection fraction (%)
dP/dtmax (mmHg.s-1)

9119 (±987)

68 (±4)*
8965 (±647)

Diastolic indices
dP/dtmin (mmHg.s-1)

-7794 (±561)

-7193 (±498)

-5,970 – -9,970

12.7 (±0.6)

10.4 (±0.4)*

10 – 13

Tau (ms)

Values are mean ± SEM (n = 11 – 12 per group). *p <0.05 vs Ketamine + xylazine
(One-way ANOVA with Bonferroni post-hoc test).
a

Values for normal range are obtained from experimental data provided by Pacher, P. et
al., 2008. Data was collected from various rat strains anaesthetised with pentobarbital
across years of experiments. b Estimated TPR calculated by dividing MAP (post) by
CO.
Abbreviations: SV = stroke volume; CO = cardiac output; ESV = end-systolic volume; EDV =
end-diastolic volume; ESP = end-systolic pressure; EDP = end-diastolic pressure.
Systolic indices: dP/dtmax = peak rate of pressure rise
Diastolic indices: dP/dtmin = peak rate of pressure decline; Tau = relaxation time constant
calculated by Glantz method (regression of dP/dt versus pressure)
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3.5 DISCUSSION

In this study, the surgical techniques and protocols for measuring in vivo left ventricular
haemodynamics were optimised. The study demonstrated that using a conductance
catheter to measure in vivo left ventricular haemodynamic performance, in animals
anaesthetised with pentobarbital, produced sensitive and reproducible results which
were comparable with previously described normative values (Pacher et al., 2008).
Comparison of anaesthetic agents demonstrated that pentobarbital had less depressive
influence on cardiac function than a ketamine + xylazine mixture. In fact,
cardiovascular depression was evident directly following anaesthesia onset when using
ketamine + xylazine and did not recover throughout the entire experimental protocol. In
addition, anecdotal evidence observed of animal depth of anaesthesia during surgical
procedures indicated that pentobarbital provided a more adequate grade of anaesthesia
than ketamine + xylazine. Therefore, using pentobarbital as the anaesthetic was
concluded to be more appropriate than the ketamine + xylazine mixture for surgical
procedures and measurement of in vivo haemodynamic indices in the following FO
studies.
Compared to pentobarbital, the use of the ketamine + xylazine mixture slowed heart rate
and increased systolic blood pressure. Heart rate, systolic blood pressure and the
product of both, rate pressure product have been demonstrated to correlate strongly with
myocardial oxygen consumption (Kitamura et al., 1972). Human and animal
experimental studies consistently demonstrate FO supplementation to cause reductions
in working myocardial oxygen consumption and heart rate (Macartney et al., 2014;
Peoples et al., 2008; Pepe & McLennan, 2002). Heart rate and blood pressures
measured in the pentobarbital group of this study were within the normal range and
directly comparable to other studies using rats anaesthetised with barbiturates (Bal et
al., 2005; Bátkai et al., 2004; Cingolani et al., 2004; Pacher et al., 2008) making it the
more appropriate anaesthetic for assessment of these indices.
Compared to the pentobarbital group, the use of ketamine + xylazine slightly resulted in
a larger stroke volume, however cardiac output was smaller. Experimental studies have
demonstrated FO supplementation to attenuate reductions in cardiac output in
hypertrophic induced heart failure models (McLennan et al., 2012), therefore the use of
ketamine + xylazine may mask this effect. Pacher et al., 2008 reported the normal range
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for stroke volume and cardiac output to be 101-154 mL and 42-62mL.min-1 respectively,
in rats anaesthetised with barbiturates. Stroke volume and cardiac output in the
pentobarbital group of this study was slightly lower in comparison to the normative data
reported by Pacher et al., 2008. However, it has been demonstrated that underestimation
of stroke volume occurs as a result of the single volume segment present on fourelectrode conductance catheters (Bal et al., 2005). To correct this underestimation, flow
probe measurements are commonly collected from the aorta to calculate a gain factor
and calibrate volume readings from the conductance catheter (Pacher et al., 2008). Flow
probe measurements were not collected in this study due to experimental constraints. It
appears likely that this contributed towards a slight underestimation of stroke volume.
In addition, the heart rate observed in this study was at the higher end of the normal
range and therefore would not provide as much time for the diastolic filling phase,
thereby contributing to a reduction in stroke volume.
End-diastolic volume was higher in pentobarbital anaesthetised animals compared to
ketamine + xylazine anaesthetised animals, but was slightly lower than values reported
in other studies using barbiturates (Bal et al., 2005; Pacher et al., 2008). As stroke
volume was similar between groups in this study, the greater end-diastolic volume
contributed to a lower ejection fraction in pentobarbital anaesthetised animals compared
to the ketamine + xylazine group. Importantly however, ejection fraction of the
pentobarbital group was within the normal range and comparable to other studies
(Cingolani et al., 2004; Pacher et al., 2008), whereas ejection fraction of ketamine +
xylazine anaesthetised animals was beyond the upper limit of the normal range.
Pressure derived indices (dP/dtmax and dP/dtmin) were within the normal range for both
anaesthetic groups confirming that systolic and diastolic contraction and relaxation was
not influenced by anaesthetic, however stroke work was lower than expected in both
groups owing to the lower volumes observed.
Overall, this study demonstrated that the Millar micromanometer conductance catheter
is appropriate to collect accurate and detailed recordings of in vivo left ventricular
haemodynamics, which were comparable with previously described normative
physiological values. However, using the ketamine + xylazine mixture as the
anaesthetic in the remaining studies of this thesis would make it considerably more
difficult to definitively identify any further changes in cardiac functional indices and
97

attribute them to FO supplementation alone, rather than side-effects of anaesthesia. The
minor differences observed between normative values and collected data for some
indices measured may be dependent on differences in rat strain used between studies
(Fisher vs Wistar vs Sprague-Dawley) and/or the effect of gender or anaesthetic dosing
(Pacher et al., 2008).
Research has demonstrated that cardiovascular depression is a common side-effect of
ketamine + xylazine induced anaesthesia if it is not dosed precisely (Hart et al., 2001).
Although not quantified with data in this study, the experimenter made anecdotal
observations that dosing is especially difficult using the ketamine + xylazine mixture
compared to pentobarbital. Animals dosed with the ketamine + xylazine mixture
according to the formerly provided for body weight by the British small animal
veterinary association took longer to reach the surgical plane of anaesthesia and
required consistent additional doses to maintain this level. Whereas, the use of
pentobarbital provided a faster onset of anaesthesia, a more satisfactory surgical grade
of anaesthesia which continued for the entire 90 min with minimal additional doses
required throughout the experiment. It is particularly important that the anaesthesia used
for the FO studies performs in this manner as the experiments will run for an extensive
time. Given the need for a surgical plane of anaesthesia, it is possible that the additional
dosing was causing the cardio-depressive effects observed with ketamine + xylazine in
this study. Importantly however, this study demonstrated that pentobarbital provides
adequate long-term surgical grade anaesthesia.
Previous research aiming to characterise the effect of FO on cardiac performance have
predominately used isolated heart protocols with either a Langendorff or working heart
perfusion system (Abdukeyum et al., 2008; McLennan et al., 2012; Pepe & McLennan,
1996). As such, isolated heart measurements have been useful in describing changes to
myocardial metabolic efficiency, inotropy, lusitropy and chronotropy associated with
myocardial phospholipid DHA incorporation. These changes demonstrate many direct
effects of FO in the myocardium and provide substantial evidence to support a
mechanism of action for the cardio-protective effects associated with fish or FO intake.
However, extension of these findings to humans is limited due to the isolation of the
heart from a physiological system including neural feedback mechanisms, humoral
factors and perfusion of the coronary arteries with whole blood.
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Neural and humoral influences along with adequate oxygenation of the heart are
essential for optimal cardiac performance in a working physiological system. In
particular, maintaining oxygenation of the myocardium is critical for obtaining
physiologically relevant measurements of cardiac function (Kuzmiak-Glancy et al.,
2015). Diminished cardiac function is attributed to the high oxygen demand required by
the myocardium to complete physiological work as demonstrated by a linear
relationship between mechanical energy and myocardial oxygen consumption (Suga,
1979). In fact, inadequate oxygenation of the myocardium through the use of perfusate
compared to erythrocytes in ex vivo models has been demonstrated to diminish cardiac
function in the absence of injury (Pepe & McLennan, 1993) and has now been argued to
be one of the biggest limitations to findings made in ex vivo research (Gutterman &
Cowley, 2006; Kuzmiak-Glancy et al., 2015). The current study demonstrated that
measurement of cardiac haemodynamic function indices using the conductance catheter
is achievable in the in vivo model. This is important because the in vivo model together
with artificial ventilation ensures high arterial oxygen concentrations are maintained
throughout the experiment to allow oxygenation of the heart through beat-to-beat whole
blood perfusion of the coronary arteries. Furthermore, the results exhibited in the study
showed that the methods used are sensitive enough to identify minor changes of cardiac
haemodynamic function and robust enough to allow reproducibility between animals to
allow statistical comparisons. This will be particularly important for the characterisation
of the effects of FO on cardiac haemodynamic function as the changes that will occur
within the heart are hypothesized to be subtle functional shifts, particularly at rest,
compared to the Control group.
In conclusion, this study demonstrated the suitability of the surgical procedures and
anaesthetic to use in order to attain physiologically stable measurements of in vivo left
ventricular haemodynamic function in the FO studies. Chapter two of this thesis used
precision dosing of FO and definitively separated dietary groups to succesfully describe
phospholipid LC n-3 PUFA incorporation patterns between groups. As such, the
following studies of this thesis used the conductance catheter and pentobarbital induced
anaesthesia in an in vivo model to characterise the effects of FO on cardiac function.

99

CHAPTER 4

Characterising rested in vivo cardiac
function following supplementation of
human dietary achievable fish oil doses
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4.1.1 Cardiovascular function

4.1 INTRODUCTION

The principal role of the cardiovascular system is to ensure all organs are constantly
perfused with an adequate supply of oxygenated blood. To achieve this goal, the heart
generates an arterial pressure wave via rhythmically contracting its muscular walls to
propel blood into the vasculature and towards the organs. To ensure the metabolic needs
of each tissue are met, cardiac function continually adjusts in response to a range of
stimuli including stress, illness, trauma, hydration status, temperature, metabolic rate
and physical activity levels (Degaute et al., 1991). Instantaneous cardiac function is
controlled via a combination of mechanisms, which can be separated into two broad
umbrella categories; 1) ‘Intrinsic control’ e.g. The Frank-Starling law of the heart
(Starling & Visscher, 1927) and spontaneous depolarisation of pace-making cells
(Mangoni & Nargeot, 2008) and 2) ‘Extrinsic control’ e.g. The autonomic nervous
system and effect of circulating hormones (Abboud & Thames, 2011). Intrinsic control
of the heart ensures that the volume of blood pumped into the arterial circulation (stroke
volume) is equal to the volume of blood returning to the heart from venous circulation
via changing myocardial contractility and beat rate. The autonomic nervous system
including both vagal (parasympathetic) and sympathetic input also play an integral
controlling role through feedback loops. Feedback integrates afferent inputs and
transmits efferent signals to control beat rate and stimulate the release of hormones
which can influence cardiac contractility. Although these mechanisms are categorised
separately they work in synchrony throughout every heart beat in order to maintain
optimal cardiac function. Investigation of acute and chronic cardiac function during
rested conditions through measurement of parameters including and not limited to: heart
rate, heart rate variability, cardiac contractility, systolic function indices, diastolic
function indices, stroke volume and cardiac output are useful for identifying functional
cardiac differences between intervention groups.
4.1.2 Resting heart rate
The relationship between heart rate and cardiovascular or all-cause mortality is of
particular interest to researchers and clinicians, making investigation of such parameters
invaluable (Cook et al., 2006; Palatini, 2009; Zhang & Zhang, 2009). In the presence of
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prior cardiovascular disease, the role of heart rate may differ according to
pathophysiological settings. Reducing a previously elevated resting heart rate in patients
with CAD and left ventricular systolic dysfunction has been demonstrated to be
associated with a small reduction in the risk of cardiovascular mortality and morbidity,
the association strengthens in heart failure related outcomes (Fox et al., 2008).
Furthermore, there is evidence that in patients with chronic heart failure reducing heart
rate with ivabradine improves prognosis (Swedberg et al., 2010). Conversely, it has
been shown that in patients with stable CAD without heart failure there is no
improvement to prognosis when heart rate is reduced with ivabradine (Fox et al., 2014).
The conflicting results suggest that elevated heart rate may be a risk factor in heart
failure whereas elevated heart rate in the absence of heart failure is a risk indicator of
other pathophysiological processes. This suggestion is supported by evidence from
studies of the use of beta-blockers in heart failure that demonstrates the magnitude of
resting heart rate reduction to be associated with the survival benefit, whereas the dose
of beta-blocker is not (Cullington et al., 2012; McAlister, 2009).

However, human studies stratified by resting heart rate have demonstrated that, in
healthy population groups free from prior CVD, increased resting heart rate is
associated with greater risk of cardiovascular and all-cause mortality (Hartaigh et al.,
2014; Zhang & Zhang, 2009). In particular, heart rate profiling during exercise and
recovery has been demonstrated to be a powerful predictor of the risk of sudden cardiac
death in healthy men (Jouven et al., 2005), and independent of fitness, levels resting
heart rate is inversely associated with all cause-mortality in both men and women
(Aladin et al., 2014). Increases in resting heart rate over five years has also been shown
to be an independent predictor of mortality in a 20 year follow up period with healthy
middle aged men free from clinically detectable CVD (Jouven et al., 2009).
Furthermore, it has been demonstrated that higher resting heart rate is associated equally
with both cardiovascular and all-cause mortality outcomes (Alhalabi et al., 2017). These
findings are supported by a recent meta-analysis of eighty seven prospective studies that
demonstrated a positive association between higher resting heart rate and the risk of
coronary heart disease, sudden cardiac death, heart failure, stroke, CVD, total cancer
and mortality (Aune et al., 2017). This highlights the important role of therapeutic
nutritional investigations, alongside pharmacological and exercise interventions, which
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could offer a favourable effect of slowing resting heart rate in the general population
free from prior CVD.
4.1.2a The effect of fish oil on heart rate
The attributable advantage of DHA incorporation is a reduction in resting heart rate by
up to 5 beats.min-1 in healthy and patient populations (Dallongeville et al., 2003; Geelen
et al., 2005; Grimsgaard et al., 1998; Mozaffarian. et al., 2005) and across many animal
species, including; rat (Abdukeyum et al., 2008; Lortet & Verger, 1995) rabbit (Verkerk
et al., 2009); dog (Billman & Harris, 2011; Billman et al., 1999); pig (Hartog et al.,
1987) and horse (O’Connor et al., 2004). Heart rate has also been demonstrated to be
reduced in athletes during exercising conditions without a compromise to peak heart
rate (Buckley et al., 2009; Macartney et al., 2014; Peoples & McLennan, 2008) and
heart rate recovery has been demonstrated to be faster in healthy males (Macartney et
al., 2014) and in post myocardial infarction patients (O’Keefe et al., 2006). The
combination of these observations suggests that DHA is acting to modify heart rate,
however the doses of FO used in the vast majority of published research to date has
been much higher than easily achievable from fish consumption in the diet. Therefore,
the first objective of this study was to confirm whether dietary achievable FO doses
cause slowing of resting heart rate in the rat.
4.1.3 Left ventricular haemodynamics
The left ventricle of the heart is responsible for the efficient pumping of oxygenated
blood to the systemic circulation. To regulate mean arterial blood pressure, the
myocardium must be able to relax and contract rapidly and adjust to acute and chronic
influences to increase or reduce its pumping capacity (Abboud & Thames, 2011). Injury
or degradation to the left ventricular myocardium can result in severe consequences
including death. Therefore measurement of left ventricular cardiac performance is an
important diagnostic and experimental tool in the assessment of cardiac performance.
4.1.3a The effect of fish oil on left ventricular haemodynamics
The intake of fish or FO is associated with reduced incidence of heart failure (Levitan et
al., 2010; Mozaffarian et al., 2005b) and non-arrhythmic cardiac deaths (Valagussa et
al., 1999) indicating that FO alters cardiac haemodynamic performance. Experimental
studies have demonstrated FO to preserve contractility in a rat hypertrophic heart failure
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model (McLennan et al., 2012), limit ischaemic cardiac damage, reduce oxygen
consumption at any given work output and increase post-ischaemic contractile recovery
(Abdukeyum et al., 2008; Pepe & McLennan, 2002). Ejection fraction of the left
ventricle has been demonstrated to increase as a result of enhanced ventricular filling in
the marmoset heart (McLennan et al., 1992a). Furthermore, isolated working heart
studies in the rat using supra-therapeutical doses of FO have demonstrated improved
haemodynamic function and the authors postulated that these effects should extend to
lower doses (Pepe & McLennan, 2002; Pepe & McLennan, 2007). Cohort and
experimental studies provide strong evidence that dietary FO supplementation can
augment cardiac haemodynamics during diseased states, particularly when using
therapeutic and supra-therapeutical doses. However, it is unknown if dietary achievable
FO doses alters cardiac haemodynamics during rested conditions. Given the evidence of
reductions in heart rate following FO supplementation, the second objective of this
study was to determine whether cardiac haemodynamic performance changes are
observed in parallel to ensure cardiac output is maintained.
4.1.4 Heart rate variability
Absolute heart rate cannot predict the balance of autonomic control pertaining to cardiac
function. This is because, even during periods of rest when the heart rate is stable, the
timing between consecutive heart beats fluctuates in order to maintain a stable cardiac
output and mean arterial blood pressure. The speeding and slowing of the cardiac cycle
between beats, as a result of vagal and sympathetic tone, is referred to as heart rate
variability (HRV). Measurement of HRV can be categorised within time, frequency and
non-linear domains in order to describe the oscillations between consecutive heart beats.
Animal and human studies use HRV as a non-invasive surrogate assessment of
autonomic control of the heart (Akselrod et al., 1981; Camm et al., 1996; Sztajzel,
2004). Decreased HRV is strongly associated with sudden cardiac death in postmyocardial infarction patients (Bigger Jr et al., 1992; Bilchick et al., 2002; Hull et al.,
1990). Furthermore, HRV has been demonstrated to independently predict
cardiovascular disease mortality in populations with prior cardiovascular disease history
(Carpeggiani et al., 2004; Galinier et al., 2000) as well as in healthy populations
(Dekker et al., 2000).
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4.1.4a The effect of fish oil on heart rate variability
The effect of FO on HRV is unclear and inconsistent. Traditionally high cardiac risk
subgroups or post-myocardial infarction patient’s display reduced HRV, however,
research has demonstrated some evidence that FO is associated with modest
improvements in HRV indices in such patients (Christensen et al., 1999; Christensen et
al., 2001; Mozaffarian et al., 2008; O’Keefe et al., 2006; Xin et al., 2013). However,
some studies have demonstrated conflicting and inconsistent results when assessing the
effect of DHA on time-domain (Dyerberg et al., 2004; O’Keefe et al., 2006) frequencydomain (Billman & Harris, 2011; Carney et al., 2010; Ninio et al., 2008) and non-linear
domain parameters (Macartney et al., 2014). However, a recent meta-analysis of human
trials concluded that there is an association between short term consumption of FO with
improved HRV, particularly frequency domain indices (Xin et al., 2013). Considering
this evidence, the final objective of this study was to investigate any associations
between HRV measures and resting heart rate following FO supplementation.
In summary, there is strong evidence that demonstrates FO to have a direct cardioprotective effect on the myocardium through slowing heart rate and altering cardiac
haemodynamics. However, previous research has relied on therapeutical and supratherapeutical doses of FO and predominately ex vivo animal models to demonstrate
these effects. Therefore, investigation of the physiological effects of dietary achievable
FO doses, using a physiologically stable in vivo model, on resting cardiac function is
warranted. Evidence-based observations of dietary FO altering cardiac haemodynamic
performance and electrophysiology at these doses will help provide plausible
physiological mechanisms of action of DHA on rested cardiac function. This will
provide direct evidence and allow more confident extrapolation of findings from
previous therapeutical and supra-therapeutical dose studies to explain the cardioprotective action of FO demonstrated in human epidemiological and cohort studies.
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4.2 AIMS AND HYPOTHESES

This study investigated electrophysiological and haemodynamic function in the rested
in vivo rat heart following supplementation of human dietary achievable FO doses to a
typical Western-style diet (high SFA and n-6 PUFA).
Specifically, these experiments had the following aims and hypotheses:
Aim 1: Determine the influence of supplementing dietary achievable FO doses on
‘intrinsic’ cardiac function.
Hypothesis 1: Animals supplemeted with FO will have a slower resting heart
rate than animals from the Control group.
Hypothesis 2: Slower resting heart rate will be observed in direct
relationship with modified cardiac haemodynamic performance in order to
maintain cardiac output at rest.
Aim 2: Determine the influence of supplementing dietary achievable FO doses on
‘extrinsic’ autonomic control of cardiac function.
Hypothesis 3: Slower resting heart rate will be associated with higher HRV.
Furthermore, the modification will be most evident in the frequency
domain.
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4.3 METHODS

4.3.1 Animals, ethical considerations and standardisation
Male rats (Sprague Dawley) were obtained and used under University of Wollongong
ethical approval for this study (Section 2.3.1). Animals were housed and weighed
according to procedures outlined in Section 2.3.2.
4.3.2 Groups
Sixty two (N = 62, cohort 2) animals were used supplied lab chow and water ad libitum
for one week prior to dietary supplementation of FO beginning. Animals were then
randomly split into three groups and supplied water and one of three pre-fabricated diets
ad libitum for four weeks before experimentation. The diets contained different amounts
of FO (Control – 0%: n = 22, LowFO – 0.31%: n = 20, ModFO – 1.25%: n = 20).
4.3.3 Experimental preparation
Left ventricular in vivo haemodynamic variables were obtained using a 6mm
miniaturised 2-French (2F) Millar pressure-volume conductance catheter (SPR-638
Millar Instruments, Houston, USA) for rats. ECG was also used to collect cardiac
electrical activity, both the conductance catheter and ECG were connected to PowerLab
8/35 software (ADInstruments, Bella Vista, NSW, Aus). Experimental preparation of
the conductance catheter was completed according to the methods outlined in Section
3.3.3.
4.3.4 Surgical procedures
Animals were prepared for experimental measurements according to the surgical
procedures outlined in Section 3.3.4. Briefly, animals were removed from their cages,
weighed and given an i.p injection of anaesthetic (Pentobarbital: 60mg/kg) before being
returned to their cage and covered with a towel until they became non responsive to the
toe pinch test. Animals were then placed on a heating pad and animal core temperature
was maintained at 37oC via automated feedback loop from a rectal probe measuring
core temperature. ECG was connected to the animal via the traditional three-lead
method. An incision was made in the midline neck to allow for artificial ventilation via
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the trachea, and cannulation of the right common carotid artery and the left internal
jugular vein was completed to allow entrance of the conductance catheter and fluid lines
respectively. The conductance catheter was prepared prior to each experiment and
calibrated using the cuvette and saline calibration methods following the end of each
experiment.
4.3.4a Left ventricular load-independent haemodynamics
To collect load-independent measurements using the pressure-volume conductance
catheter the inferior vena cava was transiently occluded after resting haemodynamics
had been collected. The abdominal wall was opened via a transverse incision just
inferior to the xiphoid process and diaphragm. The coronary ligament of the liver was
cut and removed using micro surgical scissors and the liver was held inferiorly to allow
access to the inferior vena cava. A cotton tip applicator was then used to apply pressure
on the inferior vena cava against the diaphragm and occlude it for four to six seconds,
reducing venous return to the heart and allowing load-independent indices to be
measured. Occluding the vena cava for short time frames leads to a reduction in venous
return and thereby reduces end-diastolic volume and preload. The typical response
observed in the PV-loop during vena cava occlusion is a shift of the loop towards the
left and drop in the left ventricular pressure developed (Figure 4.1). Measuring endsystolic and end-diastolic pressure-volume relationships allows assessment of cardiac
contractility and diastolic relaxation. The passive tension filling curve for the ventricle
is known as the end-diastolic pressure-volume relationship (EDPVR), the slope of this
curve is the reciprocal of ventricular compliance. Increases in EDPVR indicate impaired
diastolic relaxation or ‘stiffness’ in the left ventricle myocytes. The end-systolic
pressure-volume relationship (ESPVR) describes the maximal pressure that the ventricle
can generate at any given left ventricular volume. The ESPVR is analogous to the total
tension that the ventricle can generate as the PV-loop cannot cross the ESPVR under a
given inotropic state. Therefore, ESPVR is a useful indicator of left ventricular systolic
contractile function. The ability to measure left ventricular cardiac parameters
independently from loading conditions is particularly important for the assessment of
acute changes in left ventricular performance (Pacher et al., 2008) and emphasises the
importance of the current model.
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Figure 4.1: Representation of the effect of inferior vena cava occlusion on PVloops to calculate the ESPVR and EDPVR.
ESPVR = End systolic pressure-volume relationship
EDPVR = End diastolic pressure-volume relationship
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4.3.5 Experimental protocol and measurements
Once animals were sufficiently anaesthetised and ECG was connected, animals were
left to rest for five minutes before baseline resting ECG recording was collected for
fifteen minutes. Baseline resting heart rate and HRV analysis of data collected via the
ECG was completed in the last five minutes of recording. Upon completion of ECG
measurements surgical procedures began. Following surgical procedures animals were
given ten minutes rest while anaesthetised with the conductance catheter in the left
ventricle of the heart. Resting cardiac function and PV-loops were then recorded via the
conductance catheter for ten minutes, the last five minutes of the recorded data was used
far analyses. The abdominal cavity was then opened and load-independent indices were
measured via occlusion of the inferior vena cava on three separate occasions for each
animal with five minutes recovery between each occlusion. An overview of the
experimental protocol is given in Figure 4.2.
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Figure 4.2: Overview of the resting in vivo cardiac function experimental protocol carried out.
Groups: Control, LowFO – 0.31% fish oil & ModFO – 1.25% fish oil
Abbreviations: ECG = electrocardiogram; PV = pressure-volume; LV = left ventricle; IVC = inferior vena cava.
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4.3.6 Post-experimental data analysis
4.3.6a Heart rate and heart rate variability
Offline analysis of the saved ECG recordings was completed on the final five minutes
of data using LabChart 8 software to investigate heart rate (Section 3.3.8a) and HRV.
LabChart 8 was used to detect R waves and calculated 512 RR interval time periods
from the cleanest segment of the five minute recording for HRV analysis. Data sets of
512 RR intervals were chosen as this length has been recommended to be the best
compromise between the need for a large time series in order to achieve frequency
domain accuracy and the practicality of shorter time periods (Kuwahara et al., 1994).
The data sets were converted into a text file and exported into Kubios HRV analysis
program (Version 2.2, Department of Physics of the University of Kuopio, Finland).
The recordings were placed through an automatic filter set to low which is part of the
Kubios program. The filter was used to remove any artefacts and/or ectopic beats and
leave only normal beats. This allowed the remaining data to be referred to as NN
intervals rather than R-R intervals as they are all normal beats. HRV measures analysed
included time, frequency and nonlinear indices.
Time domain heart rate variability
Time domain parameters measured included the mean NN interval (R-R time between
successive beats), the standard deviation of NN intervals and the root mean square of
differences of successive NN intervals (Figure 4.3). The standard deviation of NN
reflects cyclic elements responsible for the variability in the corresponding period of
recording; therefore standard deviation of NN represents long term HRV (Camm et al.,
1996). The standard deviation of NN captures short term changes in variability of the
heart and has been shown to be an acceptable index of vagal (parasympathetic)
mediated change to the heart (Camm et al., 1996).
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Figure 4.3: Representative ECG recorded cardiac cycle from a rat showing the
P wave, QRS complex and T wave and measurement of beat to beat differences
between consecutive RR intervals.

Frequency domain heart rate variability
Frequency domain analysis was used to calculate power spectrum density estimates
present in the recordings. The RR interval series recording was detrended prior to
analysis using the smoothness priors method with regularization parameter (λ) set to
500 and a cubic spline interpolation technique described previously (Tarvainen et al.,
2002). Power spectrum density estimates were calculated using the fast fourier
transformation. RR interval series were resampled at 4Hz and fast fourier
transformation window length of 256 samples was used. The frequency-domain
measures calculated were low frequency and high frequency power in normalised units
and as a percentage of overall power. The frequency bands identified for analysis were:
low frequency (0.04 - 0.8Hz) which represented both sympathetic and parasympathetic
activity and high frequency (0.8 – 1.5Hz) which is considered an index of cardiac vagal
control.
Non-linear domain heart rate variability
Sample entropy and approximate entropy were assessed via non-linear domain analyses.
In terms of HRV analysis, accurate long period data sets can be hard or impossible to
obtain in animals, therefore sample entropy and approximate entropy calculations are
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acceptable to allow the measure of regularity from shorter recordings. Additionally,
Poincaré plots were used for quantitative and qualitative beat-to-beat analysis of HRV.
The Poincaré plot is a scattergram of all NN intervals in which each NN interval is
plotted as a function of the previous one (Figure 4.4). As the RR interval lengthens
progressively to its maximum then shortens progressively to minimum repeatedly, the
shape of the plot allows the fit of an ellipse, which can be used to quantify SD1 and
SD2. SD1 represents dispersion of the points perpendicular to the line of identity and is
thought to be an index of instantaneous (parasympathetic) beat-to-beat variation (Camm
et al., 1996). SD2 represents dispersion of the points along the line of identity, and
represents the slow variability (sympathetic) of the heart (Camm et al., 1996).
Additionally, the ratio of SD1:SD2 was calculated which represents the randomness in
the HRV time series recording (Camm et al., 1996).

Figure 4.4: Representation of a Poincaré plot measured in a rat during rested
cardiac function.
Figure 4.4 notes: The identity line divides the Poincaré plot into two areas, decelerations are
located above and accelerations below this line. As described the variance of the projection of
the Poincaré plot points along the identity line is the short-term variability SD1 and
perpendicular projection leads to long-term variance SD2.
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4.3.6b Left ventricular cardiac haemodynamics
Resting left ventricular cardiac haemodynamic function was analysed from the postsurgery measurements in the final five minutes of the recording period. This gave each
animal time to stabilise following surgery and reduced the chance of surgical procedures
influencing the haemodynamic measurements collected. Analysis was completed
following the methods outlined in section 3.3.8b. Load-independent indices were
analysed at each inferior vena cava occlusion and the average of all three measurements
were used to assess the ventricular systolic and diastolic function of dietary groups.
4.3.6c Statistics
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise
stated. The effects of dietary treatment were tested via ANOVA. A Bonferroni post-hoc
test for comparison between group means was then used to identify differences. A
Dunnett’s T-test was used for comparison of individual diets against the Control group.
A repeated measures ANOVA (Dietary treatment*time) was completed to investigate
changes in heart rate between the groups during three time points across the experiment.
All statistical analyses were performed in a blinded manner and completed using SPSS
21 for Windows (SPSS Inc, Chicago, IL, USA). Alpha was set as p <0.05.
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4.4 RESULTS

Sixty two (N=62) animals were used for the experimentation following dietary
supplementation (Figure 4.5). Two (2) animals in the Control and one (1) animal in the
LowFO groups died directly following injection of the anaesthetic. During surgery a
further three (3) animals in the LowFO and two (2) animals in the ModFO groups died,
likely caused by surgical damage to the conduction pathways, surgical complication
resulting in cardiogenic shock or anaesthetic overdose. Separate to these, the
conductance catheter was unable to be guided into the left ventricle of two (2) animals
in Control group and one (1) animal in the LowFO group; this meant only ECG
measurements were collected from these animals at the post-surgical stage of the
experiment. Final group numbers for resting ECG and HRV measurements were n = 19
- 20 respectively and resting left ventricle cardiac haemodynamic measurements were
collected from n = 15 - 18 respectively.

Total Animals (N=62)

Control (n=22)

LowFO (n=20)

ModFO (n=20)

ECG
recordings

Anaesthesia
2 deaths
Control (n=20)

1 death
LowFO (n=19)

ModFO (n=20)

PV
recordings

Surgery
-2 unable to
guide catheter
into LV

Control (n=18)

-3 deaths
-1 unable to
guide catheter
into LV

LowFO (n=15)

-2 deaths

ModFO (n=18)

Figure 4.5: Overview of animal group numbers throughout experimentation.
Abbreviations: ECG = electrocardiogram; PV = pressure-volume; LV = left ventricle.
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4.4.1 The effect of fish oil supplementation on resting heart rate
Resting heart rate was analysed (n = 16 – 20) at three different time points during the
experiment including baseline, pre-surgery and post-surgery (Figure 4.6). Baseline,
pre-surgical and post-surgical resting heart rate of the Control group was between 447 –
454 beats.min-1. The FO groups displayed a dose-related slowing in baseline resting
heart rate compared to the Control group. The LowFO group (429 – 445 beats.min-1)
trended slower at all time points but was only significantly slower during baseline
measures compared to the Control group (p <0.01). Whereas, resting heart rate of the
ModFO group (420 – 426 beats.min-1) was significantly slower at all three time points
compared to the Control group (p <0.05).

Heart Rate (beats.min-1)

475

450

**
†

425

400
350
0

*

*

Control
LowFO
ModFO
Baseline

Pre-surgery Post-surgery
Time (min)

0

15

90

Figure 4.6: The effect of fish oil on resting heart rate (beats.min -1 ) calculated
at different times throughout experimentation.
Values are mean ± SEM. (n = 16 – 20) *p <0.05 vs Control **p <0.01 vs Control †p
<0.001 vs Control (One-way ANOVA with Dunnett’s T-test vs Control group).
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4.4.2 The effect of fish oil supplementation on resting heart rate variability
Time domain, frequency domain and non-linear domain HRV parameters were analysed
during the pre-surgery measurements after fifteen minutes of rest. Both FO groups
displayed a dose-related higher mean NN interval time than the Control group (Control:
134 ±2, LowFO: 140 ±2, ModFO: 145 ±3ms) compared to the Control group (p
=0.015). This mirrored the slowed heart rate previously discussed. There were no
significant differences displayed in either the SDNN or RMSSD between any of the
groups (Table 4.1). Fast fourier transformation (FFT) analysis displayed high frequency
band dominance (77 - 83% of total power) compared to low frequency (16 - 22% of
total power) during the recording period regardless of dietary group. However, there
were no statistical differences observed between dietary groups for any frequency
domain measures calculated.
Non-linear domain parameters SD1, SD2, the ratio of SD1:SD2, approximate entropy
and sample entropy were calculated from the Poincaré plots produced (Figure 4.7).
The Control group displayed a SD1/SD2 ratio of 0.520 ±0.01, sample entropy of 1.154
±0.04 and approximate entropy of 0.940 ±0.02. The SD1/SD2 ratio was demonstrated to
be significantly higher in the LowFO (0.566 ±0.01) and ModFO (0.580 ±0.01) groups
compared to the Control group (Table 4.1). Sample entropy was significantly higher in
the ModFO group compared to the Control group (p <0.05). Approximate entropy
trended higher in the LowFO and ModFO groups but did not reach significance (p
=0.103). However, pooled analysis of both FO groups showed a significantly higher
approximate entropy compared to the Control group (p =0.035).
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Table 4.1: The effect of fish oil on heart rate and heart rate variability indices
during pre-surgical measurements.

Time domain
Mean HR (b.min-1)
STD (b.min-1)
Mean NN (ms)
SDNN (ms)
RMSSD (ms)

Control

LowFO

ModFO

Trend p

447 (±7)
5 (±1)
134 (±2.2)
1.3 (±0.4)
1.3 (±0.4)

430 (±6)
5 (±1)
140 (±2.1)
1.4 (±0.4)
1.4 (±0.4)

425 (±6)*
4 (±1)
145 (±3.6)*
1.2 (±0.3)
1.3 (±0.4)

0.017
0.015

Frequency domain
FFT
LF Power (%)
LF Power (nu)
HF Power (%)
HF Power (nu)
LF/HF
Pooled LF/HF

16.4 (±2.4)
16.4 (±2.4)
83.2 (±2.4)
83.4 (±2.4)
0.22 (±0.1)
0.22 (±0.04)

21.5 (±3.6)
21.1 (±3.7)
21.5 (±3.6)
21.2 (±3.7)
78.2 (±3.7)
78.4 (±3.8)
78.3 (±3.6)
78.6 (±3.7)
0.35 (±0.09)
0.36 (±0.09)
0.35 (±0.06)

0.32
0.15

Non-linear domain
SD1 (ms)
SD2 (ms)
SD1/SD2

0.94 (±0.3)
1.68 (±0.5)
0.52 (±0.1)

1.02 (±0.3)
1.76 (±0.6)
0.56 (±0.01)

0.93 (±0.2)
1.48 (±0.3)
0.58 (±0.01)*

0.031

SampEn
ApEn
Pooled ApEn

1.15 (±0.1)
0.94 (±0.02)
0.94

1.30 (±0.1)
1.42 (±0.1)*
0.99 (±0.1)
1.03 (±0.1)
1.02 (±0.02)*

0.033
0.10
0.035

Values are mean ± SEM (n = 19 – 20). *p <0.05 vs Control diet (One-way ANOVA
with Dunnett’s T-test vs Control group). Pooled analysis compared both FO diets
combined vs Control.
Abbreviations: SDNN = standard deviation of NN intervals; RMSSD = root mean square
standard deviation of NN intervals; FFT = fast fourier transformation; LF = low-frequency
power; HF = high-frequency power; SD1 = standard deviation of points perpendicular to the
axis; SD2 = standard deviation of points along the axis of line-of-identity; ApEn = approximate
entropy; SampEn = sample entropy.
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Figure 4.7: Representative Poincaré plots from a Control and ModFO animal
during rested cardiac function measurements.
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4.4.3 The effect of fish oil supplementation on resting cardiac haemodynamics
Resting aortic blood pressure was analysed from data following the surgery but before
the catheter had been advanced into the left ventricle. No significant differences were
observed in diastolic pressure, systolic pressure or MAP between any of the groups (p
>0.05). Resting left ventricular cardiac haemodynamics and preload-independent
indices were analysed from the post-surgery measurements in the final five minutes of
the recording. The average heart rate, stroke volume and cardiac output were 451
±8beats.min-1, 100 ±7µL and 44 ±3mL.min-1 respectively in the Control group. Average
heart rate in the ModFO group was significantly slower than the Control group (Table
4.2). The slower heart rate observed in the ModFO group was accompanied with a nonsignificant elevation of stroke volume compared to both the other groups. No significant
differences were observed in cardiac output between any of the groups (p >0.05).
Furthermore, there were no significant differences in systolic (ejection fraction – EF,
maximal rate of pressure change – dP/dtmax) or diastolic function (Isovolumic relaxation
constant – Tau, minimal rate of pressure change – dP/dtmin) between any of the dietary
groups.
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Table 4.2: The effect of fish oil on resting cardiac haemodynamics measured
post-surgery with a pressure volume conductance catheter.
Control

LowFO

ModFO

Diastolic BP (mmHg)

94 (±4)

90 (±3)

93 (±3)

Systolic BP (mmHg)

122 (±6)

125 (±6)

127 (±4)

MAP (mmHg)

103 (±5)

101 (±4)

104 (±4)

HR (beats.min-1)

451 (±8)

446 (±6)

426 (±8)*

SV (µL)

88 (±7)

90 (±8)

108 (±9)

39 (±3)

40 (±3)

46 (±4)

CI (mL.min x kg)

23 (±2)

23 (±2)

25 (±2)

ESV (µL)

65 (±10)

56 (±9)

71 (±10)

EDV (µL)

153 (±9)

145 (±12)

179 (±16)

ESP (mmHg)

139 (±7)

132 (±4)

140 (±5)

EDP (mmHg)

13 (±1)

12 (±1)

10 (±1)

0.068 (±0.001)

0.070 (±0.002)

0.078 (±0.002)*

1.5 (±0.2)

1.5 (±0.2)

1.2 (±0.1)

67 (±5)

70 (±4)

63 (±4)

dP/dtmax (mmHg.sec )

8688 (±441)

8796 (±288)

8537 (±401)

Diastolic indices
dP/dtmin (mmHg.sec-1)

-7735 (±483)

-7773 (±364)

-7440 (±313)

10.0 (±0.3)

9.6 (±0.4)

10.0 (±0.4)

Variable

CO (mL.min-1)
-1

DFP (sec)
Ea (mmHg/µL)
Systolic indices
EF (%)
-1

Tau (ms)

Values are mean ± SEM (n = 15 – 18). *p <0.05 vs Control diet (One-way ANOVA
with Bonferroni post-hoc test).
Abbreviations: HR = heart rate; SV = stroke volume; CO = cardiac output; CI = cardiac index,
CO/Body weight; ESV = end-systolic volume; EDV = end-diastolic volume; ESP = end-systolic
pressure; EDP = end-diastolic pressure; Ea = arterial elastance (measure of ventricular
afterload).
Systolic indices: EF = ejection fraction; dP/dtmax = peak rate of pressure rise.
Diastolic indices: dP/dtmin = peak rate of pressure decline; Tau = relaxation time constant
calculated by Glantz method (regression of dP/dt versus pressure).
Table 4.2 notes: Two (2) animals in the ModFO group were removed from the analysis due to
bradycardia associated with atrioventricular block, without preceding arrhythmia. This was
most likely caused by surgical damage to the conduction pathways, surgical complication
resulting in cardiogenic shock or anaesthetic overdose.
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Left ventricular cardiac haemodynamics during inferior vena cava occlusions were
analysed to assess preload-independent changes of systolic and diastolic function. There
were no statistical differences present between dietary groups for the slope calculated of
the ESPVR, PRSW and dP/dtmax – EDV relationships (Figure 4.8). Pooled analysis of
FO vs Control animals did not show any statistical differences either but the trend
became stronger (Table 4.3).

Table 4.3: The effect of fish oil on preload-independent indices of left
ventricular function during inferior vena cava occlusion.

Systolic indices
SW (mmHg*µL)
ESPVR

Control

LowFO

ModFO

10933 (±963)

9693 (±744)

10226 (±917)

2.11 (±0.21)

2.14 (±0.18)

2.28 (±0.14)

- Pooled
PRSW (mmHg)
- Pooled
dP/dtmax – EDV
(mmHg.s-1 ml-1)
- Pooled

2.22 (±0.11)
115 (±8)

120 (±8)

0.637

124 (±7)

122 (±5)
46 (±8)

Trend
p

49 (±8)

0.498
55 (±6)

53 (±5)

0.517

Diastolic indices
0.038
0.041
0.036
(±0.009)
(±0.008)
(±0.006)
Values are mean ± SEM (n = 9 – 12). Pooled analysis completed with both FO diets
combined vs Control.
EDPVR

Abbreviations:
Systolic indices: SW = stroke work; ESPVR = end-systolic pressure volume relation; PRSW =
preload recruited stroke work (slope of stroke work−EDV relationship); dP/dtmax−EDV =
dP/dtmax−end diastolic volume relation.
Diastolic indices: EDPVR = end-diastolic PV relation slope.
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Figure 4.8: Typical PRSW and dP/dt max – EDV relationship from one animal in
each dietary group.
*Regression lines shown are from one (1) animal per group, mean slope is calculated from
entire group.
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4.5 DISCUSSION

This study demonstrated that supplementing FO doses achievable within a typical
Western-style human diet (high SFA and n-6 PUFA) modified in vivo resting cardiac
function. Physiologically, resting heart rate was slowed in a dose-related manner,
cardiac output was maintained despite the slower heart rate and non-linear domains of
vagal tone were higher in FO supplemented animals. The dietary achievable FO doses
used in this study, for the first time, provide a compelling physiological link to explain
the consistent observation of fish or FO intake being associated with lower heart rates in
humans (Dallongeville et al., 2003; Geelen et al., 2005; Grimsgaard et al., 1998;
Mozaffarian. et al., 2005). The ability of FO to reduce resting heart rate in healthy
populations is likely associated with its consistently demonstrated cardio-protective
effect in previous epidemiology, intervention trials and animal research (Burr et al.,
1989; McLennan, 2014; Mozaffarian & Wu, 2011). Importantly, the physiological
measurements collected in all dietary groups using the conductance catheter in this
study were consistent with previous values reported in Chapter 3, and within the
normative physiological range outlined in a separate study (Pacher et al., 2008). Thus,
the in vivo experimental model used in this study provides a strong platform to examine
the differences observed in rested cardiac function between dietary groups.
4.5.1 Resting blood pressure, heart rate and cardiac haemodynamics
No differences were found for resting blood pressures following supplementation.
Blood pressure acts to maintain perfusion of oxygen and essential nutrients to the
organs, tissues and cells of the body. Thus, in a healthy population, the cardiovascular
system acts to control contributing cardiac factors such as heart rate and stroke volume
(cardiac output) and vascular factors such as total peripheral resistance in order to
maintain mean arterial blood pressure. Dietary supplementation of fish oil has only been
shown to reduce blood pressure in hypertensive subjects in a dose-dependent
relationship, but/and only in supra-therapeutic doses (Appel et al., 1993; Kris-Etherton
et al., 2009; Morris et al., 1993). Considering the normotensive blood pressures of the
animals in the current study, it would be counterproductive if fish oil acted to reduce
them further. Importantly however, this study is the first to demonstrate that resting
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heart rate is slowed by ∼20 – 40beats.min-1 in a dose-related manner in the rat heart
which has been supplemented with dietary achievable FO doses.
Previously, animal studies have demonstrated that DHA confers the ability to reduce
heart rate in rats (Abdukeyum et al., 2008; Lortet & Verger, 1995; Pepe & McLennan,
1996), exercising conditioned horses (O’Connor et al., 2004) pigs (Hartog et al., 1987),
and dogs (Billman & Harris, 2011). Additionally, FO supplementation has been
reported to slow resting heart rate in generally healthy but untrained humans
(Mozaffarian. et al., 2005), similar to the slowed resting heart rate associated with
regular physical activity (Scheuer & Tipton, 1977). Heart rate has also been shown to be
reduced by FO supplementation during cardiac induced stress from exercise protocols
(Buckley et al., 2009; Macartney et al., 2014; Ninio et al., 2008; Peoples & McLennan,
2008). However, slowed heart rates in animal models have only been associated with
the delivery of therapeutical and supra-therapeutical FO doses. Likewise, human studies
demonstrating slowed resting or exercise heart rate have provided supplementation of
FO doses in the therapeutic range (Mozaffarian. et al., 2005).
Physiologically, slowing of the heart rate in the ModFO group resulted in ∼40
beats.min-1 less than Control animals, this equates to approximately 2400 less heart
beats per hour. This slowing of heart rate is important when related to myocardial
oxygen demand (MVO2) of the heart. Cardiac MVO2 is an index of the oxygen
consumption and energy used by the heart for a given workload. Basal myocardial
energy metabolism accounts for approximately 25% of myocardial MVO2, myocardial
wall tension, rate of contraction and contractility are the other primary factors
determining MVO2. Factors that enhance tension development by myocytes, such as the
rate of tension development (systolic blood pressure), or the number of tension
generating cycles (heart rate) will increase MVO2. The importance of MVO2 was
highlighted almost a century ago in Ernest Starling’s laboratory which demonstrated
that the heart is an aerobic organ which cannot develop an oxygen debt except for very
brief periods (Evans & Ogawa, 1914). Dietary achievable FO doses slowed heart rate
thereby leading to favourable reductions in MVO2.
Slowed resting heart rate leads to increased myocardial perfusion time due to an
increased time period of the diastolic phase in the cardiac cycle. Blood flow to the
myocardium is greatest during the diastolic phase as the coronary vessels are not
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compressed due to the higher pressures associated with systole (Spaan et al., 2008).
Diastolic filling period was demonstrated to be approximately ten milliseconds longer in
the ModFO group compared to the Control group and the LowFO group also showed a
slightly longer diastolic filling period. Given that the resting heart rate observed in the
ModFO group was 425 beats.min-1 and diastolic filling period was approximately 10
milliseconds longer for each heartbeat, this would result in cardiac perfusion time to
myocardial membranes increasing by almost four and a half minutes per hour
(425beats.min-1 * 0.01sec [diastolic filling period] * 60sec).
Cardiac efficiency is improved when diastolic filling period is longer because more
volume enters the ventricle leading to a greater end-diastolic volume. The FrankStarling law of the heart demonstrates that a greater end-diastolic volume otherwise
referred to as ‘preload’ allows more myocardial stretch which results in a stronger
contraction at a lower energy cost (Starling & Visscher, 1927). This phenomenon helps
demonstrate how stroke volume is acutely adjusted when preload is changed in order to
maintain forward movement of blood volume throughout the cardiac cycle. During
periods of increased preload cardiac myocytes are stretched, this causes two processes
to occur: (i) troponin C Ca2+ binding sites to become more sensitive to Ca2+ allowing
increased rates of actin and myosin cross-bridge attachment and detachment (ii) the
amount of Ca2+ supplied to the cardiac myocytes is increased (Allen & Kentish, 1985).
Together this causes the myocyte to generate a stronger contraction when stretched.
Stroke volume was not statistically different between any of the groups in this study.
However, the ModFO group displayed the greatest stroke volume which is likely
closely linked to the greater end-diastolic volume observed and the Frank-Starling law
of the heart.
Previously, FO supplementation in animal models has shown associations with
increased left ventricular ejection fraction in healthy hearts (McLennan et al., 1992a)
and increased myocardial contractility in models of hypertrophic heart failure
(McLennan et al., 2012) and ischaemia and reperfusion (Pepe & McLennan, 2002).
Taken in combination, these findings suggest improved contractile properties of the
myocardium following incorporation of DHA. Although this study did not identify any
changes in left ventricular contractile properties at rest, the observation of maintained
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cardiac output despite slowed resting heart rate suggests that contractile function was
modified.
4.5.2 Heart rate variability
The intrinsic control of heart rate is modulated by the spontaneous depolarization of
pacemaker cells in the sino-atrial node. Moment by moment changes in heart rate are
then further mediated through the vagal nerve as part of the parasympathetic nervous
system (PNS). Acetylcholine acts on muscarinic receptors to slow heart rate with high
vagal tone, whereas vagal withdrawal causes heart rate to increase. Sympathetic nervous
system (SNS) stimulation acts via noradrenaline on β1-adrenergic receptors to increase
heart rate and force, whereas sympathetic withdrawal acts to decrease heart rate and
force. However, the SNS acts much slower than the PNS to modify heart function
(Nicolini et al., 2012). The influence of the PNS or SNS over heart rate is generally
evaluated through heart rate variability (HRV) measurements and analyses (Camm et
al., 1996).
This study demonstrated higher sample entropy and a high SD1:SD2 ratio in both FO
groups compared to the Control group. Entropy is defined as the rate of generation of
new information over a large data set, or the regularity of the data, e.g. it is a measure of
how likely an RR interval will repeat itself (Richman & Moorman, 2000). Thus, higher
entropy suggests a more irregular heart rate (increased HRV) during the recording
period. Higher SD1:SD2 has been proposed to indicate stronger vagal tone (Camm et
al., 1996), suggesting that vagal tone in this study was higher in FO supplemented
animals and may have facilitated the slowed resting heart rate. In contrast, high
frequency power which is thought to represent vagal tone (Pomeranz et al., 1985),
trended lower in both FO groups, implying decreased vagal tone. The conflicting nature
of the non-linear and frequency domain measures analysed in this study makes it
difficult to draw direct conclusions of autonomic tone slowing resting heart rate in this
study. Nevertheless, the demonstration of higher sample entropy and a higher SD1:SD2
ratio aligns with conclusions drawn from previous studies that describe therapeutical
and supra-therapeutical doses of FO to increase HRV, particularly vagal tone (Billman
& Harris, 2011; Xin et al., 2013)
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Despite the great awareness of HRV and its association with autonomic control of heart
rate, the analysis and relation of HRV to autonomic control is still controversial
(Karemaker, 2006). Animal and human studies use HRV as a non-invasive surrogate
assessment of autonomic control of the heart (Akselrod et al., 1981; Camm et al., 1996;
Sztajzel, 2004). However, it has also been demonstrated that HRV is primarily a nonlinear surrogate of heart rate itself, making it inappropriate to draw conclusions on the
autonomic nerve activity controlling the heart (Bolea et al., 2016; Monfredi et al., 2014;
Rocchetti et al., 2000; Zaza & Lombardi, 2001). Furthermore, it has been demonstrated
that variability in the beat rate remains in the human transplanted heart that cannot be
attributed to sympathetic or parasympathetic nervous influences (Camm et al., 1996;
Fallen et al., 1988; Sands et al., 1989). This variability in beat rate exists even in
isolated rabbit hearts (Janoušek et al., 2010), isolated myocytes (Zaniboni et al., 2014)
and isolated cardiomyocytes derived from human stem cells in culture (Mandel et al.,
2012). As such, variability in beat rate is likely influenced by both autonomic tone and
intrinsic mechanisms within the sino-atrial node of the heart.
The evidence for modified autonomic tone in this study was conflicting and did not
allow conclusions to be drawn in relation to what caused the slowing of resting heart
rate. Nevertheless, several studies have demonstrated slowed heart rate in cardiac
transplant patients (Harris et al., 2006b) and in rat isolated hearts following FO
supplementation (Abdukeyum et al., 2008; Pepe & McLennan, 1996, 2002), both of
which would be void of neural inputs. Interestingly, resting heart rate has been
demonstrated to remain unchanged despite a trending reduction in vagal tone which
should increase heart rate, following supplementation of dietary achievable FO doses to
healthy young males (Macartney et al., 2014). The same study also described a faster
recovery of heart rate towards resting rates following intense exercise with an associated
decrease in vagal tone. Given these observations in addition to the evidence from
transplant and isolated heart studies, it is likely that slowing and variation of beat by
beat rate is related to an intrinsic mechanism of action of DHA at the pacemaker region
of the heart, rather than altered autonomic tone.
4.5.3 Conclusions
In a dose-related manner, in vivo resting heart rate was slowed in animal’s
supplemented dietary achievable FO doses with no detriment to cardiac output. Whether
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autonomic tone or intrinsic regulation of HRV is responsible for the slower heart rate
described in this study requires further investigation. Slower resting heart rate has been
associated with reduced risk of cardiovascular related mortality and morbidity (Ivanović
et al., 2012; Palatini & Julius, 2004). In fact, clinical evidence has demonstrated that a
reduction of resting heart rate by approximately 1.6 beats.min-1 is estimated to represent
a 5% decrease in the risk of developing cardiovascular disease (Mozaffarian. et al.,
2005). Therefore, the evidence of slowed resting heart rate provided in this study
supports the notion that increased fish or FO intake reduces the risk of cardiovascular
disease. Given these findings the next chapter will explore whether supplementing
dietary achievable FO doses provides protection from arrhythmias during brief periods
of regional in vivo ischaemia and reperfusion (acute coronary syndrome).
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CHAPTER 5

Investigating arrhythmias during
ischaemia and reperfusion following
supplementation of human dietary
achievable fish oil doses
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5.1.1 Background

5.1 INTRODUCTION

The coronary arteries carry oxygenated blood and nutrients to the myocardium and are
essential for healthy functioning of the heart. A common cause of cellular dysfunction,
damage or death within the myocardium is via the temporary blockage (ischaemia) and
return (reperfusion) of blood flow in one or more of the vessels supplying the
myocardium. In cardiac patients, this is known as coronary or ischaemic heart disease.
Coronary heart disease can present clinically as either an acute coronary syndrome or as
angina, which is persistent chest pain. The heart can function during this disease
process, and it is not uncommon for people to live for prolonged periods of time without
a diagnosis. However, if left untreated the myocardial cells in the ischaemic area will
undergo necrosis and a myocardial infarction will develop. Therefore, reperfusion of
blood flow to the ischaemic area is necessary to preserve the viability of myocardial
cells. Unfortunately, it has been demonstrated that reperfusion can lead to accelerated
and additional damage to the myocardium beyond what was generated by the initial
ischaemia (Moens et al., 2005). For this reason, reperfusion has been referred to as a
‘double edged sword’ because it causes further damage to previously ischaemic tissue,
when it should attenuate damage (Braunwald & Kloner, 1985).
Of particular relevance to this study is the evidence which demonstrates a close link
between ischaemia and reperfusion of the myocardium and the manifestation of
electrical instability (arrhythmia) in the heart (Gaudron et al., 2001; Gorenek et al.,
2015). Arrhythmias can originate from the atria or ventricle of the heart and have
significant consequences on the hemodynamic functioning of the cardiovascular system.
If the arrhythmia is of atrial origin, cardiac output can be significantly reduced,
particularly when the heart is working at higher rates (>140beats.min-1) resulting in
exercise intolerance (Lee et al., 2005). However, arrhythmia of ventricular origin is
much more serious as it can result in sudden cardiac death (SCD) in the absence of rapid
medical intervention (Gorenek et al., 2015). In fact, in 20-25% of patients with
myocardial ischaemia, the first clinical manifestation may be SCD (Luqman et al.,
2007) and it has been reported that in most cases, the mechanism of onset is ventricular
tachycardia that rapidly progresses to ventricular fibrillation (Zipes & Wellens, 1998).
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5.1.2 Myocardial damage attributable to brief episodes of ischaemia and reperfusion
During ischaemia there is insufficient blood flow to maintain adequate oxygenation of
the tissue and sustain healthy metabolism within myocardial cells. Myocardial
ischaemic episodes as short as five minutes lead to depletion of energy stores and the
production of reactive oxygen species and their oxidation products within the
myocardium. The heart has very little energy stored in the form of ATP, yet very high
energy demands (Lopaschuk et al., 2010). In fact, in a contracting human heart the
entire pool of ATP is turned over six to eight times in a minute (Lopaschuk et al.,
2010). Therefore, synthesis of ATP required by the healthy heart is primarily generated
by aerobic mitochondrial oxidative metabolism of substrates including fatty acids,
glucose, ketones, lactate, amino acids and pyruvate (Lopaschuk et al., 2010). During
ischaemia the coronary vessels dilate up to three to five times in order to maintain
oxygen delivery for aerobic metabolism (Spaan et al., 2008). However, if oxygen
supply to the myocardium is not adequate even with this compensation, ATP
concentrations cannot be maintained using anaerobic pathways and will rapidly deplete
(Stanley et al., 2005). In addition, the alternative use of anaerobic metabolism to
maintain ATP production creates an excess of intracellular hydrogen (H+) ions.
Increased H+ ions and decreased washout of lactate and other metabolites associated
with anaerobic metabolism leads to a reduction in the tissue pH (Moens et al., 2005).
The combination of oxidative stress due to increased reactive oxygen species, ATP
depletion and changes in tissue pH lead to altered membrane integrity, lipid
peroxidation, impaired functioning of membrane-bound proteins, ion pumps, channels,
receptors, altered electrolyte balances and damage to DNA (Bolli, 1988; Bolli, 1990;
Ferrari et al., 1998). These cellular changes lead to mechanical dysfunction of cardiac
myocytes and functional abnormalities, particularly electrical instability even in the
absence of cell necrosis. Intracellular Ca2+ concentrations are closely linked to these
changes, as Ca2+ movement out of the cell is inhibited by the failure of ATP-reliant ion
transporters. Therefore intracellular Ca2+ concentrations overload the cells. Calcium
overload within the cell can cause the generation of further reactive oxygen species and
the activation of a range of Ca2+ dependant enzymes including ATPase’s and
phospholipases (Moens et al., 2005). The impaired ability to sequester Ca2+ can
culminate in the development of haemodynamic dysfunction and also electrical
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instability resulting in premature ventricular beats (PVB), ventricular tachycardia (VT)
and ventricular fibrillation (VF) (Luqman et al., 2007; Pogwizd & Corr, 1986).
However, the abnormalities of myocardial functioning in the absence of tissue necrosis
usually recover in the proceeding 24 - 48 hours, hence the term “stunned myocardium”
has been coined to describe the acute abnormalities observed (Bolli, 1992). The return
of blood flow allows restoration of glucose and free fatty acids concentrations, which
are essential for generating ATP via aerobic metabolism, and allows the recruitment of
inflammatory cells to the damaged region.
The rapid reactivation of aerobic pathways is associated with an overload of reactive
oxygen species due to Ca2+ sensitive proteases in the mitochondrial respiratory chain
(Kitakaze, 2010). Furthermore, the return of blood flow causes metabolites and ions
which have accumulated in the ischaemia area to be redistributed throughout the
extracellular space (Moens et al., 2005). As such, when blood flow is restored to the
ischaemic region there is rapid normalisation of the tissue pH but also overload of
intracellular Ca2+ concentration gradients (Sanada et al., 2011). The rapid normalisation
of extracellular H+ concentrations which occurs upon reperfusion leads to the activation
of the Na+ - H+ exchanger to extrude H+ to the interstitium in exchange for sodium
(Na+) influx to the cytosol. It has been postulated that this generates an excess of Na+
within the cell upon reperfusion (Tani & Neely, 1989), however, some studies have
been unable to demonstrate increased Na+ concentrations (Pike et al., 1990) or have
reported decreased Na+ concentrations (Emous et al., 2001). Increased intracellular Na+
activates the Na+ - Ca2+ exchange to remove Na+ in exchange for Ca2+ into the cell.
However, Ca2+ concentrations within the cell are already high as Ca2+ movement out of
the cell during ischaemia was inhibited. The combination of accumulated intracellular
Ca2+ and increased Ca2+ flux from activation of the Na+ - Ca2+ exchange leads to much
higher than normal intracellular Ca2+ concentrations.
Ischaemia also induces an inflammatory response that leads to the production of a range
of endogenous eicosanoids and other fatty-acid membrane derived bioactive
compounds. These compounds are formed from membrane bound AA, EPA and DHA
cleaved by phospholipases and then by cyclooxygenase enzymes (Serhan & Petasis,
2011). The eicosanoid end products derived mainly from AA include prostaglandins,
prostacylcins, thromboxanes and luekotrienes. These compounds are generally
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associated with a pro-inflammatory response and have been the target of many
pharmacological interventions including aspirin (inhibits COX-2 mediated production
of prostaglandins), which inhibit their production. They cause the recruitment and
amplification of cytokines (TNF-α), interleukins (IL-1β, IL-6) and chemokines to the
myocardium (Nah & Rhee, 2009). This inflammatory response is amplified and
accelerated when the myocardium is reperfused allowing better access for inflammatory
cells (Frangogiannis et al., 2002). The localized inflammation process is an integral part
of the recovery for the myocardium as it mediates the removal of necrotic cells and
debris and promotes tissue repair and scar formation (Nathan, 2002). However, a
sustained, exacerbated or uncontrolled inflammatory response can impede the recovery
process and lead to further damage of the ischaemic and surrounding areas. In addition,
the presence of inflammation has been demonstrated to be associated post-operative
arrhythmias (Bruins et al., 1997) and atrial fibrillation (Aviles et al., 2003). As such, the
combination of rapid reactivation of aerobic metabolism, inflammatory cascades and the
presence of catecholamines during reperfusion often facilitates the rapid generation
(∼15 seconds) of VT which frequently degenerates into fatal VF upon reperfusion of the
myocardium (Brooks et al., 1995; Pogwizd & Corr, 1986; Sanada et al., 2011).
5.1.3 The anti-arrhythmic action of fish oil during ischaemia and reperfusion
Research has established a range of actions of FO on the cardiovascular system, which
may contribute to the observed cardio-protective effects. These include an antithrombotic (Connor, 2000), anti-atherogenic (Balk et al., 2006) and an antihypertensive effect (Geleijnse et al., 2002). However, the most significant effect of FO
appears to be its anti-arrhythmic action (McLennan, 2014). This effect has been
observed at lower doses of FO than most other established effects with the
consequences potentially being of more relevance to the cardio-protective action
observed in populations which regularly consume fish (Harris et al., 2009).
Several large human based trials have demonstrated that consumption of FO leads to a
reduction in SCD. The Diet and Reinfarction observational Trial (DART) followed the
post-myocardial infarction recovery (secondary prevention) of over 2000 men and
revealed that men who consumed fish regularly (2-3 meals/week) had a 52% reduction
in the risk of SCD (Burr et al., 1989). The Gruppo Italiano per lo Studio della
Sopravvivenza nell'Infarto Miocardio (GISSI) - Prevenzione random control trial
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investigated more than 11,000 post-myocardial infarction patients (secondary
prevention) and also demonstrated a 45% reduction in the risk of SCD with the
consumption of supplements containing 850mg/day of EPA + DHA (Valagussa et al.,
1999). Additonally, doses as low as 180mg/day have been demonstrated to reduce the
risk of primary cardiac arrest in a population-based case-control study of adult females
and males free from prior clinical heart disease (Siscovick et al., 1995). As such, it has
been suggested that there is sufficient evidence to show FO reduces the incidence of
SCD in humans, however it is still unclear what dose is required and wether the
background diet influences the cardio-protective action (Reiffel & McDonald, 2006).
Physiological evidence of the direct anti-arrhythmic action of FO has been provided by
studies using both paced and unpaced in vivo and ex vivo rat, monkey and pig hearts
(Table 5.1).
In summary, it is still unknown if the anti-arrhythmic effect of FO demonstrated in
animal studies is relevant to the observational and cohort studies of diet and SCD,
because of the use of FO doses not relevant to human nutrition. Studies which have
used dietary achievable FO doses have not supplied a typical Western-style background
diet high in SFA and n-6 PUFA. Therefore, extrapolation of the findings from such
studies must be used with caution to explain reductions of SCD observed in
epidemiological and cohort trials, where arrhythmia prevention is ascribed to fish
intake. As such, the objective of this study was to establish whether supplementing
human dietary achievable FO doses to a typical Western-style diet protects against
ischaemic and reperfusion generated arrhythmias. The surgical model which will be
used in the present study to induce regional ischaemia and reperfusion was a
modification of a technique first described in 1960 (Selye et al., 1960). The clinical
relevance of this model to acute coronary syndrome has allowed it to be extensively
used in the literature to investigate arrhythmia generation in both pharmaceutical antiarrhythmic therapies (Altug et al., 1999; Walsh et al., 2010) and the investigation of
anti-arrhythmic actions of FO (Abdukeyum et al., 2008; Charnock et al., 1989;
McLennan et al., 1988).
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Table 5.1: Comparison of animal interventions investigating fish oil and arrhythmia generation.
Fish oil dose
(% wt/wt)

Type of oil

Animal

12%

DHA-rich tuna oil

Rat

In vivo

↓ Vulnerability to I & R induced VT and VF

McLennan. P.L et al.
(1988)

12%

Purified EPA-rich
Shaklee oil

Rat

In vivo

↓ Incidence of I & R induced VF

McLennan. P.L. (1993)

12%

Purified EPA-rich
Shaklee oil

Rat

Ex vivo
(paced)

Prevented reperfusion-induce VF and ↓ ischaemia induced arrhythmias

Pepe. S. et al. (1996)

8%

DHA-rich tuna oil

Marmoset
monkey

In vivo
(paced)

↑ Threshold to stimulated VF and ↓ VF incidence
(and during ischaemia)

McLennan. P.L. (1992b)

7%

DHA-rich tuna oil

Rat

Ex vivo

↓ Arrhythmia during I & R

Abdukeyum. G.G. et al.
(2008)

5%

DHA-rich Menhaden
oil

Rat

In vivo

↓ Incidence and severity of VF and VT during I & R

Hock. C.E. et al. (1990)

4.5%

Mackerel oil

Pig

In vivo

↓ Incidence of reperfusion-induced arrhythmias

Hartog. J.M. et al. (1987)

3%

Purified FO

Marmoset
monkey

In vivo
(paced)

↑ Threshold to stimulated VF
(and during ischaemia)

McLennan. P.L et al.
(1993)

3%

Purified EPA-rich
Shaklee oil

Rat

Ex vivo
(paced)

↓ Incidence of arrhythmias during 15min ischaemia

Pepe. S. et al. (2007)

1%

DHA-rich tuna oil

Rat

In vivo

↓ Episodes and duration of VF during reperfusion

Abeywardena. M. et al.
(2016)

0.4-1.1%

Purified EPA or DHA
rich oil

Rat

In vivo

Purified DHA ↓ VF incidence but Purified EPA did not

McLennan. P.L. et al.
(1996)

1.25 & 0.31%

DHA-rich tuna oil

Rat

In vivo

??

Present study

Model

Outcome

Author

Abbreviations: VT = ventricular tachycardia; VF = ventricular fibrillation; I = ischaemia; R = reperfusion.
Fill represents historically common supra-therapeutical doses of FO.
Fill represents dietary achievable doses of FO.
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5.2 AIMS AND HYPOTHESES

This study aimed to investigate arrhythmia generation, during a clinically relevant
(acute

coronary

syndrome)

ischaemia

and

reperfusion

protocol,

following

supplementation of dietary achievable FO doses to a typical Western-style diet (high
SFA and n-6 PUFA).
Specifically, this experiment had the following aims and hypotheses:
Aim 1: Determine the influence of supplementing dietary achievable FO doses on
ischaemic generated arrhythmias.
Hypothesis 1: The severity, duration and incidence of ischaemic arrhythmias
will be reduced by FO supplementation.
Hypothesis 2: The risk of fatality from arrhythmia will be reduced by FO
supplementation.
Aim 2: Determine the influence of supplementing dietary achievable FO doses on
reperfusion generated arrhythmias.
Hypothesis 3: The severity, duration and incidence of reperfusion generated
arrhythmias will be reduced by FO supplementation.
Hypothesis 4: The risk of fatality from arrhythmia will be reduced by FO
supplementation.
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5.3 METHODS

5.3.1 Animals, ethical considerations and stadardisation
The male rats (Sprague Dawley) from cohort 2 were used in this study. Directly
following the end of experimental procedures described in Chapter 4 the experimental
procedures for this study began.
5.3.2 Groups
Animals were supplied water and randomly assigned to one of three pre-fabricated diets
ad libitum for four (4) weeks before experimentation. The diets contained different
amounts of FO (Control – 0%: n = 18, LowFO – 0.31%: n = 15, ModFO – 1.25%: n =
18 (%wt/wt)).
5.3.3 Experimental preparation
Preparation of the 6mm miniaturised 2-French (2F) Millar pressure-volume
conductance

catheter

(SPR-638

Millar

Instruments,

Houston,

USA)

and

electrocardiogram (ADInstruments, Bella Vista, NSW, Aus) was completed (Section
3.3.3).
5.3.4 Surgical procedures
Animals were anaesthetised, and surgery conducted to allow cardiac measurements
including: ECG, ventricular pressure and volume and aortic blood pressure (Chapter 4).
Following this an established surgical technique which has been used extensively for
the production of arrhythmias in the in vivo heart was completed (McLennan et al.,
1988; Selye et al., 1960).
5.3.4a Thoracotomy
A 3-4cm superior-inferior midline incision was made in the chest and at the inferior end
of the incision a 2-3cm transverse incision was to made towards the left mid-axillary
line to allow the skin to be bluntly dissected and reflected back to reveal the
musculature and ribs of the left thoracic cavity. Blunt scissors were inserted between the
pectoralis major and minor muscles in order to break the fascia and allow retraction of
these muscles from the chest to expose the ribs underneath. Care was taken to not break
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the superficial thoracic vein during this step as injury to this vessel causes significant
bleeding. Once the ribs were visible the chest was then opened at the fourth intercostal
space using blunt surgical scissors to tear the intercostal muscles and make a 1-2cm
transverse incision. The incision was made 3-4mm laterally from the sternum to avoid
damaging the internal thoracic artery which results in heavy bleeding that is very
difficult to control. The fourth rib was then sectioned using surgical scissors
approximately 2-3mm from the sternum and blunt scissors were then used to increase
the space of the incision via opening the scissors at an oblique angle to the ribs. The
heart then became visible encased in the pericardium. The pericardium was grasped
with curved forceps and opened using blunt scissors to avoid damage to the
myocardium, once opened it would slide behind the heart and remain there making the
heart freely accessible.
5.3.4b Exteriorisation of the heart and suturing of the LAD coronary artery
The heart was exteriorised via placing a scoop spatula with a small amount of 0.9%
NaCl on it underneath the heart inside the thoracic cavity and then applying a small
amount of external pressure on the superior and right chest wall. The LAD runs
obliquely over the anterior surface of the left ventricle from the left coronary artery
branch with the left circumflex artery towards the apex of the heart along the
interventricular sulcus. Once the heart was exteriorised it was held between the left
thumb and forefinger with the apex facing towards the right of the animal and slightly
superiorly. A size 6-0 braided silk suture attached to a 12mm atraumatic taper needle
(Dynek Pty Ltd, Australia) was placed under the LAD using curved tip hemostat
scissors in the right hand. The LAD sits within the myocardium which makes it difficult
to directly locate visually. Therefore the left auricular appendage and pulmonary cone
were used as guides for insertion and exit points respectively of the suture. The heart
was then replaced in the chest and the animal was allowed to recover for ten minutes.
This entire process takes roughly ten to fifteen seconds.
5.3.5 Experimental protocol and measurements
Animals were checked for depth of anaesthesia (Section 3.3.3) directly following
surgical procedures being completed and prior to experimental protocols and
measurements beginning. After insertion of the occluding suture and return of the heart
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to the thoracic cavity, each animal was allowed ten minutes recovery for stabilisation of
cardiac function before commencing the ischaemia and reperfusion protocol (Figure
5.3).
5.3.5a LAD coronary artery occlusion and reperfusion
The suture was drawn through a 3mm length of polyethylene tubing with a small slit
made in the side at one end of the tubing. The tubing was allowed to slide down the
suture to come into contact with the heart where the LAD sits. The LAD was occluded
via applying tension to the suture and the tension was maintained by drawing the suture
down the slit in the tubing (Figure 5.1). Occlusion of the LAD was confirmed by
checking for visible blanching of the anterior wall of the left ventricle after a few
seconds and via confirming depression of the ST segment and elevation of R wave on
the ECG (Figure 5.2). The LAD was occluded for fifteen minutes of ischaemia while
arrhythmia generation was measured via ECG. The fifteen minutes ischaemic duration
was used because the occurrences of arrhythmias induced by regional ischaemia in the
rat peak between five to ten minutes and usually finish before fifteen minutes (Curtis et
al., 1987). The suture was released from the slit in the tubing and tension relieved after
fifteen minutes of ischaemia, allowing reperfusion of the heart following occlusion.
Reperfusion arrhythmias peak in the first five minutes but can also still be observed up
to fifteen minutes after release of the occlusion (McLennan et al., 1988), therefore
reperfusion arrhythmias were measured for fifteen minutes via ECG.
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Suture holding
pressure on tubing

Tubing placing
pressure on area
where LAD is
located

Right atrium

Left ventricle

Non-ischaemic
tissue (Stained)

Ischaemic tissue
(Non-stained)

Figure 5.1: Post-experimental isolated heart showing surgical LAD coronary
artery occlusion via placing tension on a piece of tubing over the artery &
Indian dye stained ischaemic/non-ischaemic tissue.
Figure 5.1 notes: The tubing places pressure on the area of myocardium where the LAD is
located whilst the suture places pressure from below in order to occlude it. The tubing is held in
place with tension generated from a suture being held in a slit of the tubing. Ischaemic region
(non-stained) and non-ischaemic region (stained black) can also be observed after perfusion of
coronary arteries with Indian dye while LAD is occluded.
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Elevation of R wave amplitude

Normal ST segment

Depressed ST segment

LAD occluded

Figure 5.2: Example of typical ECG trace from an animal as the LAD coronary artery occlusion is begun.
Figure 5.3 notes: The occlusion of the LAD artery was confirmed via sighting of elevation of the R wave and ST-segment depression along with blanching of the
ventricular wall.
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Dietary
supplementation
(Chapter 2)

Resting cardiac
function tests
(Chapter 4)

Ischaemic/Reperfusion protocol
Rest

LowFO (n=20)

(N=62)
ModFO (n=20)

Check anaesthesia

supplementation

Abdominal surgery

Dietary

Anaesthesia

Control (n=22)

0

5 25
Thoracotomy and
LAD suture
placement

80-90 min
Neck surgery

28-32 days

15 min
35

50

15 min
65

Suture around LAD
pulled tight

Suture around LAD
released

Ischaemia

Reperfusion

Ischaemic arrhythmia

Reperfusion arrhythmia

analysis (ECG)

analysis (ECG)

Figure 5.3: Overview of the experimental protocol used to investigate the effect of fish oil on arrhythmia generation.
Abbreviations: ECG = electrocardiogram; LAD = left anterior descending coronary artery.
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5.3.6 Post-experimental data analysis
5.3.6a Classification and scoring of arrhythmias
Arrhythmia classification was completed according to the Lambeth conventions
(Walker et al., 1988). Measurement of PVB was completed through identifying a QRS
complex which occurred earlier than would be expected in the ECG tracing of regular
sinus rhythm. Because PVB originate from the ventricle they are identifiable on the
ECG as a QRS complex without a preceding P wave (Figure 5.4A), which is why they
are also commonly referred to as Ventricular Ectopic Beats (VEB). Classification of VT
was defined as four or more consecutive PVB, and VF was defined as indistinguishable
QRS deflections where no rate could be measured along with accompanied drop in
blood pressure, torsade de pointes was also classified as VF (Figure 5.4B).
Identification of the arrhythmias allowed a previously established scoring scale to be
used to rank the severity of the arrhythmias and allow comparison between groups
(Curtis et al., 1987). This is achieved by taking into account the number of PVB, the
duration and type of arrhythmia, the timing of the arrhythmia in relation to the
ischaemic and reperfusion period and whether and when the animal spontaneously
reverted to sinus rhythm or the arrhythmia resulted in death. The scale is from zero to
nine with scores between zero and five indicating that the animal survived the entire
ischaemia or reperfusion protocol. However, an animal which scored five would have
had more incidents and/or duration of arrhythmia and/or more serious arrhythmia e.g.,
more VF than VT compared to an animal which scored one. Scores between six and
nine are given to animals which did not survive the ischaemia, the difference in scoring
for these animals is dependent upon the time that the fatal VF started, with a higher
score given for fatal VF starting earlier in the ischaemia or reperfusion (Table 5.2). The
scale was slightly modified to quantify reperfusion induced arrhythmias following an
established method in a previous study with similar design and measurement outcomes
to this one (McLennan et al., 1988). The modified scale was used to take into account
the shorter time course of reperfusion arrhythmias. Using a scoring index to represent
the severity and incidence of arrhythmias occurring is of particular value in aiding
statistical evaluation between groups where there is a low incidence of VT and/or VF.
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Table 5.2: Scoring index used to quantify arrhythmias.
Ischaemia

Reperfusion

0 = 0-49 PVB

0-49 PVB

1 = 50-499 PVB

50-249 PVB

2 = >499 PVB and/or 1 episode of spontaneously reverting VT or VF

>250 PVB and/or 1 episode of spontaneously reverting VT or VF

3 = >1 episode of VT or VF or both (<60 s total combined duration)

>1 episode of VT or VF or both (<20 s total combined duration)

4 = VT or VF or both (60-119 s total combined duration)

VT or VF or both (20-59 s total combined duration)

5 = VT or VF or both (>119 s total combined duration)

VT or VF or both (>60 s total combined duration)

6 = fatal VF starting >15 min after occlusion

fatal VF starting at >5 min after reperfusion

7 = fatal VF starting between 4 and 14 min 59 s after occlusion

fatal VF starting between 4 and 5 min after reperfusion

8 = fatal VF starting between 1 and 3 min 59 s after occlusion

fatal VF starting between 20 s and 2 min after reperfusion

9 = fatal VF starting <1 min after occlusion

fatal VF starting <20 s after reperfusion

Abbreviations: PVB = premature ventricular beats; VT = ventricular tachycardia; VF = ventricular fibrillation.
Ischaemic scoring index was established by Curtis. M.J. et al., 1987, reperfusion scoring is a modified version from McLennan. P.L. et al., 1988.
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Figure 5.4: Example experimental ECG (Pink) and aortic blood pressure (Red)
traces showing PVB (A), VT and VF (B).
A: Premature ventricular beat (PVB). It can be observed that the QRS complex occurs prior to
the P wave and then a compensatory pause before next QRS complex.
B:
Highlights a run of premature ventricular beats (PVB) leading into an episode of
ventricular tachycardia (VT:
) and an episode of torsade de pointes (ventricular fibrillation
VF:
) with the associated drop in aortic blood pressure.
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5.3.6b Statistics
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise
stated. The effects of diet treatment were tested via ANOVA. A Bonferroni post-hoc
test for comparison between group means was then used to identify differences. The
incidence of VT or VF was expressed as the percentage (%) of animals in which at least
one episode was observed. Percentage incidence data was then tested using chi-square
with Fischer’s exact test. All statistical analyses were performed in a blinded manner
and completed using SPSS 21 for Windows (SPSS Inc, Chicago, IL, USA). Alpha was
set at p <0.05.
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5.4 RESULTS

Forty-nine (N = 49) animals were used for the analysis of ischaemic arrhythmias. Two
(2) animals in the ModFO group were removed from the analysis due to bradycardia
associated with atrioventricular block, without preceding arrhythmia. This was most
likely caused by surgical damage to the conduction pathways, surgical complication
resulting in cardiogenic shock or anaesthetic overdose. The final group numbers
included in the analysis of each group were as follows: Control (n = 18), LowFO (n =
15) and ModFO (n = 16). Of the forty nine (49) animals that underwent LAD coronary
artery occlusion only twenty-eight (28) animals survived the complete occlusion.
Ischaemic induced arrhythmias were most pronounced between five and eight minutes
after the occlusion had been drawn tight. Animals which did not die from fatal VF
during the ischaemia had predominantly reverted to normal sinus rhythm after ten
minutes of ischaemia. Twenty-one (21) animals died (44%) due to VF prior to the
occlusion being released for reperfusion (Figure 5.5).

Total Animals (N=51)

15min coronary LAD occlusion induced ischaemia

Control (N=18)

11 deaths

Survival:

Control (N=7)

LowFO (N=15)

6 deaths

LowFO (N=9)

ModFO (N=16*)

4 deaths

ModFO (N=12*)

Figure 5.5: The total survivors/deaths during fifteen minutes LAD coronary
artery occlusion.
*Two (N=2) animals in the ModFO group were removed from the analysis due to bradycardia
(Abnormally low heart rate prior to the occlusion occurring) without preceding arrhythmia.
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5.4.1 The effect of fish oil supplementation on ischaemia generated arrhythmias
Nearly all the animals in the Control (94%) and LowFO (91%) group experienced at
least one VT episode during the ischaemia (Figure 5.6A). Significantly less animals
experienced at least one incidence of VT in the ModFO (31%) group compared to both
of the other groups (p <0.001). The mean total duration of VT in animals which
experienced ≥ one episode was significantly shorter in both FO groups compared to the
Control group (Figure 5.6B).

Ventricular tachycardia
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Figure 5.6: The effect of fish oil on the incidence and duration of ventricular
tachycardia during LAD coronary artery occlusion induced ischaemia of the left
ventricle.
Values are mean ± SEM (n = 15 - 18). * p <0.05 vs Control diet, † p <0.05 vs LowFO
diet (% Incidence analysed via chi-square with Fischer’s exact test, Duration analysed
by One-way ANOVA with Bonferroni post-hoc test).
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Almost all animals in the Control group (89%) experienced at least one VF episode
during ischaemia. Less animals in the LowFO (60%) group experienced at least one
episode of VF which trended toward significance (p =0.052). In the ModFO (50%)
group, a significant difference in the number of animals which experienced at least one
episode of VF was evident (Figure 5.7A). There were no significant differences
between groups in the mean number of VF episodes per animal which did experience
VF during the ischaemia (Table 5.3). A trending reduction in cases of fatal VF during
ischaemia in animals from the LowFO group (6/15 animals [40%]) compared to the
Control (11/18 animals [61%]) was evident. Whereas, cases of fatal VF in the ModFO
group (4/16 animals [25%]) were significantly less than the Control group. The mean
total duration of VF in animals which experienced ≥ one episode of VF was not
different between any group (Figure 5.7B).

Ventricular fibrillation
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Figure 5.7: The effect of fish oil on the incidence and duration of ventricular
fibrillation during ischaemia of the left ventricle induced by occlusion of the
LAD coronary artery.
Values are mean ± SEM (n = 15 - 18). * p <0.05 vs Control diet (% Incidence analysed
via chi-square with Fischer’s exact test, Duration analysed by One-way ANOVA with
Bonferroni post-hoc test).
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The arrhythmia score was significantly lower in a dose-related manner, the Control
group displaying the highest score followed by the LowFO and the ModFO groups
(Figure 5.8A). The FO supplemented groups spent significantly more time in normal
sinus rhythm compared to the Control group throughout the entire fifteen minutes of
ischaemia (Figure 5.8B). Furthermore, during the fifteen minutes of ischaemia both
FO groups had less PVB than the Control group (Table 5.3). The ModFO group had an
almost three-fold reduction in PVB which was significantly less compared to the

A

Arrhythmia Score

8
6
4

*

2
0
Legend:

Control

LowFO

Normal sinus rhythm (sec)

Control group (p =0.05).

B

900
850

*
*

800
750
700
0

ModFO

Figure 5.8: The effect of fish oil on arrhythmia score and time spent in normal
sinus rhythm during ischaemia of the left ventricle induced by occlusion of the
LAD coronary artery.
Values are mean ± SEM (n = 15 -18).* p <0.05 vs Control diet (One-way ANOVA with
Bonferroni post-hoc test). Arrhythmia score was calculated according to Curtis. M.J. et
al., 1987 (Table 5.2).
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5.4.2 The effect of fish oil supplementation on reperfusion generated arrhythmias
Twenty-one (N = 21) animals died of arrhythmias during the ischaemic period of the
ischaemia and reperfusion protocol. This resulted in twenty-eight (28) animals being
used for the analysis of reperfusion-induced arrhythmias. The final group numbers for
analysis were: Control (n = 7), LowFO (n = 9) and ModFO (n = 12). Reperfusion
induced arrhythmias were most pronounced between fifteen seconds and one minute
after the LAD coronary artery occlusion had been released. Animals which did not have
an arrhythmia during this time period predominantly would not have any arrhythmias
during the remaining reperfusion time. Animals that did have non-fatal arrhythmias
during this time had usually spontaneously reverted to normal sinus rhythm before five
minutes of reperfusion. Of the twenty-eight (28) animals that underwent reperfusion of
the LAD coronary artery only one (1) animal died of arrhythmia (Figure 5.9).

Control (n=18)
11/18

Fatal VF

LowFO (n=15)
6/15

ModFO (n=16)
4/16

Total Animals (N=28)

15min coronary reperfusion induced ischaemia

Control (N=7)

1 death

Survival:

Control (N=6)

LowFO (N=9)

0 deaths

LowFO (N=9)

ModFO (N=12)

0 deaths

ModFO (N=12)

Figure 5.9: The total survivors/deaths during fifteen minutes LAD coronary
artery reperfusion.
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All the animals in the Control and LowFO group experienced at least one VT episode
during reperfusion (Figure 5.10A). Significantly less animals experienced at least one
incidence of VT in the ModFO (33%) group compared to both of the other groups (p
<0.001). The mean total duration of VT in animals which experienced ≥ one episode
was significantly shorter in both FO groups compared to the Control group (Figure
5.10B).
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Figure 5.10: The effect of fish oil on the incidence and duration of ventricular
tachycardia during reperfusion of the LAD coronary artery.
Values are mean ± SEM (n = 7 - 12). * p <0.05 vs Control diet, † p <0.05 vs LowFO
diet (% Incidence analysed via chi-square with Fischer’s exact test, Duration analysed
by One-way ANOVA with Bonferroni post-hoc test).
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Almost all animals in the Control group (86%) experienced at least one VF episode
during reperfusion. Significantly less animals in the LowFO (22%) and ModFO (8%)
group experienced at least one episode of VF compared to the Control group (Figure
5.11A). Total mean number and duration of VF episodes per animal which did
experience VF during reperfusion were unable to be statistically analysed due to the
small number of animals in the ModFO (n=1) and LowFO (n=2) which experienced VF
(Table 5.3). However, anecdotal observation shows that the duration of VF in the
animals that did experience at least one case was dramatically lower in the ModFO and
LowFO groups compared to the Control (Figure 5.11B).
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Figure 5.11: The effect of fish oil on the incidence and duration of ventricular
fibrillation during reperfusion of the LAD coronary artery.
Values are mean ± SEM (n = 7 - 12). * p <0.05 vs Control diet (% Incidence analysed
via chi-square with Fischer’s exact test, Duration analysed by One-way ANOVA with
Bonferroni post-hoc test).
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The arrhythmia score was significantly lower in a dose-related manner across the FO
groups compared to Control during reperfusion (Figure 5.12A). Additionally, the FO
supplemented groups spent significantly longer in normal sinus rhythm compared to the
Control group throughout the entire fifteen minutes of reperfusion (Figure 5.12B).
There was one fatal VF episode in the Control group but there were no fatal VF
episodes in the FO groups. During the fifteen minutes of reperfusion both FO groups
had an approximately three-fold reduction in PVB compared to the Control group (p
=0.006) (Table 5.3).

Figure 5.12: The effect of fish oil on arrhythmia score and time spent in normal
sinus rhythm during reperfusion of the LAD coronary artery.
Values are mean ± SEM (n = 7 – 12).* p <0.05 vs Control diet, † p <0.05 vs LowFO
diet (One-way ANOVA with Bonferroni post-hoc test). Arrhythmia score was
calculated according to methods described in McLennan. P.L. et al., 1988 (Table 5.2).
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Table 5.3: The effect of fish oil on arrhythmia indices in the left ventricle during fifteen minutes ischaemia induced by occlusion of the
LAD coronary artery and fifteen minutes reperfusion.
Ischaemia
Control

LowFO

ModFO

Animals (n)
Time in NSR (Max = 900s)
PVB

18
716 (±13)
114 (±27)

15
794 (±24)*
78 (±17)

16
798 (±25)*
43 (±9)*

Animals experienced VT (n)
VT incidence
VT episodes
VT duration

17
94%
7 (±2)
64 (±14)

14
93%
5 (±2)
26 (±15)*

5
31%*†
4 (±3)
25 (±16)*

Animals experienced VF (n)
VF incidence
Fatal VF
VF episodes
VF duration

16
89%
61%
1.4 (±0.3)
124 (±16)

9
60%
40%
1.7 (±0.4)
122 (±22)

8
50%*
25%*
1.1 (±0.5)
110 (±23)

Arrhythmia score

6.1 (±0.4)

4.6 (±0.5)

3.1 (±0.7)*

Reperfusion
Trend p =
0.005
0.050
<0.001
0.043
0.042
0.045

0.0026

Trend p =

Control

LowFO

ModFO

7
795 (±34)
155 (±36)

9
884 (±5)*
58 (±15)*

12
895 (±2)*
59 (±14)*

<0.001
0.006

7
100%
6 (±1)
32 (±8)

9
100%
2 (±1)*
13 (±5)*

4
37%*†
2 (±1)
10 (±8)*

<0.001
0.01
0.04

6
86%
14%
1.6 (±0.4)
85 (±33)

2
22%*
a
0%
a
1
a
9

1
9%*
a
0%
a
1
a
7

4.6 (±0.3)

3.1 (±0.3)*

1.3 (±0.3)*†

<0.001

<0.001

Values are mean ± SEM. * p <0.05 vs Control diet † p <0.05 vs LowFO diet, a too few numbers to complete statistical comparisons (% Incidence
analysed via chi-square with Fischer’s exact test, Duration analysed by One-way ANOVA with Bonferroni post-hoc test).
Abbreviations: NSR = normal sinus rhythm; PVB = premature ventricular beats; VT = ventricular tachycardia; VF = ventricular fibrillation; Incidence =
percentage of animals which experienced at least one episode; Fatal VF = percentage of animals which died from VF; Episodes = mean number of arrhythmic
episodes per animal; Duration = mean total time in arrhythmia of animals having ≥ one episode.
Ischaemic arrhythmia score was calculated using previously outlined and established methods (Curtis et al., 1987). Reperfusion arrhythmia score was calculated
using previously outlined and established methods (McLennan et al., 1988).
Fill represents data where the LowFO has produced a comparable effect to what was demonstrated with the ModFO dose.
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5.5 DISCUSSION

This study, for the first time, demonstrated that supplementing FO doses achievable
within a typical Western-style human diet (high SFA and n-6 PUFA) provides
protection against ischaemia and reperfusion induced arrhythmias in the in vivo heart.
Arrhythmia generation, including fatal arrhythmias, were reduced by both FO diets in a
dose-related manner, suggesting that optimal cardiac electrophysiology is intimately
linked with myocardial phospholipid DHA concentrations. However, during ischaemia
anti-arrhythmic effects were not observed across all indicators in the LowFO diet,
suggesting that it may be close to the threshold dose required for protection. Whereas,
during reperfusion there were few statistically significant differences between the two
FO doses, suggesting that the threshold for effectiveness may be even lower. The
demonstration of reduced fatal ischaemia and reperfusion generated arrhythmias
provides strong evidence, for the first time, to rationalise how FO can prevent sudden
(arrhythmic) cardiac death (Burr et al., 1989; Valagussa et al., 1999). This finding
underpins the importance of increasing fish or FO intake in a typical Western-style diet
containing high amounts of SFA and n-6 PUFA.
5.5.1 Generation of arrhythmias via ischaemia and reperfusion model
Arrhythmias were successfully generated during the transient regional ischaemia and
reperfusion periods induced by the surgical occlusion and release of the LAD coronary
artery. During the ischaemic period approximately 60% of the Control group died due
to fatal VF. The incidence of fatal VF in the Control group is very similar to the
mortality rate displayed in Control groups of other studies using the same or very
similar surgical methods for the induction of arrhythmias in the rat (Abeywardena et al.,
2016; McLennan, 1993). This confirms the reliability of the surgical model used to
induce ischaemic arrhythmias in this study. Reperfusion of the myocardium is also a
very strong stimulus for arrhythmia generation (Manning & Hearse, 1984). It has been
suggested however that the preceding ischaemic period can lead to biased outcomes
(Balke et al., 1981). When LAD ligation induced ischaemia is limited to five minutes,
the proceeding reperfusion produces VT in virtually all cases and VF in approximately
80%; less cases are generated with both shorter and longer periods of ischaemia
(Manning & Hearse, 1984). The majority of arrhythmias in this study occurred between
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five and eight minutes of ischaemia and animals usually spontaneously reverted to
normal sinus rhythm for the remainder of the fifteen minute occlusion. During
reperfusion the occurrence of VT was usually observed in all animals very rapidly after
reperfusion began. The Control group incidence of VF was 86% and one case
progressed into fatal VF. Therefore, the use of a fifteen minute ischaemic period did not
seem to influence the occurrence of reperfusion VT or VF but did reduce the expected
cases of fatal VF. A possible explanation for this observation is that the ischaemic
period was sufficient enough to cause fatal VF in animals susceptible to it; therefore the
animals which reached reperfusion were more likely to not die of fatal VF upon
reperfusion. Importantly, compared to the Control group, the FO supplemented groups
were protected from the arrhythmic stimulus throughout ischaemia and reperfusion.
5.5.2 Arrhythmia protection attributable to human dietary achievable fish oil doses
The current study has demonstrated, for the first time, that the anti-arrhythmic action of
FO is present in animals when using human dietary achievable doses, equivalent to
what could be achieved in the human diet, and in the presence of a background
Western-style diet high in SFA and n-6 PUFA. This finding extends the demonstration
of FO anti-arrhythmic action in previous studies (Abdukeyum et al., 2008;
Abeywardena et al., 2016; Hartog et al., 1987; Hock et al., 1990; McLennan et al.,
1988; McLennan et al., 1993; McLennan et al., 2007) using therapeutic and supratherapeutical doses of FO. Importantly, for the first time this study has demonstrated
that the anti-arrhythmic action of FO remains present at a dose (LowFO) equivalent to
two 100g serves of fish per week or one average sized salmon fillet (≈250g) (Slee et al.,
2010). Only one other study has described an anti-arrhythmic action of FO while using
a comparable dose to the ModFO group (Abeywardena et al., 2016). The study
completed by Abeywardena et al., 2016, supplemented 1% FO and induced in vivo
arrhythmias via the same surgical protocol used in this study. The reduction in fatal VF
episodes observed in the ModFO (1.25%) supplemented rats was comparable to the
mortality rate demonstrated in rats supplemented 1% FO by Abeywardena et al., 2016.
In combination, these findings provide strong evidence that infers the anti-arrhythmic
action of FO is present using doses in the rat equivalent to what could be easily
achieved in the human diet. Interestingly, even though the two studies supplemented FO
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at similar doses, different background diets were used. This suggests that variations in
background diet do not exert any influence on the anti-arrhythmic action of FO.
The anti-arrhythmic action of FO first described several decades ago using a whole
animal model (McLennan et al., 1988) appears to be intimately linked to myocardial
phospholipid DHA concentrations. In line with this observation, studies consistently
demonstrate the anti-arrhythmic action of FO via only altering dietary LC n-3 PUFA
intake. For example, initial research demonstrated that crossover to a supratherapeutical FO diet reversed the arrhythmogenic effects of prolonged high SFA intake
(McLennan et al., 1990). Further to this, addition of supra-therapeutical doses of FO to
a diet high in SFA has been demonstrated to reduce the vulnerability of the rat heart to
ischaemic arrhythmia, whereas the addition of n-6 PUFA to the high SFA diet did not
show the same protection (Charnock et al., 1991). Similarly, ventricular fibrillation
threshold has been demonstrated to be modulated by addition of supra-therapeutical
doses of FO to a high SFA diet but it is not modified by the addition of sunflower seed
oil (n-6 PUFA) in the marmoset heart (McLennan et al., 1993). More recently,
ischaemic induced arrhythmias have been demonstrated to be inhibited by the addition
of therapeutic and supra-therapeutical doses of FO to a high SFA-enriched diet in rats
(Pepe & McLennan, 2007). It has been postulated that it is essential to change dietary
intakes of both LC n-3 PUFA and n-6 PUFA (reduce the n-6:n-3 ratio) to observe
cardiovascular benefits (Lands, 2003; Rupp et al., 2004; Simopoulos, 2008), based on
the notion that phospholipid incorporation of LC n-3 PUFA only occurs when the n-6:n3 ratio is reduced (Hulbert et al., 2005). However, there is significant evidence that
indicates that dietary n-6 PUFA intake does not affect LC n-3 PUFA incorporation,
particularly when preformed EPA+DHA are provided (Slee et al., 2010; Stark et al.,
2007a; Stark et al., 2007b). The current research supports this by demonstrating that
phospholipid concentrations of LC n-3 PUFA are closely associated with absolute
amounts of LC n-3 PUFA provided, regardless of background SFA or n-6 PUFA levels.
In addition, the current research has now demonstrated an anti-arrhythmic action
without modifying SFA or n-6 PUFA concentrations in the diet, supporting clinical
evidence which demonstrates that only LC n-3 PUFA levels need to be changed in the
diet to produce cardioprotective actions (Harris, 2006; Harris et al., 2006a).
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Previously studies have relied upon therapeutic and supra-therapeutical doses of FO to
demonstrate an anti-arrhythmic action; however, background diets has varied
considerably between studies (Charnock et al., 1991; McLennan, 1993; McLennan et
al., 1988, 1990; Pepe & McLennan, 2007). The only other study to demonstrate antiarrhythmic effects of FO with similar doses to this study used a diet which was rich in
n-6 PUFA and monounsaturated fatty acids but did not contain large amounts of SFA
(Abeywardena et al., 2016). In contrast, the monounsaturates portion (olive oil) of the
diets used in this study was substituted for FO to ensure high levels of both SFA and n-6
PUFA were present in the FO diets. The variation in SFA between this study and the
study completed by Abeywardena et al., 2016 is important as long term feeding with
SFA has been demonstrated to be arrhythmogenic (McLennan et al., 1990). As such,
this study provides novel evidence to demonstrate that the anti-arrhythmic action of FO
is not inhibited by the normally arrhythmogenic stimulus associated with high amounts
of dietary SFA, typical to the Western-style diet. In addition, it demonstrates that
variations in the background diet do not appear to exert any influence on the antiarrhythmic action of FO. Rather, the anti-arrhythmic action is closely linked to the
absolute FO intake, regardless of background SFA and n-6 PUFA intake.
Several key changes in the arrhythmic indices measured from FO supplemented animals
help explain the overall anti-arrhythmic action observed. During ischaemia, FO
supplemented animals spent approximately one to one and a half minutes longer in
normal sinus rhythm compared to Control animals, and during reperfusion this
increased towards two minutes longer. The FO groups had a reduced total number of
PVB compared to the Control group and in the case of the ModFO group the reduction
observed was almost three-fold. Increased time in normal sinus rhythm and less PVB in
FO supplemented animals is important as PVB have been demonstrated to be associated
with the initiation of VT which can progress into fatal VF in patients with and without
heart disease (Haïssaguerre et al., 2003; Haïssaguerre et al., 2002). As such, reduced
PVB in FO animals provides plausible physiological evidence to describe the lower
incidence and shorter mean duration of VT and VF observed in FO supplemented
animals during ischaemia and reperfusion. Human clinical investigations have
demonstrated that as the duration of VF increases, the defibrillation threshold required
to revert out of VF becomes larger (Gradaus et al., 2002). Furthermore,
supplementation of FO has been demonstrated to reduce the ventricular fibrillation
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threshold in the marmoset heart (McLennan et al., 1993). Unlike the human heart, the
rat heart can spontaneously defibrillate (Manoach et al., 1980). As such, it is likely that
the observation of reduced fatal VF cases in animals supplemented FO is due in part, to
the smaller mean duration of time spent in VF, and modification of the ventricular
fibrillation threshold improving the chances of the heart spontaneously defibrillating.
There has been evidence that suggests dietary FO does not protect against arrhythmias
and may even act in a pro-arrhythmic manner (Billman et al., 2012; Billman et al.,
2010; Mączewski et al., 2016). However, several reasons can be made for the
conflicting evidence provided in these studies and the findings described in this study.
The study conducted by Mączewski et al., (2016) investigated arrhythmias occurring
between the sixth and ninth hour of ischaemia. Arrhythmias investigated in the present
study and in the majority of previous work completed (Abdukeyum et al., 2008;
Abeywardena et al., 2016; Hartog et al., 1987; Hock et al., 1990; McLennan, 1993;
McLennan et al., 1988; McLennan et al., 1993) were generated during the first minutes
of ischaemia. Arrhythmia which occur within minutes of the ischaemic onset are caused
by different pathogenic mechanisms to arrhythmias which occur after hours (Opitz et
al., 1995), making a comparison between the results of the Mączewski et al., 2016 study
and others challenging. The studies completed by Billman et al., (2010 & 2012)
demonstrated a pro-arrhythmic effect when supplementing supra-therapeutical FO doses
to dogs. However, despite supplementing extraordinary doses of FO to dogs (1,2, 4g/d
(840mg; 1680mg; 3360mg EPA+DHA/d to 20kg dogs), their erythrocyte EPA+DHA
phospholipid concentrations were only 3.0% (1g); 3.7% (2g); and 6.7% (4g). This
highlights that the dog is much less amenable to phospholipid LC n-3 PUFA
incorporation following dietary FO supplementation than the rat and even humans
(700mg/d EPA+DHA in 80kg males has been shown to produce phospholipid
EPA+DHA concentrations of 6.3% (Macartney et al., 2014)). Furthermore, there is
evidence to describe that the dog model used by Billman does not fit with other studies
in the rat, mouse and human when investigating the effect of vagal tone on exercise
induced bradycardia (Boyett et al., 2017b). Likewise, the evidence of pro-arrhythmic
effects shown in dogs does not fit with the consistent anti-arrhythmic effect
demonstrated in other animal models (Matthan et al., 2005) and humans (Reiffel &
McDonald, 2006). Therefore, using dogs to investigate the effect of FO on arrhythmia
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generation does not seem appropriate, whereas, this study used a more physiologically
relevant in vivo rat model.
5.5.3 Linking reduced risk of sudden cardiac death and fish oil
The reduction in mortality associated with FO is usually attributed to reduced risk of
SCD caused by fatal arrhythmia. Research shows that myocardial ischaemia and
spontaneous reperfusion is linked to more than 80% of all fatal arrhythmias (Huikuri et
al., 2001). During regional myocardial ischaemia caused by blockage of a coronary
artery there is redistribution of a number of ions (H+, Na+, Ca2+, K+) (Rubart & Zipes,
2005), increased production of reactive oxygen species (Bolli, 1992), depletion of ATP
stores (Stanley et al., 2005) and overload of intracellular Ca2+ concentrations throughout
cells in the ischaemic area (Moens et al., 2005; Rubart & Zipes, 2005). The culmination
of these cellular changes leads to slowed conduction, altered refractory periods and
ultimately electric instability of the ischaemic zone which can trigger episodes of VT
and/or VF (Rubart & Zipes, 2005; Zipes & Wellens, 1998). Paradoxically, reperfusion
of the ischaemic area further propagates the rapid generation of VT and/or VF and is
closely linked to SCD (Wit & Janse, 2001). Ischaemia and reperfusion was induced
experimentally by occlusion of the LAD coronary artery in this study. In humans, preexisting coronary artery disease is a common pathology which can produce episodes of
ischaemia and spontaneous reperfusion of the myocardium, triggering cardiac
arrhythmias and SCD. However, even in the absence of coronary artery disease, there
are other pathologies including: acute coronary artery spasms, unstable angina and
exercise induced ischaemia which can trigger spontaneous reperfusion induced fatal
arrhythmias and SCD (Zipes & Wellens, 1998).
The unpredictable nature of these events makes it difficult to identify patients at risk of
SCD and therefore preventative prophylactic drug therapy is not possible and usually
only treatable with implantable defibrillation devices. For this reason, the evidence of
FO reducing experimentally induced fatal ischaemic and reperfusion generated
arrhythmias in this study, provides strong evidence to underpin the importance of
including dietary FO as part of a balanced diet to help prevent SCD. The hypothesis of
FO acting to prevent SCD rates through an anti-arrhythmic action is supported by
evidence from human trials also. Two prominent large scale trials have demonstrated
that increasing fish intake or supplementing doses of FO (equivalent to the ModFO diet)
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cause a reduction in cardiovascular related mortality (Burr et al., 1989; Valagussa et al.,
1999). Interestingly, these trials demonstrated that the incidence of SCD was
significantly reduced but the incidence of new ischaemic events was not significantly
reduced. Furthermore, it has been demonstrated that a 1% increase in the omega-3 index
(red blood cell EPA + DHA concentrations expressed as weight percentage of total
phospholipid fatty acids) in humans, reflects a 58% reduced risk of VF during the
ischaemic phase of acute myocardial infarction caused by coronary artery disease
(Aarsetoey et al., 2011; Aarsetoy et al., 2008). Taken in combination with the evidence
provided in this study suggests that FO acts directly on the heart in an anti-arrhythmic
manner rather than on vascular related outcomes influencing the initiation of acute
coronary syndrome. Ex vivo research supports this notion via demonstrating that the
anti-arrhythmic effect is independent of the circulating fatty acid concentrations (Pepe
& McLennan, 1996). These findings provide a physiological plausible mechanism to
assist in explaining the reduced cardiovascular mortality rates observed amongst
populations that habitually consume fish in their diet (Kromhout et al., 1985).
5.5.4 Conclusions
For the first time, the anti-arrhythmic action of FO was demonstrated using a dose of
FO equivalent to approximately two serves of fish per week in the human diet. The
protection was evident despite animals consuming a typical Western-style background
diet high in SFA and n-6 PUFA, suggesting that the anti-arrhythmic action of FO is
intimately linked to absolute intake of FO. Reduced fatal ischaemic and reperfusion VF
events strongly warrant the inference that FO is acting to reduce SCD outcomes, rather
than on vascular outcomes influencing the occurrence of ischaemia (acute coronary
syndrome). In view of these findings the next chapter explored whether supplementing
dietary achievable FO doses protects the haemodynamic integrity of the heart during
prolonged periods of regional ischaemia and post-ischaemic recovery.
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CHAPTER 6

Investigating ischaemic and postischaemic in vivo cardiac
haemodynamics following
supplementation of human dietary
achievable fish oil doses
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6.1.1 Background

6.1 INTRODUCTION

In contrast to brief periods of ischaemia, the primary outcome of prolonged ischaemia is
myocardial tissue necrosis which can develop into a myocardial infarct. This leads to
progressive left ventricle remodelling including dilation and hypertrophy of the
myocardium and haemodynamic dysfunction (Sutton & Sharpe, 2000). There is strong
evidence demonstrating that sudden cardiac death commonly occurs in patients with or
without pre-existing infarct evident, showing that the significance of arrhythmic
outcomes (Chapter 5) is not necessarily correlated to the extent of tissue necrosis
(Huikuri et al., 2001). However, haemodynamic dysfunction is correlated with the
extent of the tissue necrosis (Bolli, 1990) and evidence has highlighted that in the
decade following their myocardial infarction, more than one third of patients will
develop heart failure (Hellermann et al., 2003; Kenchaiah et al., 2004). The degree of
tissue necrosis varies, depending on the duration of the ischaemia, the presence or
absence of collateral circulation in the ischaemic zone, whether the occlusion is
complete or incomplete and the individual demands of the myocardial cells for oxygen
and nutrients (Thygesen et al., 2007).
6.1.2 The phenomenon of myocardial ischaemic pre-conditioning
Ischaemic pre-conditioning is a phenomenon in which submitting the myocardium to
brief periods of ischaemia and then reperfusion prior to prolonged ischaemia protects
and improves the recovery of the heart (Przyklenk & Kloner, 1998). Ischaemic preconditioning has been shown to significantly reduce arrhythmia generation and infarct
size (Abdukeyum et al., 2008; Shiki & Hearse, 1987), attenuate post-ischaemic
myocardial dysfunction (Efstathiou et al., 2001; Lasley et al., 1993; Przyklenk &
Kloner, 1998) and improve the recovery of rate pressure product during reperfusion
(Lasley et al., 1993). Additionally, hypoxic pre-conditioning before regional cardiac
ischemia has been demonstrated to lead to preservation of ejection fraction and preload
recruitable stroke work, indicating improved systolic function (Van der Mieren et al.,
2008). The protection afforded by ischaemic pre-conditioning occurs in two stages. The
first ‘early’ stage produces potent protection, however the protection only persists for a
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few hours and repeated applications causes desensitisation (Qiu et al., 1997). The
second ‘late’ stage occurs after twenty four hours and can be invoked repeatedly to
provide prolonged cardio-protection (Qiu et al., 1997).
Identification of the cellular mechanisms contributing to the physiological outcomes
observed with ischaemic pre-conditioning is of interest to researchers due to the
potential clinical uses in the treatment of ischaemia and reperfusion injury. It has been
demonstrated that the early stage protection offered by ischaemic pre-conditioning is
caused by the production of free radicals and reactive oxygen species, creating oxidative
stress (Yellon & Downey, 2003). However, because the stimulation is only for brief
periods, the myocardial oxidative stress generated actually leads to the production and
up-regulation of a range of antioxidant systems including: nitric oxide synthase,
superoxide dismutase and heat-shock proteins (Lin et al., 2011) which in turn induce
resistance to subsequent more prolonged ischaemic episodes (Das & Das, 2008).
Whereas, late stage protection is thought to be mediated by changes in the expression of
genes leading to altered inflammatory processes and mediation of excessive Ca2+ influx
and opening of mitochondrial K+ ATP channels during subsequent ischaemic episodes
(Das & Das, 2008; Yellon & Downey, 2003). Despite the extensive interest in research
surrounding

ischaemic

pre-conditioning,

the

unpredictable

onset

of

ischaemic/reperfusion injury and invasive methods required to implement remote or
ischaemic pre-conditioning make it impractical in clinical practice (Iliodromitis et al.,
2007).
6.1.3 Other potential methods to exert a pre-conditioning effect
There is evidence for other methods which are more clinically applicable to replicate the
cardio-protection observed with ischaemic pre-conditioning. These approaches include
exercise, remote and post ischaemic conditioning, heat stress, oxidative stress, stretch
and some pharmacological interventions (Kharbanda et al., 2002; Kharbanda et al.,
2009; Staat et al., 2005; Taylor & Starnes, 2003). Typically, the conditioning provided
involves toxic stimuli acting directly at the heart that raise defences in anticipation of an
upcoming event and the protection is persistent even after the initial agent has washed
off. However, exercise and remote ischaemic conditioning are particular interesting
therapeutic candidates because they do not require toxic stimuli to be applied directly to
the heart and protection persists after the initial stimuli has finished (Kavazis, 2009;
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Staat et al., 2005). This suggests the mechanism involves the release of protective
agents into the circulation which can produce persistent protective effects. Specifically,
studies reveal that chronic endurance exercise training protects the heart against
arrhythmias, contractile dysfunction, oxidative injury, mitochondrial damage and cell
death (Lennon et al., 2004; Liu et al., 2000). The mediators responsible for the cardioprotection offered by exercise and remote conditioning have not yet been fully
explained, however studies have shown that upregulation of antioxidant enzymes plays
a critical role in protecting the myocardium against I/R injury (Hamilton et al., 2003;
Kavazis, 2009; Liu et al., 2000; Powers et al., 1993).
Supplementation of FO appears to offer similar cardio-protective features as to those
observed when using other forms of conditioning. However, like remote and exercise
conditioning, FO supplementation results in the upregulation of antioxidant enzymes
within the myocardium without subjecting the heart to a toxic stimuli (Abdukeyum et
al., 2016). The unsaturated nature of DHA makes it prone to oxidation; therefore
increasing myocardial DHA concentrations elevates the peroxidation potential of
membrane phospholipids in the myocardium (Serhan et al., 2004; Song et al., 2000),
indirectly generating a toxic stimulus. In addition to this upregulation of antioxidant
systems, it is well-established that FO acts in an anti-arrhythmic manner at therapeutic
doses (Matthan et al., 2005; McLennan, 2014), and now at dietary achievable doses
(Chapter 5). It has also been demonstrated that MVO2 is reduced without diminishing
work output, suggesting the heart is also using oxygen more efficiently following
supplementation of therapeutic FO doses (Pepe & McLennan, 2002). Furthermore, early
post-ischaemic contractile recovery of heart function is augmented (Pepe & McLennan,
2002), there is reduced production of ischaemic damage biomarkers and infarct size is
attenuated (Abdukeyum et al., 2008; Pepe & McLennan, 2002; Pepe & McLennan,
2007).
As such, it appears that supplementing therapeutic FO doses promotes the upregulation
of antioxidants and produces similar physiological outcomes to other well researched
forms of conditioning. Importantly, the upregulation of antioxidant enzymes, antiarrhythmic and improved ischaemic and post-ischaemic contractile actions of FO are
on-going without the need for daily intake. It has been demonstrated that the most
effective manner to increase tissue LC n-3 PUFA concentrations is from a single weekly
168

dose of FO (Ghasemifard et al., 2015). As such, FO supplementation, like remote and
exercise conditioning offers a more lifestyle applicable, sustainable and effective form
of cardio-protection referred to by Abdukeyum et al., 2008 as ‘nutritional preconditioning’. However, previous studies investigating conditioning of the myocardium
by FO supplementation have relied upon therapeutic and supra-therapeutical doses and
ex vivo experimental models to describe changes. Therefore, the objective of this study
was to evaluate the conditioning efficacy of human dietary achievable FO doses in a
physiologically stable in vivo ischaemia and reperfusion experimental model.
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6.2 AIMS AND HYPOTHESES

This study investigated whether supplementing dietary achievable FO doses to a typical
Western-style diet (high SFA and n-6 PUFA) provides ‘nutritional pre-conditioning’ of
the heart during prolonged regional ischaemia and reperfusion, in a similar manner to
ischaemic pre-conditioning, remote pre-conditioning and exercise training.

Specifically, this experiment aimed to test the following hypotheses:
Aim 1: Determine the influence of supplementing dietary achievable FO doses on
ischaemic haemodynamic function.
Hypothesis 1: Cardiac haemodynamic dysfunction induced by ischaemia,
particularly changes to heart rate, will be attenuated by supplementation of
FO.
Aim 2: Determine the influence of supplementing dietary achievable FO doses on postischaemic haemodynamic recovery.
Hypothesis 2: Post-ischaemic haemodynamic recovery of the left ventricle as
reflected by PV-loops will be modified in FO supplemented animals.
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6.3 METHODS

6.3.1 Animals, ethical considerations and stadardisation
The male rats (Sprague Dawley) from cohort 2 were used in this study. Directly
following the end of experimental procedures described in Chapter 5 the experimental
procedures for this study began.
6.3.2 Groups
Animals were supplied water and randomly assigned one of three pre-fabricated diets ad
libitum for four weeks before experimentation. The diets contained different amounts of
FO (Control – 0%: n = 6, LowFO – 0.31%: n = 9, ModFO – 1.25%: n = 12).
6.3.3 Experimental preparation
Preparation of the 6mm miniaturised 2-French (2F) Millar pressure-volume
conductance

catheter

(SPR-638

Millar

Instruments,

Houston,

USA)

and

electrocardiogram (ADInstruments, Bella Vista, NSW, Aus) was completed (Section
3.3.3).
6.3.4 Surgical procedures
Animals were anaesthetised, and surgery conducted to allow cardiac measurements
including: ECG, ventricular pressure and volume and aortic blood pressure (Chapter 4).
An established surgical technique was used to create an ischaemia and reperfusion
model within the in vivo heart via occluding and reperfusing the LAD coronary artery
(Chapter 5).
6.3.5 Experimental protocol and measurements
Following completion of the in vivo acute ischaemia and reperfusion experimental
protocol and arrhythmia generation measurements (Chapter 5), animals were checked
for depth of anaesthesia prior to experimental protocols and measurements being
collected for this study. After depth of anaesthesia was confirmed, measurements of
heart rate and aortic systolic blood pressure were collected as pre-ischaemic reference
values. The LAD coronary artery was then occluded by placing tension on the ligature
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for forty five minutes to generate a prolonged ischaemic episode, followed by the
release of tension from the ligature, allowing reperfusion of the myocardium (Figure
6.1). During ischaemia the catheter was placed in the aorta to monitor arterial blood
pressure, heart rate was also collected. Following the ischaemia, the myocardium was
reperfused for forty five minutes before the conductance catheter was moved into the
left ventricle and post-ischaemic cardiac function was measured for fifteen minutes.
Upon completion of post-ischaemic cardiac function measurements, the inferior vena
cava was occluded for four to six seconds using a cotton tip applicator. Three separate
occlusions were completed for each animal with five minutes recovery between each
occlusion, this allowed measurement of post-ischaemic load-independent cardiac
function. Saline calibration procedures (Section 3.3.5a) were completed with the
conductance catheter and then animals were euthanased.
6.3.5a Euthanasia and tissue collection
Following the completion of experimental procedures all animals were euthanased
without recovery from the anaesthetic via removing the artificial ventilator and then
rapid exsanguination and removal of the heart. During exsanguination, blood was
collected into a 5mL syringe containing 0.2mL of a 5,000 U/mL Heparin Sodium
solution (Hospira, Lyypards, SA, AUS). The blood was then used to fill the wells of
calibration cuvette and then placed on a heating pad set to 37 oC for calibration of the
pressure volume transducer (Section 3.3.7). Hearts were rapidly removed from animals
following exsanguination, weighed and snap frozen in liquid nitrogen (Section 2.3.5a).
Following exsanguination and removal of the heart, a pre-determined selection of
skeletal muscles were dissected from the upper thigh and lower leg of the left hind-limb,
weighed and snap frozen in liquid nitrogen (Section 2.3.5b).
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Figure 6.1: Overview of the experimental protocol which occurred during the prolonged ischaemia and subsequent reperfusion.
Abbreviations: I = ischaemia; R = reperfusion; LAD = left anterior descending coronary artery; IVC = inferior vena cava; BP = blood pressure.
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6.3.5b Zone at risk measurement
The heart was arrested and flushed with ice cold saline and the zone at risk was
delineated according to previously established methods (McLennan et al., 1988). A
5mL plastic syringe filled with an Indian-dye solution was inserted into the aorta and
the aorta was tightly bound to the syringe via suture. The coronary arteries were then reoccluded and pressure was placed on the syringe in order to cause retrograde perfusion
of Indian dye into the aorta and coronary arteries. The ischaemic zone at risk was then
delineated via staining of the perfused (non-ischaemic) and non-perfused (ischaemic)
tissue. The heart was then weighed (total weight, total left + right ventricular weight and
left ventricle weight only) and cut into five transverse sections (Figure 6.2). The slices
were then separated into non-ischaemic and zone at risk and weighed again. The zone at
risk was calculated as % of total wet left ventricle weight. Tissue was then snap frozen
and stored at –80°C for future biochemical analysis following weight and zone at risk
measurements.

Left Ventricle
Right ventricle
Ischaemic tissue

Non-ischaemic
tissue

Figure 6.2: An isolated heart slice showing ischaemic/non-ischaemic
ventricular tissue following Indian dye tissue staining.
Figure 6.2 notes: Ischaemic region (non-stained) and non-ischaemic region (stained black) can
be observed after perfusion of coronary arteries with Indian dye while LAD is occluded.
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6.3.6 Post-experimental data analysis
Average heart rate was calculated (Section 3.3.8a) at five minute intervals during
ischaemia and reperfusion from the saved electrocardiogram recordings in parallel with
measurements of systolic blood pressure. Rate pressure product was calculated from
these measurements at the corresponding time points. In vivo left ventricular cardiac
haemodynamic function was analysed in the final five minutes of the recordings
collected by the conductance catheter during post-ischaemic measurements. Analysis of
haemodynamic indices was completed following the methods outlined in section 3.3.8b.
Load-independent indices were analysed at each inferior vena cava occlusion and the
average of all three measurements were used to assess the ventricular systolic and
diastolic function of dietary groups.
6.3.6a Statistics
All results are expressed as mean ± standard error of the mean (SEM) unless otherwise
stated. The effects of dietary treatment during ischaemia and post-ischaemia were tested
via ANOVA. A Bonferroni post-hoc test for comparison between group means was then
used to identify differences. A Dunnett’s T-test was used for comparison of individual
diets against the Control group. All statistical analyses were performed in a blinded
manner and completed using SPSS 21 for Windows (SPSS Inc, Chicago, IL, USA).
Alpha was set as p <0.05.
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6.4 RESULTS

Six (6) animals died during the forty five minute ischaemia period due to cardiogenic
shock and diminished mean arterial pressure. Therefore, final group numbers for
comparisons of ischaemic cardiac function and recovery were n = 6 – 8. Zone at risk
measurements showed that on average ∼39 – 45% of the left ventricle wall across all
animals was ischaemic during the LAD occlusion and at risk of becoming infarcted
(Figure 6.3). There were no statistical significant differences in the zone at risk
between any groups.

Figure 6.3: The effect of fish oil on the percentage wet weight of left ventricle
wall at risk of ischaemia following prolonged LAD coronary artery occlusion.
Values are mean ± SEM (n = 6 – 8 per group). No statistical significant differences
present. Figure obtained from Wikimedia commons and adapted.
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6.4.1 The effect of fish oil supplementation on ischaemic cardiac function
There were no significant differences between any of the groups in pre-ischaemic heart
rate, systolic blood pressure and rate pressure product. Five minutes after the onset of
ischaemia heart rate and systolic blood pressure had dropped in all groups resulting in
decreased rate pressure product (Cross hatch red, Figure 6.4). Ten minutes after the
onset of ischaemia heart rate and systolic blood pressure returned toward pre-ischaemic
levels in the ModFO group but remained depressed in the Control and LowFO groups.
The recovery of heart rate and systolic blood pressure in animals from the ModFO
group generated a significantly higher rate pressure product then the Control and
LowFO group. The ModFO maintained the significantly higher rate pressure product
for the remaining time in ischaemia. Five minutes after the onset of reperfusion, rate
pressure product remained significantly higher in the ModFO group compared to the
Control and LowFO group (Cross hatch green, Figure 6.4). There were no further
significant differences between any of the groups for the remaining time in reperfusion.
All groups displayed a recovery towards pre-ischaemic heart rate, systolic blood
pressure and rate pressure product measurements.
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Figure 6.4: The effect of fish oil on heart rate, aortic systolic blood pressure
and rate pressure product throughout ischaemia and subsequent reperfusion of
the left anterior descending coronary artery.
Values are mean ± SEM (n = 6 – 8 per group). *p <0.05 vs Control diet (One-way
ANOVA with Dunnett’s T-test vs Control)
Notes: ‘Pre’ measurements are taken directly prior to ischaemia occurring and are not
equivalent to baseline measurements shown in Figure 6.5 which were collected prior to any
surgery being completed.
Abbreviations: HR = heart rate; BP = blood pressure.
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6.4.2 The effect of fish oil supplementation on post-ischaemic cardiac haemodynamic
function
Heart rate was significantly slower during post-ischaemic measurement when compared
to baseline measurements in the Control and LowFO groups, whereas the postischaemic heart rate of the ModFO group returned towards its resting baseline
measurement (Figure 6.5).

Figure 6.5: The effect of fish oil on resting heart rate (beats.min -1 ) following
ischaemia and reperfusion.
Values are mean ± SEM (n = 6 – 8 per group). *p < 0.05 within group, vs baseline
measurements (One-way ANOVA with Bonferroni post-hoc test). †p < 0.05 between
group, vs Control diet (One-way ANOVA with Bonferroni post-hoc test).
Notes: ‘Baseline’ resting heart rates are the measurements reported in Chapter 4 (Table 4.2)
which were collected using the conductance catheter prior to the chest cavity being surgical
opened.
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Stroke volume and cardiac output were lower in all groups, but the reductions did not
reach statistical significance (Table 6.1). Compared to baseline, the Control group
displayed a significantly lower end-systolic pressure and a significantly greater endsystolic and end-diastolic volume. Compared to baseline, both FO groups displayed a
significantly lower end-systolic pressure, there were no other changes in the LowFO
group but the ModFO group also showed a significantly greater end-diastolic pressure.
As a result of these changes there was a clear downward shift of the PV-loop on the yaxis for all groups. However, rightward shifting along the x-axis was only reflected in
the Control PV-loop (Figure 6.6). Comparison of calculated haemodynamic variables
showed all groups to have a significantly lower dP/dtmax and significantly higher
dP/dtmin and Tau (Table 6.2).
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Figure 6.6: Representative in vivo baseline and post-ischaemic left ventricular
PV-loops following FO supplementation.
Values are mean ± SEM (Baseline n = 15 – 18, Post n = 6 – 8) *p <0.05 vs baseline
(One-way ANOVA comparing within diet conditions with Bonferroni post-hoc test).
Abbreviations: ESP = end-systolic pressure; ESV = end-systolic volume; EDP = end-diastolic
pressure; EDV = end-diastolic volume.
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Table 6.1: The effect of fish oil on baseline resting and post-ischaemic left ventricular measured haemodynamic variables.
Control
Variable

HR (beats.min-1)
SV (µL)
CO (mL.min-1)
CI (mL.min-1 x kg)
ESV (µL)
EDV (µL)

Baseline

Post

451
(±8)
100
(±7)
45
(±3)
23
(±2)
65
(±10)

382*
(±17)
69
(±11)
26
(±4)
17
(±3)
115*
(±15)
184*
(±36)
84*
(±7)
13
(±2)

154
(±9)

LowFO
∆

-69
-31
-19
-6
50
30

Baseline

Post

445
(±6)
98
(±8)
43
(±3)
23
(±2)
55
(±9)

388*
(±15)
80
(±15)
31
(±6)
18
(±4)
58
(±14)

144
(±12)

140
(±18)

∆

-57
-18
-12
-5
3
-4

Baseline

Post

421
(±8)
109
(±9)
46
(±4)
25
(±2)
71
(±10)

410
(±10)
85
(±10)
34
(±3)
17
(±2)
80
(±11)

179
(±16)

165
(±18)

∆

-11
-24
-11
-7
9
-14

98*
-42
(±6)
13
12
10
16*
EDP (mmHg)
2
6
(±1)
(±1)
(±1)
(±4)
Values are mean ± SEM (Baseline n = 15 – 18, Post n = 6 – 8) *p < 0.05 vs baseline (One-way ANOVA comparing baseline vs post-ischaemic
measures within diet conditions using a Bonferroni post-hoc test).
ESP (mmHg)

139
(±7)

-55

132
(±4)

96*
(±9)
14
(±3)

ModFO

-36

140
(±5)

Abbreviations: HR = heart rate; SV = stroke volume; CO = cardiac output; CI = cardiac index, CO/Body weight; ESV = end-systolic volume; EDV = end-diastolic
volume; ESP = end-systolic pressure; EDP = end-diastolic pressure; Post = post ischaemia; ∆ = difference between baseline and post-ischaemia.
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Table 6.2: The effect of fish oil on baseline resting and post-ischaemic left ventricular calculated haemodynamic variables.
Control
Variable

Baseline

Post

1.5
(±0.2)
65
(±5)

1.2
(±0.4)
38*
(±10)
4055*
(±382)

LowFO
∆

Baseline

Post

1.5
(±0.2)
68
(±4)

1.5
(±0.2)
57
(±9)

8796
(±288)

4845*
(±724)

ModFO
∆

Baseline

Post

1.2
(±0.1)
62
(±4)

1.7
(±0.3)
52
(±3)

8537
(±401)

4648*

∆

Systolic indices
Ea (mmHg/µL)
EF (%)
dP/dtmax (mmHg.sec-1)

8688
(±441)

-0.3
-27
-4633

-11
-3951

(±162)

0.5
-10
-3889

Diastolic indices
-7773
-7440
-3074*
-4351*
-3955*
4661
3422
3445
(±364)
(±313)
(±207)
(±436)
(±882)
10.0
9.6
10.0
15.0*
14.4*
14.4*
Tau (ms)
5
4.8
4.4
(±0.4)
(±0.4)
(±0.3)
(±2.0)
(±1.9)
(±1.3)
Values are mean ± SEM (Baseline n = 15 – 18, Post n = 6 – 8) *p < 0.05 vs baseline (One-way ANOVA comparing baseline vs post-ischaemic
measures within diet conditions using a Bonferroni post-hoc test).
dP/dtmin (mmHg.sec-1)

-7735
(±483)

Abbreviations:
Post = post ischaemia; ∆ = difference between baseline and post-ischaemia.
Systolic indices: Ea = arterial elastance; EF = ejection fraction; dP/dtmax = peak rate of pressure rise.
Diastolic indices: dP/dtmin = peak rate of pressure decline; Tau = relaxation time constant calculated by Glantz method (regression of dP/dt versus pressure).
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6.4.3 The effect of fish oil supplementation on post-ischaemic preload-independent
cardiac function
All groups displayed a significant reduction in stroke work compared to baseline resting
measurements (Table 6.3). There were no significant changes to the ESPVR, preloadrecruitable stroke work and dP/dtmax – end-diastolic volume relationships following
ischaemia when they were calculated for all groups. In addition, there were no clear
changes observed within any of the groups when the slope of the diastolic index
EDPVR was calculated.
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Table 6.3: The effect of fish oil on baseline and post-ischaemia left ventricular preload-independent haemodynamic function.
Control

LowFO

ModFO

Baseline

Post

∆

Baseline

Post

∆

Baseline

Post

∆

SW (mmHg*µL)

10933
(±963)

4559*
(±1020)

-6374

9693
(±744)

5276*
(±879)

-4417

10226
(±917)

3929*
(±883)

-6297

ESPVR

2.1
(±0.2)

1.9
(±0.2)

-0.2

2.1
(±0.2)

1.8
(±0.2)

-0.3

2.2
(±0.1)

2.2
(±0.2)

-

115
(±8)

100
(±9)

-15

120
(±8)

102
(±10)

-18

124
(±7)

108
(±8)

-16

46
(±8.8)

32
(±7.6)

-14

49
(±8.0)

35
(±6.5)

-14

55
(±6.1)

43
(±6.6)

-12

0.038
(±0.01)

0.036
(±0.01)

-0.002

0.041
(±0.01)

0.042
(±0.01)

0.001

0.036
(±0.01)

0.041
(±0.01)

0.005

Systolic indices

PRSW (mmHg)
dP/dtmax – EDV
-1

-1

(mmHg.s ml )
Diastolic indices
EDPVR

Values are mean ± SEM (Baseline n = 15 – 18, Post n = 6 – 8) *p < 0.05 vs baseline (One-way ANOVA comparing baseline vs post-ischaemic
measures within diet conditions using a Bonferroni post-hoc test).
Abbreviations:
Post = post ischaemia; ∆ = difference between baseline and post-ischaemia.
Systolic indices: SW = stroke work; ESPVR = end-systolic pressure volume relation; PRSW = preload recruited stroke work (slope of stroke work−EDV
relationship); dP/dtmax−EDV = dP/dtmax−end diastolic volume relation
Diastolic indices: EDPVR = end-diastolic PV relation slope
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6.5 DISCUSSION

The current study demonstrated that supplementing FO doses achievable within a
typical Western-style human diet (high SFA and n-6 PUFA) modified in vivo ischaemic
and post-ischaemic cardiac function. Importantly, a physiologically and clinically
relevant ischaemic episode induced by regional blood flow restriction was used, typical
of major vessel disease and myocardial infarction. Previously, the effects of FO on
cardiac haemodynamic function during ischaemia and reperfusion have generally been
restricted to ex vivo models and relied upon therapeutic and supra-therapeutical doses
(Abdukeyum et al., 2008; Goo et al., 2014; Herrera et al., 2015; McLennan et al., 2012;
Pepe & McLennan, 2002). Furthermore, with the exception of the study completed by
Abdukeyum, et al., 2008; ischaemia has been induced by globally restricting blood flow
to the entire coronary circulation. As such, findings from this study offer novel and
clinically relevant evidence to demonstrate that dietary achievable FO doses are
associated with cardio-protective physiological actions akin to the protection provided
by regular exercise training and remote or ischaemic pre-conditioning.
6.5.1 Fish oil effects on cardiac dysfunction induced by regional ischaemia
Shortly after the onset of the regional ischaemic stimulus before cellular necrosis
occurred, cardiac function was depressed in a manner which fits with the previously
described physiological outcomes of non-infarcted ischaemic damage to the
myocardium (Indolfi & Ross, 1993; Moens et al., 2005). Physiologically, this was
observed as acute reductions to heart rate, systolic blood pressure and as a consequence
of these changes, rate pressure product was lower. Supplementation of dietary
achievable FO doses did not influence this initial reduction to heart rate, systolic blood
pressure or rate pressure product. However, at the onset of ischaemia, the decline in
cardiac function observed across all groups is a normal compensatory mechanism.
During ischaemia, myocardial substrate and oxygen supply is reduced, it is well
established that in an attempt to compensate the reduced sub-endocardial perfusion,
reductions in transmural wall thickening or segment shortening occur (Canty & Suzuki,
2012). This is often referred to as ‘perfusion-contraction matching’ (Indolfi & Ross,
1993; Ross, 1991) or ‘hibernation’ of the myocardium (Heusch et al., 1997). This
response of the myocardial tissue occurs as an effort to preserve the viability of
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myocytes and delay the occurrence of myocyte necrosis by maintaining substrate
availability. A major factor influencing transmural blood flow and ultimately substrate
availability is heart rate. Sub-endocardial perfusion only occurs during diastole when
coronary vasodilation is maximal (Spaan et al., 2008). For this reason, using betablockers to reduce heart rate is a common therapeutical intervention during ischaemia
(López-Sendó et al., 2004) and during heart failure (Cullington et al., 2012) based on
the rationale of indirectly modulating MVO2 during periods of mismatched oxygen
supply and demand to reduce myocyte necrosis. Therefore, the initial reduction in heart
rate, systolic blood pressure and rate pressure product observed across all groups at the
onset of ischaemia was a normal intrinsic cardiac mechanism for maintaining
myocardial perfusion-contraction matching. Heart rate slowing also reflects another
mechanism to maintain cardiac output by increasing the diastolic filling phase between
beats. As such, FO modification of cardiac function, particularly heart rate during this
response would be detrimental to the preservation of viable myocytes during ischaemia.
Within ten minutes of the onset of ischaemia heart rate, systolic blood pressure and rate
pressure product started recovering in all groups and this gradual recovery continued
throughout the remainder of ischaemia towards pre-ischaemic levels. The recovery in
cardiac function observed during ischaemia in this study highlights some important
differences between in vivo regional ischaemia and ex vivo global ischaemia
experimental models. The typical ex vivo response to global ischaemia can be
understood by detailed experiments completed using a erythrocyte-perfused isolated
working heart model (Pepe & McLennan, 1993). The experiments demonstrated
external work, heart rate and the pressure-time integral per heart beat (dP/dtmax) to be
significantly reduced after five minutes of ischaemia, similar to the physiological
changes observed in this study. In contrast to this study, these indices of cardiac
function remained depressed or progressively deteriorated following twenty minutes of
global ischaemia in the ex vivo model (Pepe & McLennan, 1993). This highlights the
dubious physiological relevance of using ex vivo global ischaemia models to assess
cardiac interventions or treatments.
Global ischaemia models have no non-ischaemic tissue capable of compensatory
responses during ischaemia. Whereas, the region at risk of becoming infarcted due to
ischaemia in this study was ∼45%, meaning ∼55% of the heart tissue remained viable.
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Importantly, zone at risk was not different between any of the groups, indicating an
equivalent ischaemic insult and the proportion of ventricular wall that was ischaemic
was comparable to previous studies using similar surgical protocols (Abdukeyum et al.,
2008; Curtis et al., 1987; Ertracht et al., 2011; Spadaro et al., 1980; Xue et al., 2016).
Interestingly, the location of staining consistently demonstrated that the free left
ventricular wall was at risk of ischaemia rather than the interventricular septum (Figure
6.2). In humans the LAD coronary artery usually (90%) supplies the anterior two-thirds
of the interventricular septum. However, there is evidence to demonstrate that in the rat
the interventricular septum is supplied by a branch that originates close to the origin of
the left coronary artery (Spadaro et al., 1980). Thus, occlusion of the LAD coronary
artery in the rat would not obstruct flow to the interventricular septum and explains why
staining consistently showed that the free wall of the left ventricle was at risk of
ischaemia.
Cardiac function in ex vivo models are devoid of neural, humoral and blood pressure
feedback regulatory mechanisms. Thus, the heart’s response to decreased perfusion
during ischaemia in an isolated system is to depress contractile function in order to
preserve myocardial tissue while oxygen supply is not adequate. Whereas, the recovery
in heart rate and systolic blood pressure observed across all groups in this study are
linked to the important regulatory role of the baroreceptor reflex in maintaining
physiological homeostasis. The baroreceptor reflex acts to maintain mean arterial
pressure at all times, to do so it exerts potent control over the heart and vasculature
(Cowley et al., 1973). The sudden decrease in arterial blood pressure at the onset of
ischaemia triggers the baroreceptors to stimulate the medulla leading to vagal
withdrawal and increased sympathetic nervous tone to the heart. This response explains
how heart rate and systolic blood pressure partially recovers in the in vivo heart during
ischaemia but not in the ex vivo heart. This makes the in vivo experimental model used
in this study more clinically relevant and provides a strong basis to assess the effects of
FO on cardiac function during ischaemia.
The current study demonstrated, for the first time, that there was a distinct accelerated
recovery of heart rate, systolic blood pressure and rate pressure product in the ModFO
group compared the Control group. Chapter 4 of the current thesis demonstrated dietary
FO to slow in vivo resting heart rate, supporting previous in vivo (Hartog et al., 1987;
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Lortet & Verger, 1995) and ex vivo research (Abdukeyum et al., 2008; Pepe &
McLennan, 1996). Interestingly, in contrast to the slowed resting heart rate consistently
observed with FO, this study demonstrated that heart rate rapidly recovered to preischaemic rates and remained stable for the duration of the ischaemic episode in the
ModFO group. This provides evidence to suggest that FO does not act solely to slow
heart rate. Rather, it appears FO acts in a manner to adjust contractile function of the
heart to a physiologically appropriate rate and force. Further support for this notion is
found in a study which demonstrated that slowing of heart rate driven by oxygen
deficits during ischaemia were attenuated by FO in blood perfused isolated hearts
devoid of neural feedback (Pepe & McLennan, 1996).
The rapid recovery of heart rate and systolic blood pressure in the ModFO group
facilitated a higher rate pressure product. Heart rate, systolic blood pressure and the
product of both, rate pressure product have been demonstrated to correlate strongly with
in vivo MVO2 (Kitamura et al., 1972), but this correlation was unable to be shown in ex
vivo hearts (Aksentijevic et al., 2016). However, it is likely that the inability to
demonstrate a correlation in the ex vivo model is because low-oxygen carrying perfusate
was used instead of whole-blood leading to altered oxygen conductance. Therefore, the
higher rate pressure product demonstrated in vivo in the current study indirectly
suggests that MVO2 is greater in the ischaemic heart following FO supplementation.
Interestingly, during ex vivo ischaemia, it has been demonstrated that FO lowers MVO2
when the heart is electrically paced to maintain a uniform beat rate, and left ventricular
preload and afterload are strictly controlled, ensuring the same amount of work was
conducted (Pepe & McLennan, 2002). In contrast, the present study demonstrated a
faster heart rate and higher systolic blood pressure, indirectly suggesting a greater
MVO2 and indicative of greater cardiac work. The indirect observation of greater MVO2
in this study in contrast to lowered MVO2 in the study conducted by Pepe et al., 2002
demonstrates the important role FO plays in the efficient use of oxygen rather than
exclusively as a depressor of oxygen use. This further highlights a role of FO in
maintaining cardiac muscular contractile function, via the efficient use of available
oxygen during ischaemia, in a similar manner to what has been demonstrated in skeletal
muscle (Henry et al., 2015; Peoples & McLennan, 2010, 2014, 2017).
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It has been demonstrated that during ischaemia, MVO2 can remain paradoxically high in
the presence of abnormal wall motion and decreased contractile function in the canine
heart (Dean et al., 1990) emphasizing the normal inefficient increases of MVO2 during
ischaemia. The current study demonstrated that dietary achievable FO doses instigated
productive increases of myocardial MVO2 during ischaemia. That is, when the heart is
adapting to adverse conditions, FO enables ongoing function. Contradictory recent
research has declared that FO does not improve the oxygen efficiency or mechanoenergetic performance of the ex vivo working heart (Goo et al., 2014). The conflicting
evidence described from the study conducted by Goo et al., 2014 and the current one
can be clarified by comparing the experimental models used. The study conducted by
Goo et al., 2014 used an ex vivo heart at low temperature (32°C), perfused with a tyrode
solution bubbled with 100% oxygen, which despite very high PO2 carry much less
oxygen than blood (Pepe & McLennan, 1993). In contrast, this study used an in vivo
model where the heart was perfused by the animals own blood, core temperature was
maintained at 37°C and all physiological feedback mechanisms remained intact. Neural
and humoral influences, temperature regulation and most importantly, adequate
oxygenation of the heart, are essential for optimal cardiac performance in a working
physiological system (Kuzmiak-Glancy et al., 2015). Inadequate oxygenation of the
myocardium through the use of red blood cell-free perfusate in ex vivo models has been
demonstrated to diminish cardiac function, even in the absence of injury (Pepe &
McLennan, 1993). It has been suggested that whole blood perfusate provides superior
preservation of myocardial function during ex vivo heart preparations where in vivo
methods are not available (White et al., 2015). This clarifies why whole blood perfused
ex vivo models consistently demonstrate improved cardiac (Pepe & McLennan, 2002;
Pepe & McLennan, 2007) and skeletal (Henry et al., 2015; Peoples & McLennan, 2010,
2017) muscle contractile function with FO supplementation that contrast the findings of
Goo et al., 2014. It is therefore likely that the conflicting evidence demonstrated by Goo
et al., 2014 is driven by the low temperature that experiments were conducted in and
inadequate oxygenation of the heart as a result of non-whole blood perfusate being used
in their ex vivo heart model.
Another factor which may have increased apparent oxygen consumption in the ModFO
group is the possibility that there were more viable myocardial cells during the
ischaemia. Although infarct size was not investigated directly in this study, previous
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research has demonstrated that therapeutic and supra-therapeutical doses of FO can
reduce infarct size in the rat heart (Abdukeyum et al., 2008; Pepe & McLennan, 2002;
Pepe & McLennan, 2007). Less extensive damage resulting in a greater proportion of
viable cells within the ischaemic region would also help explain why the ventricle was
able to generate greater contractile function than the other groups during ischaemia.
Contractile function has previously been demonstrated to improve in isolated hearts
supplemented supra-therapeutical doses of FO (Abdukeyum et al., 2008; Pepe &
McLennan, 2002). Although measured indirectly as systolic blood pressure, this study is
the first to demonstrate improved contractile function during ischaemia in a clinically
relevant in vivo model coupled with dietary achievable FO doses. The comparison of
systolic blood pressure to left ventricular contractile function is appropriate in this study
as the catheter was sitting in the aorta directly outside the left ventricle which is
representative of the afterload or ‘tension’ generated by the left ventricle.
6.5.2 Fish oil effects on post-ischaemic cardiac dysfunction
Assessment of Control post-ischaemic in vivo pressure and volume relations,
demonstrated the typical contractile dysfunction associated with the loss of viable
myocardium caused by ischaemia. Acutely, myocardial ischaemia reduces total
contractility (Pfeffer, 1995; Yang et al., 2004); this was reflected in Control animals by
lower end-systolic pressure and the PV-loop shifting downwards on the y-axis. Reduced
force of ventricular contraction results in decreased ventricular emptying and a greater
end-systolic volume. Increased end-systolic volume means the diastolic filling phase of
the cardiac cycle starts at a greater volume, therefore normal venous return added to an
already partially filled ventricle results in a greater end-diastolic volume (preload). This
is reflected by significant rightward shifting of PV-loops acutely following ischaemia in
rats (Pfeffer et al., 1991). In comparison to their baseline PV-loop, the post-ischaemic
Control PV-loop shifted rightwards on the x-axis, reflecting greater end-systolic volume
and end-diastolic volume. Acutely, increased stretch of the myocytes caused by a
greater end-diastolic volume generates a stronger contraction via the Frank-Starling law
to ensure stroke volume is maintained and the increased blood volume in the ventricle is
ejected into circulation rather than pooling within the ventricle (Glower et al., 1985).
Although post-ischaemic stroke volume is maintained by this compensation, ejection
fraction was lower in the Control group because of the greater end-diastolic volume.
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The degree of post-ischaemic ventricular haemodynamic dysfunction has been
demonstrated to be directly related to the extent of viable myocardium loss (Pfeffer et
al., 1979). Together, the zone at risk measurements collected and the haemodynamic
dysfunction observed confirms that the ischaemic episode was sufficient to cause
typical post-ischaemic contractile dysfunction, consistent with what has been described
in other studies. Therefore, the alterations observed between the Control baseline and
post-ischaemic in vivo PV-loop provided a suitable basis to assess whether
supplementing FO doses achievable within a typical Western-style human diet modified
haemodynamic function after ischaemia.
Post-ischaemic stroke volume and cardiac output was decreased by ∼15 - 20% and ∼25 30% respectively across all groups compared to baseline measures. However,
supplementation of dietary achievable FO doses maintained PV-loop integrity leading
to attenuated declines in left ventricular ejection fraction, despite the decrease in stroke
volume. Ejection fraction has been demonstrated to be increased as a result of enhanced
ventricular filling in the resting in vivo marmoset heart following supra-therapeutical
FO doses (McLennan et al., 1992a). This is the first study to show preservation of
ejection fraction following ischaemia while using dietary achievable FO doses.
Diastolic function was impeded in all groups indicated by increases in the relaxation
constant Tau and the maximal rate of relaxation (dP/dtmin). The myocardium commonly
becomes stiff and slower to or less able to relax during and following ischaemia
resulting in impaired diastolic filling (Varma et al., 2003). Nevertheless, this study
demonstrated post-ischaemic dP/dtmin to be ∼1000mmHg.sec-1 faster in the FO
supplemented animals compared to the Control group. This reflects observations made
in an ex vivo study which also demonstrated supra-therapeutical doses of FO to improve
maximum rate of ventricular relaxation (Abdukeyum et al., 2008). Therefore, it is likely
that this in part contributed to the maintenance of left ventricular ejection fraction
observed in FO supplemented animals of this study.
The lower stroke volume and cardiac output were likely related to the reductions in the
maximal rate of pressure development (dP/dtmax) observed across all groups. This
indicates the left ventricle was in a weakened systolic inotropic state following
ischaemia (Kass et al., 1989). However, this study demonstrated that dP/dtmax was
∼700mmHg.sec-1 faster in the FO supplemented animals compared to the Control group.
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In addition, although not statistically significant, end-systolic pressure in FO
supplemented animals was ∼10-15mmHg higher during post-ischaemic measurements.
These findings reflect a study which demonstrated supra-therapeutical doses of FO to
preserve in vivo systolic heart function twenty four hours after permanent ligation of the
LAD in the rat (Lescano de Souza Junior et al., 2017). Furthermore, findings from this
study support an ex vivo study which demonstrated that during reperfusion left
ventricular developed pressure (equivalent to end-systolic pressure) is increased in
hearts supplemented supra-therapeutical doses of FO (Abdukeyum et al., 2008). As a
result of these changes, the time for ejection would be greater, allowing stroke volume
to be maintained and stopping rightward shift of the PV-loop. These changes were
similar to an in vivo sheep heart model assessing the effect of ischaemic preconditioning on global ischaemia (Tanoue et al., 2002). The PV-loops of Control groups
in both studies shifted downwards and rightwards compared to baseline. The FO
supplemented group in this study and the ischaemic pre-conditioned group in the study
conducted by Tanoue et al., 2002 did not show any rightward shifting compared to their
baseline loops. The remarkable resemblance of the effects of human dietary achievable
FO doses on cardiac function to the effects demonstrated with ischaemic preconditioning suggests they share a similar mechanism of action to provide cardioprotection. Such changes indicate that post-ischaemic left ventricular contractile
function was improved independent of the Frank-Starling law. The Frank-Starling
compensation observed in the Control group during post-ischaemic function would be
causing increased contractility to maintain stroke volume. Therefore, systolic contractile
dysfunction in the Control group may have been masked by the powerful Frank-Starling
compensation, meaning the differences between groups could become more evident
over longer time frames when the compensation diminishes.
6.5.3 Conclusions
Ischaemia and reperfusion induced cardiac dysfunction characterised by reduced rate
pressure product during ischaemia and reduced post-ischaemic ejection fraction, was
largely prevented by prior feeding with FO. The moderate dose was more effective than
the low dose but many effects were observed with both indicating that the addition of
FO doses achievable within a typical Western-style human diet can protect against
ischaemia and reperfusion induced cardiac dysfunction. Until now this protective action
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of FO was only demonstrated while using therapeutic and supra-therapeutic doses not
nutritionally relevant to the human diet. Furthermore, the cardio-protective actions
demonstrated mimicked both the potent ‘early’ phase and the long lasting ‘late’ phase
protection previously only attributable to ischaemic pre-conditioning. The modification
of ischaemic and post-ischaemic cardiac function described in this study, together with
the demonstration of slowed resting heart rate and reduced arrhythmia generation,
provides novel evidence to support increasing fish or FO intake for nutritional preconditioning of the heart.
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CHAPTER 7

Discussion and conclusions
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7.1 GENERAL DISCUSSION

Pharmacological and therapeutic strategies aimed at reducing and treating
cardiovascular disease are important to improve patient quality of life. The majority of
studies

to

advance

cardiovascular

outcomes

are

pharmacologically

based.

Notwithstanding the success such treatment has on decreasing the impact of
cardiovascular disease on healthcare systems,

research targeting modification of

lifestyle related risk factors, such as diet and exercise (Eckel et al., 2014), are just as
essential in reducing mortality and morbidity rates and underpinning the prevention of
disease burden. Regular fish intake is consistently associated with a cardio-protective
action in human population based studies (Bang & Dyerberg, 1972; Burr et al., 1989;
Hirai et al., 1980; Kagawa et al., 1982; Kromhout et al., 1985). Now for the first time,
this thesis provides physiological evidence of heart rate slowing, reduced arrhythmia
generation and attenuated post-ischaemic contractile dysfunction, all of which would
contribute to reducing the risk of cardiovascular disease (Fox et al., 2008; Gorenek et
al., 2015). Importantly, the modification of in vivo heart function was attributable to
supplementing FO doses achievable within a typical Western-style human diet (high
SFA and n-6 PUFA). This highlights that in the typical Western-style diet which
contains very small amounts of LC n-3 PUFA (Micha et al., 2014), as also could be
implied from global erythrocyte EPA+DHA levels (Stark et al., 2016), and high
amounts of SFA and n-6 PUFA, the cardiovascular benefits of FO can be produced
solely through increasing LC n-3 PUFA intake without the need to concurrently reduce
n-6 PUFA intake as previously postulated by Simopoulos, A.P., 2008, Lands, E.M.,
2003 & Rupp et al., 2004. As such, this research emphasises the importance of
nutritional interventions aimed at increasing fish or FO intake in the Western-diet for
optimal cardiac function and provides further support for the recommendation to
establish a dietary reference intake (Flock et al., 2013).
7.1.1 Direct effect of dietary achievable fish oil doses on heart function
The heart is remarkably adaptive to both acute and chronic stimuli. This research
demonstrated that the preferential incorporation of DHA into myocardial phospholipids
influences both chronotropic and inotropic heart function. Specifically, the
physiological changes observed included i) modification of heart rate independent of
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well-defined autonomic tone changes, suggestive of an intrinsic mechanism, ii) less
severe and reduced incidence of arrhythmias (including fatal) during simulated acute
coronary syndrome and iii) improved left ventricular post-ischaemic contractile
function.
7.1.1a Heart rate
In each cardiac cycle, the beat to beat interval is controlled, along with stroke volume
and together they are responsible for cardiac output. Control of cardiac output is
essential as it contributes to maintaining mean arterial pressure for the adequate
perfusion of organs and tissues in the body. This research demonstrated that
supplementing FO to a typical Western-style diet slows resting heart rate, in a similar
fashion to exercise training (Blomqvist & Saltin, 1983; D’Souza et al., 2015b).
Previously heart rate slowing had only been demonstrated in animals using FO doses in
the therapeutic or supra-therapeutical range (McLennan, 2014). The dietary achievable
doses used in this series of projects provides a compelling physiological link to explain
the consistent observation of FO supplementation being associated with lower heart
rates in humans (Dallongeville et al., 2003; Geelen et al., 2005; Grimsgaard et al.,
1998; Mozaffarian. et al., 2005). Increased resting heart rate in patient and healthy
populations is associated with a greater risk of CVD and all-cause mortality (Aune et
al., 2017; Cullington et al., 2012; Hartaigh et al., 2014; McAlister, 2009; Zhang &
Zhang, 2009). As such, the cardio-protective action of regular fish consumption is likely
to be associated with its ability to slow resting heart rate when physiological strain is
absent.
In contrast to FO-induced slowing during rest, heart rate (initially depressed by
ischaemia) rapidly recovered in FO supplemented animals. This suggests that during
physiological strain (ischemia), the heart is protected against a loss of mechanical
function and as a consequence sustained reduction in heart rate is attenuated. Support
for this hypothesis can be found in previous studies which have demonstrated FO to
slow resting heart rate but not impair peak heart rate during exercise in humans
(Buckley et al., 2009; Macartney et al., 2014; Peoples et al., 2008). Interestingly, betablockers, commonly used in the treatment of hypertension and heart failure (Lechat et
al., 1998), inhibit peak heart rate responses by up to 30beats.min-1, and slow resting
heart rates by up to 10beats.min-1 through blocking sympathetic input to the heart
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(Epstein et al., 1965). Heart rate reserve (the difference between resting and peak heart
rate) is reduced by these changes, which can limit exercise tolerance in patients
prescribed beta-blockers (Hradec et al., 2013; Piña et al., 2003). This highlights a
potential clinical role for FO to modulate heart rate without compromising heart rate
reserve and exercise tolerance.
Resting heart rate was slowed without any well-defined changes to autonomic tone,
suggestive of an intrinsic mechanism. Slowing of resting heart rate is commonly
attributed to increased vagal tone, particularly in studies investigating exercise training
induced bradycardia (Billman et al., 2015; Coote & White, 2015). It is likely that vagal
tone contributes to slowing of resting heart rate but the exclusive action of increased
vagal tone is to slow heart rate. In addition to heart rate slowing, supplementation of FO
was shown to modulate heart rate and allow it to increase during ischaemia. Exercise
training can also cause resting bradycardia without compromising peak heart rate
(Blomqvist & Saltin, 1983; Scheuer & Tipton, 1977). Furthermore, both exercise
training and dietary FO slow resting heart rate of hearts studied ex vivo (Abdukeyum et
al., 2008; D'Souza et al., 2014; Pepe & McLennan, 2002) and even in cardiac transplant
patients (Harris et al., 2004), none of which would receive vagal stimulation. Given the
findings from the current project and what is observed in exercise training induced
slowing of resting heart rate, it is reasonable to suggest that both stimuli modify heart
rate intrinsically, as was originally hypothesised for exercise training decades ago
(Sutton et al., 1967).
It is well established that the sino-atrial node is responsible for intrinsic pace-setting of
the rhythmic electrical excitation patterns of the heart (Mangoni & Nargeot, 2008).
Originally it was theorised that sarcolemma membrane ion channels were responsible
for the ignition of action potentials in the sino-atrial node (Weidmann, 1955). However,
it has now been postulated that the control of sino-atrial node firing is tightly regulated
by two coupled processes (Yaniv et al., 2015). The first being, the hyperpolarisation
activated sarcolemma cation current, commonly referred to as the ‘funny current’ and
the second being, the spontaneous release of calcium from the sarcoplasmic reticulum,
otherwise referred to as the ‘calcium clock’ (Maltsev & Lakatta, 2009; Yaniv et al.,
2015). It has been hypothesised that the funny current is responsible for stabilizing the
beat to beat rate, whereas the calcium clock is the main source of beat to beat
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variability, independent of autonomic tone (Zaniboni et al., 2014). Supplementation of
FO has been demonstrated to slow the funny current in rabbit sino-atrial cells (Verkerk
et al., 2009), in a similar fashion to exercise training induced electrical remodelling of
the sino-atrial node (Boyett et al., 2017a; D'Souza et al., 2014; D’Souza et al., 2015a).
It has also been demonstrated that LC n-3 PUFA can modulate other ion channel
activities including voltage-gated Na+ (Xiao et al., 2005), K+ (Farag et al., 2016), Ca2+
channels (Pepe & McLennan, 2002) and the spontaneous release of Ca2+ from the
sarcoplasmic reticulum which is closely linked to the calcium clock (Siddiqui et al.,
2008). Analysis of cellular mechanisms responsible for the heart rate slowing was
beyond the scope of the experiments described in this thesis. However, the cellular
evidence in conjunction with the physiological findings presented provides support for
the hypothesis that LC n-3 PUFA mediated slowing of heart rate is closely linked to
intrinsic beat rate modification at the sino-atrial node.
7.1.1b Arrhythmias
Ischaemic episodes as short as five minutes in the myocardium can lead to electrical
instability and arrhythmias even in the absence of cell necrosis and reperfusion can
exacerbate the instability (Bolli, 1988). This project demonstrated a potent antiarrhythmic action of dietary achievable FO doses during ischaemia and reperfusion,
previously only described using therapeutic and supra-therapeutic doses (Abdukeyum et
al., 2008; Abeywardena et al., 2016; Hartog et al., 1987; Hock et al., 1990; McLennan
et al., 1988; McLennan et al., 1993; McLennan et al., 2007). This finding provides
strong evidence, for the first time, to justify how increasing dietary FO intake in a
typical Western-style diet containing high amounts of SFA and n-6 PUFA leads to the
prevention of sudden (arrhythmic) cardiac death (Burr et al., 1989; Valagussa et al.,
1999) and addresses the confusion regarding the minimum dose required (Reiffel &
McDonald, 2006) .
The protection afforded by FO supplementation can be rationalised by comparing to
ischaemic pre-conditioning of the myocardium, as both have been demonstrated to
provide an effective anti-arrhythmic action (Abdukeyum et al., 2008). The cardioprotective actions of ischaemic pre-conditioning are closely linked to alteration of
intracellular signalling cascades, particularly Ca2+ regulation (Das & Das, 2008; Otani,
2008; Yellon & Downey, 2003). Abnormalities in Ca2+ regulation can provide an
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opportunity for intracellular Ca2+ concentrations within myocardial cells to overload.
Intracellular Ca2+ overload is associated with spontaneous depolarisation of nonpacemaking cells and the generation of arrhythmias (Brooks et al., 1995; Rubart &
Zipes, 2005), including the initiation of VT, VF and triggered activity (Antzelevitch &
Burashnikov, 2011; Undrovinas et al., 1992). It was hypothesised that the slowing of
heart rate was likely linked to modified Ca2+ regulation in pacemaker cells of the sinoatrial node. Thus, it is plausible that the anti-arrhythmic action of myocardial DHA
incorporation is also attributable to stabilisation of Ca2+ movement within nonpacemaking myocytes.
Paradoxically, increased incorporation of DHA into myocardial phospholipids would
increase the peroxidation index, potentially leading to the production of arrhythmogenic
oxidative products. However, when the peroxidation index is increased by phospholipid
DHA incorporation persistent basal lipid oxidation occurs, as a consequence, antioxidant enzymes such as mitochondrial superoxide dismutase (MnSOD) are continually
upregulated (Abdukeyum et al., 2016). This observation is consistent with the upregulation of anti-oxidant systems that occurs with the regular oxidative stress of
exercise training (Hoshida et al., 2002) or ischaemic pre-conditioning of the
myocardium (Otani, 2008; Yellon & Downey, 2003). Furthermore, increased ADP
sensitivity and reactive oxygen species generation are physiological consequences of
DHA incorporation in skeletal muscle mitochondria, yet there is no evidence of
oxidative damage (Herbst et al. 2014). It has also been demonstrated that
cyclooxygenase and lipoxygenase enzymes are up-regulated in the myocardium during
inflammatory events such as ischaemia and reperfusion (Jenkins et al., 2009).
Enzymatic oxygenation of membrane bound EPA and DHA, via cyclooxygenases and
lipoxygenases, leads to the formation of a range of unique PUFA-derived bioactive
compounds involved in the resolution of inflammation, including: resolvins;
neuroprostanes; maresins; protectins; and lipoxins (Serhan & Petasis, 2011).
Furthermore, non-enzymatically generated endogenous lipid mediators have been
shown to have the same anti-arrhythmic properties as DHA, suggesting they are also
directly involved in the process (Roy et al., 2016; Roy et al., 2015). Although cellular
mechanisms were not investigated in this research, the anti-arrhythmic action of dietary
achievable FO doses described is almost certainly linked to intrinsic changes of Ca2+
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regulation, anti-oxidant systems and the resolution of inflammation and in many ways
holds similarities to ischaemic preconditioning and exercise preconditioning.
7.1.1c Contractile performance
In addition to heart rate and rhythm, inotropy and lusitropy are critical for maintaining
cardiac output and are therefore tightly controlled within the working physiological
system. This project has provided evidence, for the first time, that dietary achievable FO
doses attenuate post-ischaemic myocardial contractile dysfunction, previously described
using therapeutic doses (Abdukeyum et al., 2008; Pepe & McLennan, 2002) and in a
similar manner to ischaemic pre-conditioning (Efstathiou et al., 2001; Lasley et al.,
1993; Przyklenk & Kloner, 1998). Improved post-ischaemic myocardial contractile
performance provides evidence that helps link the observation of reduced heart failure
incidence amongst populations that regularly consume fish (Levitan et al., 2010).
The modulation of myocardial post-ischaemic contractile dysfunction is remarkably
similar to the contractile changes FO supplementation produces in skeletal muscle,
particularly muscles susceptible to fatigue (Henry et al., 2015) and muscles acutely
subjected to hypoxia (Peoples & McLennan, 2017). A common mechanism of action
hypothesised to account for the physiological actions of FO on contractile performance
is enhanced oxygen efficiency across organs, including the healthy or failing rat heart
(McLennan et al., 2012; Pepe & McLennan, 2007), skeletal muscle (Peoples &
McLennan, 2010, 2014, 2017) and confirmed as lower whole body oxygen consumption
during exercise in healthy humans (Peoples et al., 2008). This hypothesis is
strengthened by evidence that when rats are supplemented DHA they have increased
chances of surviving asphyxia-induced cardiac arrest, suggestive of enhanced
myocardial oxygen efficiency (Kim et al., 2016). Attributing enhanced contractile
oxygen efficiency to increased phospholipid DHA concentration from FO is reinforced
by environmental adaptations found in comparative physiology. Phospholipid DHA
incorporation of excitable tissue increases in response to chronic hypoxia exposure in
rats, presumably as a protective response (Jezkova et al., 2002). Equally, DHA is
concentrated in the swimming muscles of the deep diving seal where contractile
function is maintained in a low oxygen environment during breath hold periods of
exceeding 12 minutes (Trumble & Kanatous, 2012). Likewise, phospholipid n-3 PUFA
concentrations are high in migrating birds which are exposed to high altitude for
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prolonged periods of time while maintaining wing contractile performance
(McWilliams et al., 2004). Notably, DHA concentrations were shown to be highest in
muscles with high proportions of fast oxidative glycolytic muscle fibres responsible for
powerful yet sustained contraction in this thesis. Fast oxidative glycolytic muscles
contain an extensive network of sarcoplasmic reticulum and mitochondria (Berchtold et
al., 2000). Double packing of the mitochondrial membrane has been proposed as an
explanation for such high LC n-3 PUFA concentrations (Infante et al., 2001). This
suggests that phospholipid incorporation of DHA from FO is integral to maintaining
contractile performance, particularly during conditions where oxygen availability is
challenged.
Regulation of Ca2+ recurs (already discussed in reference to heart rate and arrhythmia)
as a unifying cellular mechanism to help justify the hypothesis that enhanced oxygen
efficiency allows maintained contractile performance. Abnormalities in excitationcontraction coupling as a result of Ca2+ regulation have been shown to cause inefficient
oxygen use leading to contractile dysfunction (Brooks et al., 1995; Kristian & Siesjo,
1998; Pepe & McLennan, 2002; Rubart & Zipes, 2005). In fact, it has been shown that
the attenuation of post-ischaemic contractile dysfunction associated with ischaemic preconditioning is partly due to optimised Ca2+ regulation (Das & Das, 2008). Research has
identified that LC n-3 PUFA alters both sarcoplasmic reticulum Ca2+-ATPase (SERCA)
mediated Ca2+ reuptake and ryanodine receptor (RyR) mediated Ca2+ release in isolated
ventricular and atrial myocytes (Honen et al., 2003; Negretti et al., 2000; O'Neill et al.,
2002). Of physiological consequence, the maximal contractile rate of developed tension
and relaxation in skeletal muscle has been shown to be partially protected during acute
hypoxia in rats supplemented FO (Peoples & McLennan, 2017). Furthermore, from
within a fatigued state, hind-limbs of animals fed FO demonstrated an augmented
response to a caffeine bolus facilitates sarcoplasmic reticulum Ca2+ release (Fryer &
Neering, 1989). For the reasons discussed, myocardial phospholipid DHA
incorporation, caused by the provision of dietary achievable FO doses is essential for
attenuating post-ischaemic contractile dysfunction demonstrated in this project.
7.1.1d Linking the effects of fish oil in the heart to phospholipid composition
The dose-dependent and preferential incorporation of DHA into cardiac and skeletal
muscle phospholipids when made available via the diet highlights the important role LC
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n-3 PUFA have in the healthy physiological functioning of excitable tissue, particularly
the heart. Historically, animal studies supplementing FO have used doses which are
mostly unachievable in the equivalent human diet, making extrapolation of the
physiological findings to human health ambiguous. Dose response studies (Slee et al.,
2010), covering the range used in the current research show that previous supratherapeutical doses of FO maximally increased myocardial DHA phospholipid fatty
acid composition (Abdukeyum et al., 2008; Hock et al., 1990); the ModFO diet
contributed 1/5 these doses or less, yet myocardial phospholipid DHA concentration
was close to maximal. Remarkably, the LowFO diet, which supplemented FO at
roughly 1/20th the dose of those previous studies, still resulted in about half maximal
myocardial phospholipid DHA incorporation. Thus, the dietary equivalence of the doses
used in this study (Human equivalence: LowFO ≈ EPA+DHA 570mg/d or ≈ 2 salmon
[100g] serve/week; ModFO ≈ EPA+DHA 2.3g/d or ≈ 6 capsules per/day) allows
translation of the cardiac physiological effects described to the reduced risk of
cardiovascular disease consistently described in populations that regularly consume fish
(Bang & Dyerberg, 1972; Burr et al., 1989; Hirai et al., 1980; Kagawa et al., 1982;
Kromhout et al., 1985) ranging up to supplemental intake (Valagussa et al., 1999).
Furthermore, phospholipid DHA incorporation and cardiac physiology was modified
despite n-6 PUFA and SFA concentrations being held constant in the diet, in-line with
relative concentrations consumed in a typical Western-style diet (Broadhurst et al.,
1998; Simopoulos, 1991; USDA, 2016). This supports and strengthens the notion that
the addition of small amounts of FO to the diet exerts a protective effect directly on the
heart (McLennan, 2014), similar to exercise training and ischaemic pre-conditioning.
Therefore, nutritional interventions aiming to increase fish or FO intake could prove
effective in improving heart function and reducing the risk of cardiovascular disease in
high risk sedentary populations unable to exercise. The effectiveness of the LowFO diet
suggests it is near threshold, thus supporting the suggestion that a dietary reference
intake may be derived on the basis of healthy heart function (Flock et al., 2013).
7.1.2 Future directions
This series of experiments provided physiological evidence of FO modifying intrinsic
heart rate and cardiac inotropic state. There was no well-defined indication that
autonomic tone was altered to account for these changes. Modified autonomic input to
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the heart provides a justification for the slowing of resting heart rate observed, however
the contradicting evidence of stabilised sinus rhythm and faster recovery of heart rate
during ischaemia alludes to the possibility that other processes were involved. As such,
optimisation of cardiac function observed with FO feeding is likely related to an
intrinsic action on the myocardium and pacemaker regions of the heart. Studies in heart
transplant patients (Harris et al., 2004) and in ex vivo animal heart preparations provide
further support to this hypothesis (Abdukeyum et al., 2008; Pepe & McLennan, 1996).
However, the surgical and methodological process involved in setting up an ex vivo
heart preparation, including the choice of perfusate or whole blood can significantly
alter baseline cardiac function. It is even possible that the brief periods of ischaemia
during setup may actually impart an ischaemic pre-conditioning like effect on the heart.
Such investigations would benefit from less invasive surgical protocols such as
echocardiography tracking of cardiac haemodynamic function. Therefore, further
investigation of the influence of FO on intrinsic cardiac function is warranted using a
pithed in vivo animal preparation to remove the influence of the autonomic nervous
system while maintaining the heart in a working physiological system.
Investigation of the mechanisms responsible for the physiological outcomes described
was out of the scope of the current research. As such, cellular studies investigating sinoatrial node spontaneous activity, sarcoplasmic reticulum Ca2+ regulation, anti-oxidant
up-regulation and resolution processes are warranted. Studies aiming to investigate such
outcomes would achieve more physiologically relevant outcomes through using cells
obtained directly from animal’s fed dietary achievable FO doses, rather than using acute
application of LC n-3 PUFA to the cell culture medium. This type of cellular
experiment would allow a more direct translation of any observed changes to be
specifically attributed to DHA phospholipid concentrations and the effects of diet as
opposed to the effects of circulating DHA, solvents or non-specific detergent actions
exposed in some studies when added acutely to the cell culture medium (refer to
McLennan, P.L., 2014).
Finally, the experiments completed in this research demonstrated physiological effects
of dietary achievable FO doses on cardiac function while using an appropriate in vivo
animal model and a background diet relevant to the typical Western-style diet. Skeletal
muscle contractile function has been investigated in the physiologically appropriate
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auto-perfused rat hind-limb model using both dietary achievable (Henry et al., 2015)
and supra-therapeutical FO doses (Peoples & McLennan, 2010, 2014, 2017); however
never on the basis of muscle fibre content. The current research identified a strong
association between increased DHA phospholipid concentrations in skeletal muscle
with a high proportion of fast oxidative glycolytic fibres. Therefore, further
investigation is warranted to determine if FO modifies contractile function uniformly
across striated muscles (including heart), regardless of fibre type proportion, or is more
effective in the presence of a high proportion of a particular fibre type.
7.1.3 Application of the findings and final conclusions: The importance of nutritional
pre-conditioning with increased fish or fish oil intake
Cardiovascular disease persists as a principal contributing factor to worldwide
morbidity and mortality. According to recent data released by the World Health
Organisation almost one third of all deaths worldwide in 2008 were related to
cardiovascular disease. Furthermore, the impact of cardiovascular disease is expected to
increase substantially as the proportion of the aged population increases (Heidenreich et
al., 2011). The physiological outcomes described in the current thesis are similar to the
cardio-protective effects commonly observed with exercise training, remote and
ischaemic pre-conditioning. The unpredictable onset of ischaemic/reperfusion injury
and invasive methods required to implement remote or ischaemic pre-conditioning
make it impractical in clinical practice (Iliodromitis et al., 2007). Additionally, the lack
of specificity of potential therapeutic candidates drawn from ischaemic pre-conditioning
further reduces the viability of such an approach (Otani, 2008). The shortfalls of
implementing ischaemic pre-conditioning to prevent arrhythmias and cardiac contractile
dysfunction induced by ischaemia and reperfusion injury could be overcome via
‘nutritional pre-conditioning’ with increased dietary fish or FO intake (Abdukeyum et
al., 2008). Increased physical activity (exercise training) is well-established to reduce
the risk of cardiovascular disease (Mozaffarian et al., 2016; Thompson et al., 2003).
The evidence from this research suggests that nutritional pre-conditioning with FO
offers cardio-protection in a similar manner. Importantly, a habitual dietary approach to
prevent cardiovascular disease, like increased physical activity levels, overcomes the
need to predict the onset of ischaemia and reperfusion. Pharmacological therapies are
constrained to populations which are identified to be at risk or have already suffered a
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form of cardiovascular disease, this makes dietary and exercise modifications a more
effective preventative approach as they can be applied across vast populations with no
prior indication of cardiovascular disease.
It may be argued that the studies conducted in the current thesis were completed in rats,
making the findings less applicable to human health. However, one of the main design
issues of current trials in humans, which have often been unable to replicate the
epidemiological findings, is the failure to measure or control for how much LC n-3
PUFA an individual is consuming within and outside of the trial. A properly designed
randomised controlled trial relies upon absolute seperation of the treated and control
group. However, it has been highlighted that in investigations of FO supplements there
is often considerable overlap of LC n-3 PUFA red blood cell phospholipid
concentrations between study groups (James et al., 2014), yet trials often conclude that
FO is ineffective, when in fact the design is flawed and sound conclusions can not be
made. For example, the ORIGIN trial (Bosch et al., 2012) showed equal median
EPA+DHA intake in control and treated groups at baseline but the interquartile dietary
range (40-568mg/d) extended beyond the 250mg EPA+DHA which has been identified
in epidemiology and randomized trials for maximal reduction in the risk of
cardiovascular death (Kris-Etherton et al., 2009; Mozaffarian et al., 2005a). Using an
animal model in the current studies allowed for precise FO dosing and definitive
separation of dietary groups to identify physiologically plausible mechanisms of cardioprotection. Thus, the current study was more akin to cohort and other observational
studies that separate participants into quintiles or other percentiles according to
estimated dietary intake or erythrocyte LC n-3 PUFA phospholipid concentrations
(Siscovick et al., 1995). Human observational studies commonly describe differences
in relative risk between those who eat no fish and those who regularly eat some fish or
much fish (Kromhout et al., 1985; Levitan et al., 2010; Mozaffarian et al., 2005a;
Mozaffarian et al., 2005b) making them like the control group in comparison to dietary
FO groups.
Identification and correction of dietary deficiencies has led to considerable public health
benefits in the prevention and treatment of a range of health problems (Blot et al., 1993;
Holick, 2007). The applications of nutritional pre-conditioning with FO in the typical
Western-style diet which contains very low amounts of LC n-3 PUFA (Micha et al.,
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2014), as also could be implied from global erythrocyte EPA+DHA levels (Stark et al.,
2016), far outreach those of ischaemic pre-conditioning. In fact, extensive savings in
European health budgets have been predicted if dietary FO intake can be increased
(Shanahan, 2016). Despite this, there is evidence to suggest that there is insufficient
nutritional

education

amongst

current

cardiovascular

specialists,

leading

to

misinformation and reluctance to provide patients with dietary advice (Devries et al.,
2017). Confusion surrounding the cardiovascular effects of dietary FO (Nestel et al.,
2015) likely exacerbates this problem. This research provides further evidence to
demonstrate FO as a safe and effective tactic for improving intrinsic heart health and
providing protection from cardiovascular disease and stress, with a clear translation path
from animal to human health due to the nutritional relevance and physiologically
appropriate in vivo model used. As such, observations made in this study could form
part of the evidence used to inform and set dietary guidelines for fish intake (Flock et
al., 2013), offering real potential to improve heart health outcomes.
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